424B4 1 a2221776z424b4.htm 424B4

Use these links to rapidly review the document
TABLE OF CONTENTS
TABLE OF CONTENTS1

Table of Contents

Filed Pursuant to Rule 424(b)(4)
Registration No. 333-198013

Prospectus

10,500,000 American Depositary Shares

representing 10,500,000 ordinary shares

Forward Pharma A/S

GRAPHIC

        This is an initial public offering of American Depositary Shares, or ADSs, representing ordinary shares of Forward Pharma A/S. We are offering 10,500,000 ADSs. Each ADS will represent one issued ordinary share, nominal value DKK 0.10 per share. All proceeds of the offering, net of expenses, are to be paid to the Company. The initial public offering price is $21.00 per ADS. Currently, no public market exists for the ADSs or our ordinary shares.

        Our ADSs have been approved for listing on the Nasdaq Global Select Market under the symbol "FWP."

        We are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements.

 
  Per ADS   Total  

Initial public offering price

  $ 21.00   $ 220,500,000  

Underwriting discounts and commissions

  $ 1.47   $ 15,435,000  

Proceeds to us, before expenses

  $ 19.53   $ 205,065,000  

        We have granted the underwriters an option for a period of 30 days to purchase up to an additional 1,575,000 ADSs to cover over-allotments.

        Delivery of the ADSs will be made on or about October 20, 2014.

        Investing in the ADSs involves a high degree of risk. See "Risk Factors" beginning on page 15.

        Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Prospectus. Any representation to the contrary is a criminal offense.

Leerink Partners   Jefferies   RBC Capital Markets

JMP Securities

   

October 14, 2014


Table of Contents


TABLE OF CONTENTS

 
  Page

PROSPECTUS SUMMARY

  1

THE OFFERING

 
10

SUMMARY FINANCIAL INFORMATION

 
13

RISK FACTORS

 
15

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

 
54

PRESENTATION OF FINANCIAL AND OTHER INFORMATION

 
55

USE OF PROCEEDS

 
56

DIVIDEND POLICY

 
57

CAPITALIZATION

 
58

DILUTION

 
59

SELECTED FINANCIAL INFORMATION

 
61

EXCHANGE RATE INFORMATION

 
63

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 
64

BUSINESS

 
82

MANAGEMENT

 
116

PRINCIPAL SHAREHOLDERS

 
128

RELATED PARTY TRANSACTIONS

 
131

DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION

 
136

DESCRIPTION OF AMERICAN DEPOSITARY SHARES

 
148

SHARES AND ADSs ELIGIBLE FOR FUTURE SALE

 
157

TAXATION

 
159

UNDERWRITING

 
167

EXPENSES OF THE OFFERING

 
173

LEGAL MATTERS

 
174

EXPERTS

 
174

ENFORCEMENT OF CIVIL LIABILITIES

 
175

WHERE YOU CAN FIND MORE INFORMATION

 
176



        Unless otherwise indicated or the context otherwise requires, all references in this Prospectus to "Forward Pharma A/S" refer to Forward Pharma A/S, and all references to "Forward Pharma," the "Company," "we," "our," "ours," "us" or similar terms refer to Forward Pharma A/S or Forward

i


Table of Contents

Pharma A/S and its wholly owned subsidiaries, Forward Pharma GmbH and Forward Pharma USA, LLC, as the context may require.

        Through and including November 8, 2014 (25 days after the date of this Prospectus), all dealers that buy, sell or trade in the ADSs, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.



        We have not authorized anyone to provide any information or to make any representations other than that contained in this Prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the underwriters (i) have authorized any other person to provide you with different or additional information, or (ii) are making an offer to sell the ADSs in any state or other jurisdiction where the offer or sale is not permitted. This offering is being made in the United States and elsewhere solely on the basis of the information contained in this Prospectus. You should assume that the information appearing in this Prospectus is accurate only as of the date on the front cover of this Prospectus, regardless of the time of delivery of this Prospectus or any sale of the ADSs. Our business, financial condition, results of operations and prospects may have changed since the date on the front cover of this Prospectus.

ii


Table of Contents

 

 


PROSPECTUS SUMMARY

        This summary highlights information contained elsewhere in this Prospectus. This summary may not contain all the information that may be important to you, and we urge you to read this entire Prospectus carefully, including the "Risk Factors," "Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections and our consolidated financial statements, including the notes thereto, included in this Prospectus, before deciding to invest in our ADSs.

Our company

        Forward Pharma A/S is a Danish biopharmaceutical company preparing to initiate a Phase 3 clinical trial using FP187, a proprietary formulation of dimethyl fumarate, or DMF, for the treatment of multiple sclerosis, or MS, patients. Since our founding in 2005, we have worked to advance unique formulations of DMF, an immune modulator, as a therapeutic to improve the health and well-being of patients with immune disorders including MS. FP187, our clinical candidate, is a DMF formulation in a delayed and slow release oral dose, which we plan to advance for the treatment of relapsing remitting MS, or RRMS, and other immune disorders, such as psoriasis.

Our focus on Dimethyl Fumarate, or DMF

        Oral drugs employing DMF as an active pharmaceutical ingredient, or API, have been in use for over half a century. Today, DMF is the API found in Tecfidera®, which Biogen Idec Inc., or Biogen, began selling for the treatment of RRMS following approval by the U.S. Food and Drug Administration, or FDA, in March 2013 (and approval by the European Commission, or EC, in February 2014). Tecfidera®, which is an oral dose of 480 mg of DMF daily (240 mg twice daily), generated global sales from launch in April 2013 through June 30, 2014 of $2.08 billion. DMF is also an API found in Fumaderm®, which has been sold for the treatment of psoriasis since 1994 in Germany.

        In 2004, a private Swedish company Aditech Pharma AB (collectively with its successor-in-interest, a Swiss company Aditech Pharma AG, or Aditech), controlled by Nordic Biotech General Partner ApS (an affiliate of one of our largest shareholders), assessed the potential for DMF to become a significant global product. Aditech specifically focused on the development of an innovative delayed and slow release formulation of DMF, with the goal of limiting side effects typically associated with DMF treatment.

        We were founded in 2005 for the purpose of exploiting a patent family Aditech filed relating to, among other things, its delayed and slow release formulation for DMF, and in 2010 we acquired this patent family from Aditech. Under our agreements with Aditech, we obtained, among other things, Aditech's patents and associated know-how related to DMF formulations. For more, see "Related Party Transactions—Aditech Agreement."

        The patent family that we acquired from Aditech included an international patent application filed on October 7, 2005, disclosing, among other things, formulations of DMF that provide for its slow release in the small intestine, where we believe that DMF has its immunomodulatory impact. This international application became the basis for a family of national patent applications which were subsequently filed relating to DMF. Two European patents, one from the original Aditech patent family and one from a patent family of ours (involving erosion matrix formulations of DMF with a thin enteric coating) have been granted and both are now the subject of opposition proceedings (i.e., special proceedings heard by the European Patent Office, or EPO, where one or more third parties request that the patent, or a part thereof, be revoked) which have been instigated by multiple third parties. In the U.S. our Erosion Matrix Patent application has been allowed and we have pending patent applications that we believe will soon be allowed (i.e., will meet the statutory requirements of patentability), one of which claims particular up-titration schedules (e.g., increasing the dose over a

 

1


Table of Contents

specified number of weeks) of using DMF to treat MS, and the other of which claims treating MS using particular compositions containing DMF and that also specifies levels of a DMF metabolite called mono methyl fumarate, or MMF, in the bloodstream. These claims are substantially the same as the respective claims in two other applications that the U.S. Patent and Trademark Office, or USPTO, Examiner recently found allowable but which we elected to abandon (i.e., voluntarily requested to be irrevocably removed from the USPTO docket of active patent applications). In another of our patent applications, U.S. Patent Application No. 11/576,871, the USPTO Examiner has found our claims directed to methods of treating MS using a 480 mg dose of DMF to be allowable and has recommended that an interference be declared against Biogen's U.S. Patent No. 8,399,514 and a USPTO official has indicated that we will be designated as the so-called senior party. An interference is an administrative proceeding at the USPTO that is used to determine which party is the first to invent a common invention claimed by the parties. The party with the earliest effective filing date to the common invention is designated "senior party" and is entitled to the presumption that it is the first inventor. Once an interference has been suggested, a supervisory Examiner refers the suggested interference to the Patent Trial and Appeal Board, or PTAB. An administrative patent judge at the PTAB declares the interference and administers the proceeding. During the interference, each party can dispute the patentability of the other parties' claims, challenge the senior party designation and present proof of dates of invention prior to the effective filing date. In an initial motions phase, a three judge panel at the PTAB decides the patentability and senior party issues raised and, if that decision does not resolve the interference, then after priority proofs are submitted in a second priority phase, enters final judgment on priority (i.e., who is first to invent).

        On August 22, 2014, an administrative law judge at the PTAB returned our U.S. Application No. 11/576,871 to the patent examining group within the USPTO, or the Examining Group, in which our USPTO Examiner is assigned. Based on an earlier discussion with a USPTO official, we believe the return is to address formal matters. However, we do not know whether the return has any accompanying communication to the Examining Group and we cannot rule out the possibility that the return was made for substantive reasons, which may adversely affect, delay or prevent our planned interference proceeding. For more, see "Risk Factors—Risks Related to Intellectual Property."

        In order to assess FP187's safety profile for human use, we have performed 28 pre-clinical studies on DMF since 2006, gathering data through animal testing (and in certain cases in vitro testing of DMF in cells) on its pharmacological activity, toxicity profile, and on dosing level effects. All pre-clinical studies apply to both MS and psoriasis development. Beginning in 2007, we commenced a set of Phase 1 clinical trials followed by a Phase 2 clinical trial to investigate, among other things, safety and dosing tolerability of FP187. We have successfully completed all of these clinical studies, collectively involving over 300 psoriasis patients and healthy volunteers, and gathering substantial positive safety and dosing data. Importantly, as of the date hereof we have conducted no clinical trials involving patients with MS.

        To advance FP187 for use as a drug to treat RRMS in the U.S., we held a pre-Investigational New Drug, or IND, application meeting with the FDA in August 2013. Prior to this pre-IND meeting, we submitted a briefing book to the FDA, which included our high-level description of a proposed 48-week Phase 3 trial, which we expect will include up to 2,000 RRMS patients. We intend to compare FP187 to an active beta interferon, or IFNb, comparator drug. The primary efficacy endpoint for the proposed Phase 3 trial will be the Annualized Relapse Rate, or ARR. The key secondary efficacy endpoint will be the Sustained Accumulation of Disability, or SAD, based on repeated assessments of the Expanded Disability Status Scale, or EDSS. Further secondary endpoints are based on magnetic resonance imaging, or MRI, markers.

        EDSS has been recognized by the EMA as the most widely used and known scale to assess disability in RRMS patients. EDSS scores are measured periodically (generally in intervals of three to six months) based on a standard neurological examination of seven major functional systems and

 

2


Table of Contents

observations concerning gait and use of assistive devices. EDSS is reported using a scale ranging from 0 to 10 in 0.5 unit increments that each represent higher levels of disability. SAD is defined as a specified increase from baseline in EDSS that persists for at least 12 weeks.

        Consistent with our pre-IND meeting and submissions, we filed our IND for RRMS on April 30, 2014 and expect to be able to submit the protocol and draft Statistical Analysis Plan, or SAP, for our Phase 3 study in the fourth quarter of 2014.

        Following completion of our planned Phase 3 trial, we intend to submit our NDA for FP187 to treat RRMS. Approval by the FDA of a New Drug Application, or NDA, is dependent on a number of factors. A final decision as to whether the program we shared with the FDA in advance of our pre-IND meeting is sufficient for approval (including the sufficiency of our proposed single Phase 3 trial and whether a favorable effect on SAD or other secondary endpoints will need to be demonstrated by us at the time of our NDA submission) can only be made by the FDA once it has reviewed our full NDA package.

        We expect that patient enrollment for the Phase 3 trial we are contemplating will take at least 18 months, with completion of the final patient's initial 48-week treatment period after a total of 30 months. When the last patient dosed has completed the 48-week treatment period, we expect that we will have a substantial number of patients with two years of data, which we believe will allow us to complete an analysis of the effects of FP187 on SAD which can be provided to the FDA when we submit our NDA. As a result, we believe that any requirement by the FDA for data on EDSS/SAD will not delay a decision on whether to approve FP187 for the treatment of RRMS.

        We intend to submit our NDA for FP187 to treat RRMS under Section 505(b)(1) of the U.S. Federal Food, Drug, and Cosmetic Act, or FDC Act, based on pre-clinical and clinical data we have and will have developed and independently own. Section 505(b)(1) of the FDC Act prescribes how a product may be submitted for approval by the FDA as a new drug based on clinical trial data and other information independently developed and owned by the party making the NDA submission, or obtained from a third-party with a right of reference.

        In Europe, we have held preliminary discussions concerning marketing authorization for FP187 in moderate to severe psoriasis with the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, or BfArM) in Germany, and more recently in November 2013 held a scientific consultation on FP187 for the treatment of MS with the European Medicines Agency, or EMA. We expect to apply for a European Union, or EU, marketing authorization for FP187 to treat RRMS.

        We also intend to pursue the development of FP187 for the treatment of psoriasis, and expect to commence a Phase 3 clinical trial program for psoriasis, including the commencement of dosing of patients by early 2015.

History of DMF

        A German pharmacist discovered in the late 1950s that fumaric acid derivatives were useful for the treatment of psoriasis. Over the following years, various blends of fumaric acid derivatives, including DMF, were tested and used in different doses throughout Germany and, later, in other parts of Europe. Pharmacies in Germany often made their own compounded versions for the treatment of psoriasis.

        In 1994, Fumapharm AG (acquired by Biogen in 2006) received approval in Germany to market Fumaderm®, which contains DMF and three ethyl fumarate salts, for the treatment of psoriasis. DMF is also the API in Biogen's Tecfidera®. Fumaderm® has not been approved outside of Germany, but it is nonetheless available throughout Europe as a prescription drug sourced from German pharmacies.

 

3


Table of Contents

Tecfidera® is sold in both the U.S. and Europe. We estimate that there have been well over 150,000 patient years of exposure to drugs containing DMF.

Our intellectual property

        We divide our intellectual property portfolios primarily into two basic patent families, which we refer to as our "Core Composition Patent" family and our "Erosion Matrix Patent" family. Our Core Composition Patent family, based on international application PCT/DK2005/000648, filed by Aditech in 2005, discloses, we believe, among other things, a broad range of controlled release pharmaceutical compositions of DMF, including the use of a dose of about 480 mg of DMF per day to treat MS. Our Erosion Matrix Patent family, based on international application PCT/EP2010/050172, filed in 2010, covers our delayed and slow release formulations of DMF in FP187, as used in the set of Phase 1 clinical trials and Phase 2 clinical trial mentioned above.

Core Composition Patent Family

        A patent from our Core Composition Patent family, EP2316430, has been granted by the EPO. EP2316430 covers DMF formulations with certain in vitro dissolution profiles. In the U.S., we have pending patent applications that we believe will soon be allowed.

        Pending U.S. Application No. 14/213,399 claims the use of delayed release formulations of DMF to treat MS according to an up-titration schedule (e.g., increasing the relevant dose over a specified number of weeks) that reaches a total daily dose of 480 mg. Pending U.S. Application No. 14/212,503 claims a method of treating an MS subject with 480 mg of DMF per day, using delayed release formulations containing from 120 mg to 240 mg of DMF which, following administration, result in certain levels of MMF in the bloodstream. These claims are substantially the same as the respective claims in two other applications that the U.S. Patent and Trademark Office, or USPTO, Examiner recently found allowable (U.S. Application Nos. 13/957,117 and 13/957,220) but which we elected to abandon (i.e., voluntarily requested to be irrevocably removed from the USPTO docket of active patent applications).

        Two third-party pre-issuance submissions were filed with the USPTO, questioning the patentability of the claims in each of the two U.S. patent applications from our Core Composition Patent family that had been allowed but were subsequently abandoned by us. We believed that these third-party submissions were defective. It is possible that similar third-party pre-issuance submissions may also be filed if our currently pending patent applications (having substantially the same claims as our earlier allowed but now abandoned applications) are allowed.

        We were recently informed by the USPTO Examiner that she believes the claims in another of our patent applications in the Core Composition Patent family, U.S. Application No. 11/576,871, to be allowable and in consultation with her supervisor and a patent interference specialist, has recommended that an interference be declared against Biogen's U.S. Patent No. 8,399,514, whose claims also cover a method of treating MS using about a 480 mg daily dose of DMF, and a USPTO official has indicated that we will be designated as the so-called senior party.

        The USPTO website indicates that the Examiner has prepared a memorandum in support of an interference, which will be reviewed by an administrative patent judge. Such interference, if declared, will give us the opportunity to prove to the USPTO that we were the first to invent the method of treating MS using about a 480 mg daily dose of DMF.

        On August 22, 2014, an administrative law judge at the PTAB returned our U.S. Application No. 11/576,871 to the Examining Group. Based on an earlier discussion with a USPTO official, we believe the return is to address formal matters. However, we do not know whether the return has any accompanying communication to the Examining Group and we cannot rule out the possibility that the

 

4


Table of Contents

return was made for substantive reasons, which may adversely affect, delay or prevent our planned interference proceeding. For more, see "Risk Factors—Risks Related to Intellectual Property."

        Multiple third parties, including Biogen, are opposing our patent EP2316430 (covering DMF formulations) before the European Patent Office, or EPO. In view of the publication of WO2006/037342, the international application in the Core Composition Patent Family, on April 13, 2006, prior to Biogen's February 8, 2007 priority date for its EP2137537 B1 patent, we (along with multiple other parties) have filed an opposition against that patent which has claims directed to the use of the 480 mg daily dose of DMF to treat MS.

Erosion Matrix Patent family

        A patent from our Erosion Matrix Patent family, EP2379063 (covering matrix formulations with a thin enteric coating), has been granted by the EPO. Multiple third parties, including Biogen, are opposing this patent before the EPO. The U.S. counterpart, U.S. Application No. 13/143,498, was allowed by the USPTO but withdrawn from allowance to permit the USPTO Examiner to consider the opposition papers in EP2379063. On July 11, 2014, the USPTO has again allowed the application following its review of the European oppositions.

Other patent families

        Beyond our Core Composition Patent and Erosion Matrix Patent families, our other patent families include PCT/EP2013/066285, PCT/EP2014/068094 (not yet published) and PCT/EP2014/068095 (not yet published), mainly directed to dosing regimens of DMF. We believe that our overall patent portfolio, if matured, should position FP187 competitively in the key markets of the U.S. and the EU.

Our business strategy

        We have focused on DMF's potential as an immune-modulating drug to improve the health and well-being of patients with immune disorders for approximately the past 10 years, during which time we have assembled and continue to develop our intellectual property portfolio and regulatory strategy. We believe our intellectual property portfolio, combined with the clinical data we have and will have independently obtained and the discussions we have had with the FDA, BfArM and EMA, provide us with the opportunity to pursue the development of FP187 for the treatment of RRMS in the U.S. and the EU. We intend to use the net proceeds from this offering to, among other things, pursue a Phase 3 clinical trial of FP187 for the treatment of RRMS which we believe, if successful, would (in combination with other data on FP187 we have and are obtaining) allow us to submit an NDA in the U.S. and a separate marketing authorization application in the EU for FP187 to treat RRMS. We intend to also pursue the development of FP187 for the treatment of psoriasis, including commencing a Phase 3 clinical trial program by early 2015. In addition, we intend to use part of the net proceeds from this offering to commence the remaining studies in our pre-clinical program.

        Components of our business strategy include:

    Successfully develop FP187 for the treatment of Relapsing Remitting Multiple Sclerosis.  We plan to pursue approval from the FDA and the EC of FP187 for the treatment of RRMS. We believe that, if approved, FP187 could become an important therapeutic in the multi-billion dollar MS drug market.

    Successfully develop FP187 for the treatment of psoriasis.  We plan to pursue FP187 for the treatment of psoriasis. We believe that, if approved, FP187 could become a compelling treatment option for patients with psoriasis.

    Exploit and defend our intellectual property rights.  We believe our patents and patent applications related to, among other things, our proprietary formulation technology, combined

 

5


Table of Contents

      with our patents and patent applications claiming dosing levels of DMF, are critical assets of our company. We intend to exploit our intellectual property by continuing to pursue our patent applications, and to defend our patent rights as we deem necessary for our business.

    Obtain marketing exclusivity in the U.S. and the EU for FP187.  In addition to patent protection, if and when an NDA is approved, we will be eligible for up to three and one-half years of marketing exclusivity against generic versions of FP187 in the U.S. In the EU, we will be entitled to up to 11 years of exclusivity from the first date of authorization in the EU.

    Potentially partner FP187 with third parties.  We may opportunistically seek commercial partners for FP187 to offset risk and preserve capital, if appropriate, although we intend to retain key development and commercialization rights. We believe retaining this strategic flexibility will help us to maximize shareholder value.

    Continue to explore, and potentially develop, FP187 and other DMF-related formulations for the treatment of other immune disorders.  We intend to continue to explore and potentially develop FP187 and other DMF-related formulations for the treatment of other immune disorder indications, if we determine that such development could be commercially viable.

Mode of action of DMF and our proprietary formulation

Mode of action

        While the exact mode of action of DMF is not fully understood, we believe that some of its therapeutic effects are mediated via modulation of the immune system. From studying scientific literature on immune cells in vitro and Company-sponsored research, we believe that DMF can rapidly form adducts by combining with the antioxidant molecule glutathione, or GSH, leading to the functional depletion of GSH, followed by the modulation of various cellular pathways. We believe that one important downstream event of intracellular GSH depletion is the increased expression of the anti-inflammatory stress protein HO-1, with subsequent induction of type II dendritic cells leading to a reduction of inflammatory responses. We also believe that the depletion of GSH can induce apoptosis or cell death in different cell types including activated T cells, reducing inflammatory responses. Other pre-clinical data, we believe, have indicated that DMF can also protect cells, including neuronal cells, against oxidative stress.

        In animal models, described in scientific literature and from Company-sponsored research, GSH/DMF adducts have been found in the gastrointestinal, or GI, mucosa and in the portal vein blood, but not in organs like the heart, brain and liver, which suggests to us that the clinical effects of DMF may be mediated at least in part by DMF exerting its action within the tissues in the intestine or pre-systemic circulation. Such a mode of action of DMF is also supported, we believe, by the fact that DMF has not been directly detected in the bloodstream.

        Some proportion of DMF is thought by us to be metabolized by esterases (enzymes ubiquitous in the GI tract) to produce MMF. In contrast to DMF, MMF can be measured in the bloodstream, but the extent to which it may contribute to clinical efficacy is currently unclear to us. However, recent pre-clinical research suggests to us that sudden plasma peaks of MMF may contribute to the side effect of flushing via interaction with nicotinic acid receptors. Flushing is the visible reddening of the skin and is often accompanied by a sensation of heat and prickling or itching of the skin.

Formulation and clinical profile of FP187

        Our proprietary DMF formulation, FP187, employs two strategies which we believe improve the release of DMF by reducing the peaks of MMF in the bloodstream while maintaining overall DMF exposure levels, which, in turn, may control DMF's side effects. FP187 uses an enteric coating material, which forms a polymeric barrier around each DMF-containing core tablet for the purpose of inhibiting

 

6


Table of Contents

the release of DMF in the stomach and allowing for release in the small intestine. Due to the enteric coating, the FP187 tablet remains intact in acid conditions like those found in the stomach but dissolves in a less acidic environment like the one found in the small intestine. The enteric coating employed by FP187 is thinner than the coating used by the other DMF products, which we believe results in the earlier onset of release of DMF in the small intestine. In addition, the DMF in FP187 is embedded in a slow eroding interior structure, which we call our erosion matrix formulation, resulting in what we believe to be a slower release of DMF in the small intestine after the enteric coating has dissolved.

        We believe that all currently available products containing DMF have an enteric coat that controls and inhibits the undesired release of DMF in the stomach and permits the release only in the more neutral environment of the small intestine. Once the enteric coat is dissolved in the small intestine, DMF-containing products such as Tecfidera® or Fumaderm® that are formulated with an immediate release technology and not an erosion matrix formulation or other rate-controlling release technology may result in DMF being released in a more concentrated and immediate burst. We believe that the slow rate of release of DMF permitted by FP187's erosion matrix formulation greatly reduces, or may even eliminate, the peaks of MMF in the bloodstream observed with formulations in which the DMF is not incorporated into a rate-controlling release formulation, while ensuring that a therapeutically effective dose of DMF is administered, potentially producing fewer and less severe flushing episodes. In addition, we believe that the rate-controlled release of DMF from the erosion matrix formulation, together with the earlier start of release in the small intestine, may allow absorption of DMF over a larger area of GI mucosa, potentially leading to lower local GI concentrations and therefore, we believe, potentially less severe GI-specific side effects.

        In the clinical trials we performed with FP187, flushing, GI complaints (primarily diarrhea and abdominal pain) and changes in white blood cell counts occurred. All of these side effects resolved or the white blood cell counts returned to their pre-treatment values during the treatment period (without any change in the treatment regime) or during the follow up period or were deemed to not be clinically relevant at the end of the study. Despite the white blood cell count changes, no increase in infections was observed. In our Phase 2 study of FP187, seven Serious Adverse Events, or SAEs, were reported. Five cases were classified by the investigator as being unrelated to the use of FP187, while two cases were judged by the investigator as being possibly related to the use of FP187. One patient was hospitalized with severe GI pain but was discharged the next day, after receiving intravenous fluid overnight, and continued on with the study until its conclusion without further complaints. The second patient had a transient ischemic attack, or TIA. This patient had hypertension prior to participating in the trial and a family history for cardiovascular diseases. Based on our review of the German spontaneous reporting system (a database maintained by BfArM for drug-related Adverse Events, or AEs) covering an estimated patient exposure for Fumaderm® of more than 150,000 patient years, and the recent FDA approval of Tecfidera® in the U.S., we do not believe there is any evidence of an increased risk for cardiovascular related AEs.

Risks associated with our business

        We are a late clinical-stage biopharmaceutical company, and our business is subject to a number of risks of which you should be aware before making an investment decision. These risks, which are discussed more fully in the "Risk Factors" section of this Prospectus, include:

    We have no products approved for commercial sale, and we have not received regulatory approval for, nor have we generated commercial revenue from, our sole clinical candidate, FP187.

    FP187 is in pre-clinical and clinical development, and clinical trials of FP187 and other studies required for marketing approvals may not be successful. Our planned clinical trials may not be considered sufficient to support marketing authorization appropriately. If we are unable to

 

7


Table of Contents

      obtain marketing approvals for, or successfully commercialize, FP187, our ability to generate revenue will be materially impaired.

    The occurrence of SAEs in patients using FP187, either during our clinical program or after regulatory approval, may pose a risk to our ability to obtain regulatory approval or continue to market FP187, if ultimately approved for sale, which would have a material adverse effect on our business. To date, none of the seven SAEs that have occurred in connection with our clinical program have required a change in protocol treatment or monitoring of patients. Five of the SAE cases were classified by the investigator as being unrelated to the use of FP187, and two cases (one involving severe GI pain and one involving a TIA) were judged by the investigator as being possibly related to the use of FP187.

    Completion of required clinical trials may take longer than we anticipate, which could result in increased costs, limit our access to funding and delay or limit our ability to obtain regulatory approval for FP187. FP187 may not receive the regulatory approvals we plan to seek in a timely manner, or at all.

    We may be unable to obtain, maintain, and exploit the protection of our intellectual property assets, which could harm our ability to compete and impair our business.

    FP187 is still under development and, if we pursue versions of FP187 that are modified from those used in our set of Phase 1 clinical trials and Phase 2 clinical trial, such modified FP187 products may be considered outside the scope of our patent families.

    We could be involved in costly litigation or other legal proceedings with respect to our intellectual property.

    Ownership of our patents or patent applications may be challenged by third parties.

    Third-party patents, or pending or future patent applications, if issued, including those of Biogen, may have an adverse effect on our business.

    The audit opinion and notes that accompany our consolidated financial statements disclose a "going concern" qualification to our ability to continue in business. Our ability to continue as a going concern is dependent on our ability to raise additional capital to fund the advancement of FP187, and if we are unable to successfully raise sufficient additional capital, through future equity or debt financings or through strategic and collaborative ventures with third parties, we will not have sufficient cash flows and liquidity to fund our planned business operations.

    We will require substantial additional funding beyond the net proceeds from this offering to continue and complete the development and commercialization of FP187 and/or exploit or defend our intellectual property.

    We have a history of operating losses and anticipate that we will continue to incur losses for the foreseeable future. As of December 31, 2013, we had an accumulated deficit of $51.9 million.

    Should we raise additional funds through the sale of equity or convertible debt securities, such funding may cause substantial dilution to our shareholders.

    We have not commercialized FP187 and, even if approved, it may not be reimbursed by governmental authorities, health insurers and other third-party payors at acceptable levels.

Implications of being an emerging growth company

        We qualify as an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced

 

8


Table of Contents

reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include:

    the ability to include only two years of audited financial statements and only two years of related management's discussion and analysis of financial condition and results of operations disclosure;

    an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; and

    the ability to provide less disclosure on compensation than is required otherwise under the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.

        We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.0 billion in annual revenue, have more than $700 million in market value of our equity securities held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a three-year period.

Corporate information

        We are a Danish public limited liability company. Our principal executive offices are located at Østergade 24A, 1, 1100 Copenhagen K, Denmark. Our telephone number at this address is +45 33 44 42 42.

        Our website address is www.forward-pharma.com. We do not incorporate the information on, or accessible through, our website into this Prospectus, and any information on, or accessible through, our website is not part of this Prospectus.

        Investors should contact us for any inquiries at the address and telephone number of our principal executive offices.

 

9


Table of Contents

 

 


THE OFFERING

ADSs offered by us   10,500,000 ADSs, representing 10,500,000 ordinary shares.

Ordinary shares to be outstanding immediately after this offering

 

45,813,760 ordinary shares.

Over-allotment option

 

We have granted the underwriters the right to purchase up to an additional 1,575,000 ADSs from us within 30 days of the date of this Prospectus, to cover over-allotments, if any, in connection with the offering.

American Depositary Shares

 

Each ADS will represent one ordinary share, nominal value DKK 0.10 per share. You will have the rights of an ADS holder as provided in the deposit agreement among us, the depositary and holders and beneficial owners of ADSs from time to time. To better understand the terms of the ADSs, you should carefully read the section in this Prospectus entitled "Description of American Depositary Shares." We also encourage you to read the deposit agreement, which is filed as an exhibit to the registration statement that includes this Prospectus.

Depositary

 

The Bank of New York Mellon

Share Loan

 

To facilitate the orderly closing of this offering of ADSs, the shares underlying the ADSs immediately prior to and concurrent with the consummation of the offering and the time of delivery of the ADSs will be shares (referred to as the Borrowed Shares) loaned by Nordic Biotech Opportunity Fund K/S to the Company under the terms of a Stock Lending Agreement. In connection with the consummation of the offering and at or promptly after the delivery of the ADSs, newly issued ordinary shares of equal number of the Company will be exchanged for the Borrowed Shares held by the Depositary of the American Depositary Receipt Program and the Borrowed Shares underlying the ADSs will be returned to Nordic Biotech Opportunity Fund K/S. See "Related Party Transactions—Stock Lending Agreement".

Use of proceeds

 

We estimate that the net proceeds to us from the offering will be approximately $198.8 million, or approximately $229.6 million if the underwriters' over-allotment option is exercised in full, based on the initial public offering price of $21.00 per ADS, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We currently expect that we will use the net proceeds from this offering, together with a fully drawn down €8.4 million principal amount bridge financing we entered into on May 30, 2014 with NB FP Investment II K/S, a fully drawn down $10 million principal amount bridge financing we entered into on August 6, 2014 with BVF Forward Pharma L.P. (an affiliate of BVF Partners LP, which is itself affiliated with certain of our principal shareholders), and our cash and cash equivalents on hand, as follows:

 

10


Table of Contents

 

approximately $80.0 million for the clinical development of FP187 for the treatment of RRMS;

 

approximately $25.0 million to fund the exploitation and protection of our intellectual property rights (including in connection with oppositions and interference cases);

 

approximately $22.0 million for the clinical development of FP187 for the treatment of psoriasis;

 

approximately $12.0 million for execution of our pre-clinical program, for our manufacturing activities, and for related Phase 1 clinical trials; and

 

the remainder for working capital and other general corporate purposes. See "Use of Proceeds."


Dividend policy

 

We have never paid or declared any cash dividends on our shares, and we do not anticipate paying any cash dividends on our shares in the foreseeable future.

Risk factors

 

See "Risk Factors" and the other information included in this Prospectus for a discussion of factors you should carefully consider before deciding to invest in the ADSs.

Listing

 

Our ADSs have been approved for listing on the Nasdaq Global Select Market, or NASDAQ, under the symbol "FWP."

        The number of our ordinary shares to be outstanding immediately after this offering is based on 1,736,540 of our Class A shares and 56,851 Class B shares outstanding as of June 30, 2014 and the initial public offering price of $21.00 per ADS and assumes:

    the issuance of 7,590 Class A shares to Morten Priskorn on July 3, 2014 by way of exercise of 7,590 warrants at a subscription price of DKK 70.06 per share;

    the automatic conversion of all of our Class A shares and Class B shares into an aggregate of 1,915,290 ordinary shares of DKK 1 prior to the consummation of this offering, as well as the other transactions contemplated, pursuant to our Framework Agreement, including the issuance of bonus shares to our Class B shareholders, as described under "Related Party Transactions—Framework Agreement," which we refer to as the Share Conversion (after which we will only have one class of shares, termed ordinary shares);

    the conversion of €8.4 million principal plus accrued interest under our bridge financing dated May 30, 2014, for which we have drawn down the entire principal amount available thereunder, into 33,782 ordinary shares of DKK 1, based on a 15% discount to the public offering price, which we refer to as the EUR Bridge Conversion;

    the conversion of $10.0 million principal plus accrued interest under our bridge financing dated August 6, 2014, for which we have drawn down the entire principal amount available thereunder, into 31,764 ordinary shares of DKK 1, based on a 15% discount to the public offering price, which we refer to as the USD Bridge Conversion and, together with the EUR Bridge Conversion, we refer to as the Bridge Conversions;

    the issuance of 1,550,540 ordinary shares of DKK 1 in the form of bonus shares to all existing shareholders including our bridge lenders, which we refer to as the Bonus Share Issuance;

 

11


Table of Contents

    no issuance of shares pursuant to a deferred share award granted to our Chief Financial Officer Joel Sendek on August 12, 2014 allowing for the subscription of 31,895 Class A shares, which was converted into a deferred share award allowing for the subscription of 56,861 ordinary shares of DKK 1 in connection with the Share Conversion and the Bonus Share Issuance;

    no issuance of shares pursuant to non-qualified stock options granted upon the consummation of this offering allowing for the subscription of 26,384 Class A shares, which were converted into non-qualified stock options allowing for the subscription of 47,038 ordinary shares of DKK 1, at an exercise price equal to the price per share in this offering, in connection with the Share Conversion and the Bonus Share Issuance;

    no exercise of warrants held by warrant holders allowing for the subscription for an aggregate of 131,052 Class A shares outstanding as of June 30, 2014, which were converted into warrants to subscribe for an aggregate of 229,383 ordinary shares of DKK 1, at a weighted average exercise price of approximately $15.10 per share, in connection with the Share Conversion and the Bonus Share Issuance;

    no exercise of warrants issued subsequent to June 30, 2014, held by warrant holders allowing for the subscription of an aggregate of 5,000 Class A shares, which were converted into warrants to subscribe for an aggregate of 8,914 ordinary shares of DKK 1, at a weighted average price of approximately $110.64 per share, in connection with the Share Conversion and the Bonus Share Issuance;

    the split of our ordinary shares, including all ordinary shares referred to above, to the effect that one share of DKK 1 was split into 10 shares of DKK 0.10 each, which we refer to as the Share Split; and

    no exercise of the option granted to the underwriters to purchase up to 1,575,000 additional ADSs to cover over-allotments, if any, in connection with this offering.

        As part of this offering, we have received commitments in the form of proxies and undertakings from all of our shareholders to complete the corporate steps required to convert all outstanding Class A and Class B shares into ordinary shares and complete the other contemplated transactions described above prior to completion of the offering.

 

12


Table of Contents

 

 


SUMMARY FINANCIAL INFORMATION

        The summary statement of profit or loss and statement of financial position for the years ended and as of December 31, 2013 and 2012 of Forward Pharma A/S are derived from the audited consolidated financial statements as of December 31, 2013 and 2012 and January 1, 2012 and for each of the two years in the period ended December 31, 2013 included in this Prospectus. The summary unaudited consolidated statement of profit or loss and unaudited consolidated statement of financial position for the six month periods ended June 30, 2014 and 2013 and as of June 30, 2014 of Forward Pharma A/S are derived from the unaudited condensed consolidated interim financial statements as of June 30, 2014 and for each of the six month periods ended June 30, 2014 and 2013 included in this Prospectus. We have prepared our consolidated financial statements in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or the IASB. The historical results set forth below are not necessarily indicative of the results expected in future periods.

        This summary financial information should be read in conjunction with "Presentation of Financial and Other Information," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements, including the notes thereto, included in this Prospectus.

Consolidated statement of profit or loss data

 
  Year ended
December 31,
(Audited)
  Six months ended
June 30,
(Unaudited)
 
(USD in thousands, except share and per share data)
  2013   2012   2014   2013  

Research and development costs

    (8,018 )   (4,445 )   (4,821 )   (2,982 )

General and administrative costs

    (1,014 )   (928 )   (2,618 )   (385 )
                   

Operating loss

    (9,032 )   (5,373 )   (7,439 )   (3,367 )
                   

Fair value adjustment to net settlement obligations to shareholder warrants

    (6,676 )   (17,071 )   (1,005 )   2,084  

Other finance costs

    (84 )   (35 )   (108 )   (12 )
                   

Net loss before tax

    (15,792 )   (22,479 )   (8,552 )   (1,295 )
                   

Income tax

    96     0     57     87  
                   

Net loss for the period

    (15,696 )   (22,479 )   (8,495 )   (1,208 )
                   
                   

Historical net loss per share

                         

Basic

    (9.53 )   (14.25 )   (4.91 )   (0.75 )

Diluted

    (9.53 )   (14.25 )   (4.91 )   (1.88 )

Weighted-average shares outstanding used to calculate net loss per share

                         

Basic

    1,599,000     1,577,000     1,678,000     1,599,000  

Diluted

    1,599,000     1,577,000     1,678,000     1,737,000  

Historical as adjusted net loss per share (unaudited)(1)

                         

Basic

    (0.95 )   (1.43 )   (0.49 )   (0.07 )

Diluted

    (0.95 )   (1.43 )   (0.49 )   (0.19 )

Historical as adjusted weighted-average shares outstanding used to calculate historical as adjusted net loss per share (unaudited)

                         

Basic

    15,990,000     15,770,000     16,780,000     15,990,000  

Diluted

    15,990,000     15,770,000     16,780,000     17,370,000  

(1)
The historical as adjusted net loss per share amounts and the historical as adjusted weighted-average shares outstanding have been computed to retroactively reflect the Share Split for all periods presented. The historical as adjusted share and per share amounts exclude the effect of the Bonus Share Issuance.

 

13


Table of Contents

Consolidated statement of financial position data

 
  As of
December 31,
(Audited)
  As of
June 30,
(Unaudited)
 
(USD in thousands)
  2013   2012   2014  

Cash and cash equivalents

    2,955     828     244  

Adjusted working capital (deficit)(1)

    2,317     213     (1,814 )

Total assets

    3,599     970     2,901  

Long-term debt, including current portion

    2,613     2,100     0  

Accumulated (deficit)

    (51,913 )   (36,796 )   (58,889 )

Total shareholders' deficit

    (26,415 )   (20,250 )   (1,810 )

(1)
We define adjusted working capital as current assets minus trade and other payables. We use adjusted working capital to, among other things, evaluate our short-term liquidity requirements. We find adjusted working capital a useful metric in evaluating our short-term liquidity requirements because it eliminates the non cash impact of shareholder warrants.


Adjusted working capital is not an IFRS measure, and our definition may vary from that used by others in our industry. Accordingly, our use of adjusted working capital has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our financial position as reported under IFRS.

 

14


Table of Contents


RISK FACTORS

        You should carefully consider the risks and uncertainties described below and the other information in this Prospectus before making an investment in the ADSs. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our ordinary shares and the ADSs could decline and you could lose all or part of your investment. This Prospectus also contains forward-looking statements that involve risks and uncertainties. See "Cautionary Statement Regarding Forward-Looking Statements." Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors.

Risks Related to Our Business and Industry

We are a clinical-stage company with no approved products and no historical product revenues, which makes it difficult to assess our future prospects and financial results.

        We are a biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of uncertainty. Our operations to date have been limited to developing our formulation technology and undertaking pre-clinical studies and clinical trials of our proposed drug candidate FP187. As an early stage company, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. Consequently, the ability to accurately assess our future operating results or business prospects is more limited than if we had a longer operating history or approved products on the market. Accordingly, the likelihood of our success must be evaluated in light of many potential challenges and variables associated with an early-stage drug development company, many of which are outside our control, and the occurrence of any setbacks could adversely affect our business and prospects.

We depend entirely on the success of our only clinical candidate, FP187. We cannot give any assurance that this clinical candidate will successfully complete clinical trials or receive regulatory approval, which is necessary before it can be commercialized.

        We have invested almost all of our efforts and financial resources in the development of FP187. As a result, our business and future success is almost entirely dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize FP187, which has completed Phase 1 testing in healthy volunteers for release characteristics and tolerability, as well as a Phase 2 trial in moderate to severe psoriasis patients, and is being prepared for Phase 3 trials for RRMS and psoriasis. FP187 will require additional pre-clinical and clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions (if regulatory approval can be obtained at all), securing sources of commercial manufacturing supply, building of or partnering with a commercial organization, and substantial investment and significant marketing efforts before any revenues can be generated from product sales. We are not permitted to market or promote FP187 before we receive regulatory approval from the FDA, the EC or other foreign regulatory authorities, and we may never receive such regulatory approval for FP187. We cannot assure you that our clinical trials for FP187 will be completed in a timely manner, or at all, or that we will be able to obtain marketing approvals or labeling from the FDA, the EC or other foreign regulatory authorities necessary or desirable for the successful commercialization of FP187. If FP187 or any future product candidate is not approved and commercialized, we will not be able to generate any product revenues, which would materially affect our business, financial condition and result of operations. Moreover, any delay or setback in the development of any product candidate could adversely affect our business and prospects.

15


Table of Contents

Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel.

        Our success depends upon the continued contributions of our management, scientific and technical personnel, many of whom have substantial experience with or been instrumental for us and our development of FP187. These individuals currently include the members of our board of directors consisting of our Chairman, Florian Schönharting, as well as J. Kevin Buchi, Torsten Goesch, and Jan G. J. van de Winkel, and our Chief Executive Officer and Chief Operating Officer, Peder Møller Andersen, our Chief Financial Officer, Joel Sendek, and our Vice President, Finance and Controller, Thomas Carbone. Our senior scientific advisors include Dr. Kristian Reich, Dr. Ulrich Mrowietz, Dr. Fred D. Lublin, Dr. Per Soelberg Sørensen, Dr. Giancarlo Comi and Dr. Jerry S. Wolinsky.

        The loss of managers and senior scientific advisors could materially delay our research and development activities and could have a material adverse effect on our business. In addition, the competition for qualified personnel in the biopharmaceutical field is intense, and our future success may depend upon our ability to attract, retain and motivate highly-skilled scientific, technical and managerial employees and consultants. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful, it may be difficult for us to implement our business strategy, which could have a material adverse effect on our business.

We expect to expand our drug development, regulatory and business development capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

        We expect to experience significant growth in the number of our employees and consultants and the scope of our operations, particularly in the areas of drug development, regulatory affairs and business development. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations, and have a materially adverse effect on our business.

Our information technology systems could face serious disruptions that could adversely affect our business.

        Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions in our collaborations with our partners and delays in our research and development work.

Risks Related to Intellectual Property

We rely on patents and other intellectual property rights to protect our rights with respect to the development and commercialization of FP187 and other product candidates, the attainment, defense and maintenance of which may be challenging and costly. Failure to obtain, defend or maintain these rights adequately could materially adversely impact our ability to compete and impair our business.

        Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for FP187, as well as on the defense and exploitation of such rights. Failure

16


Table of Contents

to protect or to obtain, maintain or extend adequate patent and other intellectual property rights could materially adversely impact our competitive advantage and impair our business.

        Our patent portfolio consists primarily of two basic patent families, our "Core Composition Patent" family and our "Erosion Matrix Patent" family, along with three other patent families. We do not have any issued patents in the U.S. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. We have two granted patents in Europe: EP2316430, which covers DMF formulations with certain in vitro dissolution profiles, and EP2379063, which covers erosion matrix formulations with a thin enteric coating. Our other patent families include pending applications PCT/EP2013/066285, PCT/EP2014/068094 and PCT/EP2014/068095 directed, among other things, to dosing regimens of DMF.

        Both of our European patents have been opposed by third parties before the EPO. Multiple parties, including Biogen, are opposing before the EPO our patents EP2316430 and EP2379063. The EPO may determine that one or more, possibly all, of our claims are invalid and/or may require us to narrow the scope of the claims to avoid a finding of invalidity. Narrowing the scope of the claims may result in FP187 being outside the scope of such claims.

        Moreover, our other pending applications may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, and the EPO and/or any patents issuing thereon may become involved in opposition, derivation, reexamination, inter partes review, post grant review, interference proceedings or other patent office proceedings or litigation, in the United States or elsewhere, challenging our patent rights. Such third-party pre-issuance submissions were filed with the USPTO, questioning each of the two U.S. patent applications from our Core Composition Patent family that had been allowed but have since been abandoned by us. It is possible that similar third party preissuance submissions may also be filed if our currently pending patent applications (having substantially the same claims as our earlier allowed but now abandoned applications) are allowed. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, and allow third parties to commercialize our technology or products and compete directly with us, without payment to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to exploit our intellectual property or develop or commercialize current or future product candidates.

        The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S., the EU and elsewhere. Such challenges may result in loss of ownership or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit the duration of the patent protection of our technology and products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

        In addition, other companies may attempt to circumvent any regulatory data protection or market exclusivity that we obtain under applicable legislation, which may require us to allocate significant resources to preventing such circumvention. Such developments could enable other companies to circumvent our intellectual property rights and use our clinical trial data to obtain marketing authorizations in the EU and in other jurisdictions. Such developments may also require us to allocate significant resources to prevent other companies from circumventing or violating our intellectual property rights.

17


Table of Contents

        Our attempts to prevent third parties from circumventing our intellectual property and other rights may ultimately be unsuccessful. We may also fail to take the required actions or pay the necessary fees to maintain our patents.

Intellectual property rights of third parties could adversely affect our ability to commercialize FP187, such that we could be required to litigate with or obtain licenses from third parties in order to develop or market FP187. Such litigation or licenses could be costly or not available on commercially reasonable terms.

        Our commercial success depends upon our ability and the ability of our potential collaborators to develop, manufacture, market and sell FP187 or other product candidates without infringing valid intellectual property rights of third parties. If a third-party intellectual property right exists that covers the composition of FP187 or the uses and dosages that the regulatory authorities approve for FP187, we may not be in a position to commercialize FP187 unless we successfully pursue litigation or administrative proceedings to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, which may not be available on commercially reasonable terms, if at all.

        It is possible that we are unaware of all patents or applications relevant to the manufacture, use or commercialization of FP187. For example, we have not conducted a recent freedom to operate search in connection with FP187 and its use to treat MS. Any freedom to operate search previously conducted may not have uncovered all relevant patents and patent applications, and there may be pending or future patent applications that, if issued, would block us from commercializing FP187. For example, U.S. applications filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States (filed November 29, 2000 or later) and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering FP187 or its use to treat MS could have been filed by others without our knowledge. In addition, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover FP187 or the use of FP187. As a result, we do not know whether the manufacture, use, or commercialization of FP187 or any of our other product candidates will infringe any third-party patents with valid claims that have been or will in the future be issued.

        Third-party intellectual property right holders, including our competitors, may actively bring infringement claims against us. We may not be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims or otherwise resolve such claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from, or experience substantial delays in, marketing our product candidates.

        If we fail to settle or otherwise resolve any such dispute, in addition to being forced to pay damages, we or our potential collaborators may be prohibited from commercializing FP187 or other product candidates we may develop that are held to be infringing, for the duration of the patent term. We might, if possible, also be forced to redesign our formulations so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.

18


Table of Contents

There can be no assurances that an interference proceeding involving Biogen's U.S. Patent No. 8,399,514 will be declared by the USPTO in the near term or at all, and even if declared, there can be no assurance that any interference proceeding will ultimately result in judgment against Biogen and its patent claims cancelled. In addition, there can be no assurance that claims substantially similar to those in our U.S. Application No. 11/576,871 will ever issue in a patent.

        An interference is a proceeding within the USPTO to determine priority of invention of the subject matter of patent claims. The decision to declare an interference is solely within the power of the Patent Trial and Appeal Board, or PTAB, and can be made only after claims in a patent application are deemed allowable by the examiner but for the interfering subject matter (in this case U.S. Patent No. 8,399,514 issued to Biogen) and a determination is made that interfering subject matter exists.

        An interference initial memorandum is prepared by an examiner when the examiner believes that at least one pending claim is allowable but for the interfering subject matter (in this case Biogen's issued patent, referenced above) and an interference is appropriate. The interference initial memorandum is forwarded to the PTAB, to determine whether an interference should be declared. If an interference is declared, the PTAB will issue a declaration of interference within a matter of months or, possibly, years from the date of the initial interference memorandum. The declaration of interference initiates an adversarial proceeding in the USPTO before the PTAB. That proceeding would involve issues including but not limited to, whether an interference proceeding is appropriate, whether the involved claims of the parties are patentable and which party was first to invent any interfering subject matter. Although our USPTO examiner has recommended that an interference proceeding be declared between our U.S. Application No. 11/576,871 and Biogen's U.S. Patent No. 8,399,514, we cannot estimate at this time when or, ultimately if, such interference proceeding will be declared, and even if declared, we cannot know or anticipate whether Biogen might be able to assert valid defenses. Failure to prevail in any such interference could adversely impact our ability to market FP187 for RRMS, which would have a material adverse effect on our business.

        On August 22, 2014, an administrative law judge at the PTAB returned our U.S. Application No. 11/576,871 to the patent examining group within the USPTO, or the Examining Group, in which our USPTO Examiner is assigned. We do not know whether the return has any accompanying communication to the Examining Group and we cannot rule out the possibility that the return was made for substantive reasons, which may include alleging potential defects in our patent claims, a disagreement by the administrative law judge with the recommendation by the USPTO Examiner for an interference and that we be designated as the senior party in the interference, or any other recommendations the USPTO Examiner may have made. Any adverse findings or recommendations by the PTAB could significantly and adversely affect, delay or prevent our planned interference case against Biogen. Any adverse findings or recommendations on our interference could have a material adverse effect on our business, our results or operations and our business prospects. Any such adverse findings or recommendations would have a material adverse impact on the trading price of our shares and the value of your investment in us.

There can be no assurance that even if we are successful in the opposition proceedings involving our patents currently pending before the EPO, we won't be subject to subsequent or parallel invalidity proceedings (also called "nullity actions" or "revocation actions") involving these same or other patents of ours before a national court in any of the European Patent Convention member states where our patents were validated, which subsequent or parallel proceedings could result in our challenged patents being subject to continued uncertainty as to their validity until such proceedings have been fully concluded. We cannot at this time anticipate how long any such proceedings may last and so when, if at all, our patents currently under challenge will finally be declared to be valid or not.

        The possibility of parallel validity proceedings in national courts and in the EPO is inherent in the legal arrangements under the European Patent Convention under which the EPO was established. If a

19


Table of Contents

third party files an opposition to an EU patent with the EPO and also, in parallel, initiates a revocation action (also called "nullity action" or "validity proceedings") against the same patent before a national court, certain national courts may exercise their discretion to either (i) stay the national proceedings, in order to wait the outcome of the EPO opposition proceedings, or (ii) allow the revocation proceedings to go ahead, without awaiting the outcome of the EPO proceedings. The rules and practice differ from country to country in the EU. For example, certain countries will stay the main proceeding until a final decision has been reached by the EPO whereas in other countries a stay is not automatic and in such cases the courts may continue the proceedings notwithstanding the opposition. In Germany, for example, national nullity proceedings cannot be started before the German Federal Patent Court until the EPO opposition proceedings have been concluded or the opposition period has expired. As a result, it is possible that certain of our patents now subject to opposition proceedings before the EPO will, even if we are ultimately successful before the EPO, again become subject to a revocation action in a country like Germany, which means our challenged patents could be subject to continued uncertainty in the EU as to their validity until such proceedings have been fully concluded. We cannot at this time anticipate how long any such proceedings may last and so when, if at all, our patents currently under challenge will finally be declared to be valid or not.

Biogen may initiate legal proceedings alleging that we are infringing its intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.

        Biogen has several issued patents and is also prosecuting a number of additional patent applications that could adversely impact our commercial efforts if FP187 were ultimately found to infringe any valid claim by Biogen, in particular if Biogen obtains patent term extensions for certain patents in the U.S. and/or Supplemental Protection Certificates (which also extend the effective life of patents for drugs) in the EU.

        We are aware of the seven patents Biogen has listed in the FDA's "Orange Book" (See "Business—Government Regulation—United States—Hatch-Waxman Act and Orange Book Listing.") in connection with Tecfidera®, U.S. Patent Nos. 6,509,376, 7,320,999, 7,619,001, 7,803,840, 8,399,514, 8,524,773 and 8,759,393. Our planned regulatory path does not require that we make patent certifications to the FDA in connection with Biogen's Orange Book-listed patents, and at least two of the Biogen patents will expire before we anticipate receiving marketing approval for FP187. In Germany, and possibly other or all European countries (including member states of the EU and the European Economic Area, or EEA, as well as Switzerland), Biogen has filed an application for a Supplementary Protection Certificate, or SPC, using EP1131065B1 (European counterpart to U.S. Patent No. 6,509,376) and EP2137537B1 (European counterpart to U.S. Patent No. 8,399,514) as the basic patents. The applications of the SPCs in Germany have the application Nos. DE122014000068.9 and DE122014000069.7. An SPC may extend the effective monopoly of a basic patent by a maximum of five years. The SPC term may be further extended by an additional six months in accordance with Art. 36 of Regulation 1901/2006, if the requirements for a pediatric extension are met.

        We are also aware of the European counterpart to U.S. Patent No. 8,399,514, EP2137537 B1. As discussed with respect to our "Core Composition Patent" family, we have opposed EP2137537 B1 and are seeking to provoke an interference between one of our U.S. patent applications and Biogen's U.S. Patent No. 8,399,514.

        In the U.S., Biogen's pending patent applications include U.S. Application No. 13/266,997 (notice of allowance mailed on August 14, 2014), U.S. Application No. 13/767,014, U.S. Application No. 13/800,128, U.S. Application No. 14/119,373, U.S. Application No. 14/124,562, U.S. Application No. 13/760,916, and U.S. Application No. 13/827,228. In Europe, Biogen's pending patent applications include EP2424357, EP2713724 and several others. One or more of these applications could adversely impact our commercial efforts if our marketing of FP187 once approved by the FDA for the treatment

20


Table of Contents

of RRMS and/or psoriasis was ultimately found to infringe any valid patent claim issuing from any one of these applications.

        Biogen's patents and patent applications are said to relate to pharmaceutical preparations of DMF and methods for treating immune disorders such as psoriasis and MS using DMF. Some of the patents and patent applications claim dosing regimens, and include claims directed to a method for treating MS through the administration of a therapeutically effective amount of DMF at about a 480 mg daily dose. If such patent claims were asserted against us, we would vigorously contest such an action. However, the outcome of such potential proceedings would be unpredictable and if such patents were held to be valid, enforceable and infringed by the commercialization of FP187, we could be prevented from continuing to commercialize our product candidates, unless we obtain a license to such patents, which may not be available on commercially reasonable terms or at all. If we market FP187 and are later found to infringe one or more of Biogen's patents, we could also be required to pay substantial damages.

Our drug candidate FP187 is still under development and, if we pursue versions of FP187 that are modified from those used in our set of Phase 1 trials and Phase 2 clinical trial, such modified FP187 products may be considered outside the scope of our patent families and, as a result, our ability to protect our overall patent estate could be threatened.

        In connection with our set of Phase 1 trials and Phase 2 clinical trial, we have used various versions of FP187 we believe to be within the scope of our existing patent families. There can be no assurance, however, that if we choose to pursue new or different versions of FP187 from those used in our set of Phase 1 trials and Phase 2 trial, that such modified FP187 products will not be considered outside of the scope of our patent families. In such event, such modified FP187 products could be subject to challenges in connection with new patent proceedings or otherwise by patent registry offices, our competitors and others, the outcome of which challenges could, if ultimately determined adversely to us, materially adversely affect our business, financial condition and prospects.

We may become involved in lawsuits to protect and defend our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.

        Competitors may infringe our patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file claims, and any related litigation and/or prosecution of such claims can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid in whole or in part, unenforceable, or construe the patent's claims narrowly allowing the other party to commercialize competing products on the grounds that our patents do not cover such products.

        Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. The effects of patent litigation or other proceedings could therefore have a material adverse effect on our ability to compete in the marketplace.

21


Table of Contents

We enjoy only limited geographical protection with respect to certain of our patents and may face difficulties in certain jurisdictions, which may diminish the value of our intellectual property rights in those jurisdictions.

        Our two earliest patent filings, PCT/DK2005/000648 and PCT/EP2010/050172, have limited geographic reach beyond the U.S. and Europe. PCT/DK2005/000648 has multiple pending U.S. counterparts, a granted European patent, a pending European patent application, three divisional applications, a German utility model and a pending Japanese counterpart. PCT/EP2010/050172 has a U.S. counterpart pending, a European patent granted, a European application pending, has Japanese, Eurasian, Indian, Chinese, Korean, Russian and Georgian counterparts pending and a granted patent in the Ukraine. We may decide to abandon national and regional patent applications in Europe and outside Europe and the U.S. before they are granted, if at all. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, the scope of patent protection may vary for the same product. For example, in some jurisdictions, it is not possible to obtain patents on dosing regimens.

        The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the U.S. and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our collaboration partners encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions.

        Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be adversely affected.

Third parties may claim rights including ownership rights in our intellectual property.

        None of the named inventors on our patent and patent applications were our employees at the time of the filing of the Core Composition Patent family, which we acquired from Aditech. Two of the named inventors of the Core Composition Patent family were consultants of Aditech and, while obligated under their consulting agreements to assign their rights in the Core Composition Patent family to Aditech, were employed by other institutions at the time they were named as inventors. While such institutions have not made any claims to ownership, there can be no assurance they will not do so in the future.

        Later-filed patent families were filed by us, but some of the named inventors were acting only in a consultant capacity to us. Some of these consultants, while obligated under their consulting agreements to assign their rights in such patent families to us, were employed by other institutions prior to or at the time they made their inventions. While such institutions have not made any ownership claims to the inventions disclosed in the later-filed patent families, there can be no assurance they will not do so in the future.

        Named inventors on our patent applications, whether filed by us or acquired from Aditech, could also challenge whether their property rights were properly assigned, if at all. Further, other individuals (including persons not known to us or their employers) could make claims or assertions that they are inventors and/or owners of our intellectual property.

22


Table of Contents

        Under mandatory Danish law, a salaried employee having made a patentable invention (and products that may be subject to registration as an industrial designer right) through his service with an employer has the rights to such invention, provided however, that the rights to the patentable invention upon the employer's request shall be transferred to the employer, to the extent not otherwise agreed, provided that the use of such patentable invention falls within the "working area" of the employer or it is a result of a specific assignment given by the employer to the employee. Such a transfer is, however, subject to an obligation on the employer, following which the employer shall pay to the employee a "reasonable compensation." The fee shall be fixed considering the value of the invention and its consequences for the employer, the employee's terms of employment and the impact that the employee's service has had for the invention. In the event that the value of the invention does not exceed what the employee, taking his working conditions as a whole into account, reasonably could be expected to achieve, the employee is not entitled to any fee. The compensation payable by the employer is not subject to any maximum amount and may be paid either as a lump sum or as a continuing royalty payment based on, for example, the number of items produced based on the invention. An employee's claim for compensation may become time-barred or forfeited due to the employee's passive behavior. The general relative time-barring deadline under Danish law is five years with respect to claims based on employment matters, whereas the general absolute deadline for such claims is ten years.

        Some of the named inventors on our newer applications (not the Core Composition Patent or Erosion Matrix Patent) are employees of our wholly owned German subsidiary Forward Pharma GmbH and thus are subject to German employment law. German employment law governs the transfer/assignment of any intellectual property rights generated by such employees. In particular, any inventions eligible for patent protection made by such employees are subject to the provisions of the German Act on Employees' Inventions (Gesetz üeber Arbeitnehmererfindungen), which regulates the ownership of, and compensation for, inventions made by employees. The law provides for a formal procedure for the transfer of employee's rights to patentable inventions which result from performance of the tasks the employee is charged with at the Company or which are based to a significant extent on the experiences or works of the Company, upon employer's request within a certain period of time after notification by employee.

        We believe that inventive contributions made by employees of Forward Pharma GmbH were made after the amended version of the German Act on Employees' Inventions came into force on October 1, 2009 and thus the amended version of the law exclusively applies to such inventions. Prior to October 1, 2009, such formal procedure had been susceptible to faults. The amendments to the law facilitate the transfer of rights in employees' inventions to the employer by replacing the former opt-in approach by an opt-out approach.

        Following the transfer of rights, an employee is entitled to a claim for "reasonable compensation" to be calculated on an individual basis (e.g., revenue achieved through exploitation of the patent). In addition, the German Act on Employees' Invention provides for certain obligations on the employer including the obligation to apply for patent protection in Germany, the obligation to release the invention for application in those countries where the employer does not want to apply for a patent and the obligation to offer to the employer granted patents or pending patent applications if the employer intends to abandon rights in any country.

        We face the risk that disputes can occur between us and employees or ex-employees of Forward Pharma GmbH pertaining to alleged non-adherence to the provisions of this act. Such disputes may be costly to defend and take up our management's time and efforts whether we prevail or fail in such dispute. If we are required to pay additional compensation or face other disputes under the German Act on Employees' Inventions, in particular in case of a failed transfer of rights, our results of operations could be adversely affected.

23


Table of Contents

Intellectual property rights do not address all potential threats to our competitive advantage.

        The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:

    Others may be able to make DMF-based products that are similar to FP187 but that are not covered by the claims of the patents that we own.

    Others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights.

    We or any of our collaboration partners might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license.

    We or any of our collaboration partners might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license.

    It is possible that our pending patent applications will not lead to issued patents.

    Issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.

    Our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.

    Ownership of our patents or patent applications may be challenged by third parties.

    The patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.

Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products or product candidates.

        As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and exploiting patents in the biopharmaceutical industry involve both technological and legal complexity. Therefore, obtaining and exploiting biopharmaceutical patents is costly, time-consuming and inherently uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Such examples include:

    Nautilus, Inc. v. Biosig Instruments, Inc.  (2014), where the Court imposed a stricter requirement for clarity of claim language than previously applied by the Federal Circuit, thereby making it easier to invalidate patents for insufficiently apprising the public of the scope of the invention.

    Limelight Networks, Inc. v. Akamai Technologies, Inc.  (2014), where the Court articulated a standard for inducement of infringement that makes it more difficult to establish liability for inducing infringement of a multi-step method claim that is performed by multiple parties.

    Association for Molecular Pathology v. Myriad Genetics, Inc.  (2013), where the Court held that isolated naturally-occurring DNA is patent ineligible subject matter.

24


Table of Contents

    KSR v. Teleflex (2007), where the Court decided unanimously that the Federal Circuit Court had been wrong in taking a narrow view of when an invention is "obvious" and thus cannot be patented.

    EBay Inc. v. MercExchange, LLC (2006), where the Court heightened the standard for an injunction after a finding of patent infringement.

    Merck KGgA v. Integra Lifesciences (2004), where the Court adopted an expansive interpretation of the activities associated with regulatory approval exempt from patent infringement.

        In addition, the America Invents Act, or AIA, has been recently enacted in the United States, resulting in significant changes to the U.S. patent system. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, the combination of the U.S. Supreme Court decisions and AIA has created uncertainty with respect to the value of patents, once obtained. A few highlights of changes to U.S. patent law under the AIA are:

    Under the AIA, a patent is awarded to the "first-inventor-to-file" rather than the first to invent.

    There is a new definition of prior art which removes geographic and language boundaries found in the pre-AIA law. At the same time, certain categories of "secret" prior art have been eliminated.

    The AIA introduced new procedures for challenging the validity of issued patents: post-grant review and inter partes review.

    Patent owners under the AIA may now request supplemental examination of a patent to consider, reconsider, or correct information believed to be relevant to the patent.

    The AIA allows third parties to submit any patent, published application, or publication relevant to examination of a pending patent application with a concise explanation for inclusion during prosecution of the patent application.

        The "first-inventor-to-file" system and the new definitions of prior art apply to U.S. patent applications with claims having an effective filing date on or after March 16, 2013. Until at least 2034, patent practice will involve both pre-AIA and AIA laws.

        Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to exploit our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution and opposition proceedings. Changes in patent law or patent jurisprudence could limit our ability to obtain new patents in the future that may be important for our business.

Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information.

        We consider proprietary trade secrets and/or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets and/or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. However, trade secrets and/or confidential know-how can be difficult to maintain as confidential.

        To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of

25


Table of Contents

confidential information. Enforcing a claim that a third-party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.

        Failure to obtain or maintain trade secrets and/or confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how.

Risks Related to the Development, Pre-clinical Testing, Clinical Testing, Regulatory Approval and Commercialization of FP187

Pre-clinical and clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes. If pre-clinical or clinical trials of FP187 are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize FP187 on a timely basis or at all.

        To obtain the requisite regulatory approvals to market and sell FP187, we must demonstrate through extensive pre-clinical and clinical trials that it is safe and effective in humans for its intended use. The process for obtaining governmental approval to market FP187 is rigorous, time-consuming and costly. It is impossible to predict the extent to which this process may be affected by legislative and regulatory developments. Due to these and other factors, FP187 or future product candidates could take a significantly longer time to gain regulatory approval than expected or may never gain regulatory approval. This could delay or eliminate any potential product revenue by delaying or terminating the potential commercialization of FP187.

        Pre-clinical trials must be conducted in accordance with FDA, EMA and other applicable regulatory authorities' legal requirements, regulations or guidelines, including good laboratory practice, or GLP, an international standard meant to harmonize the conduct and quality of nonclinical studies and the reporting of findings. Pre-clinical studies including long-term toxicity studies and carcinogenicity studies in experimental animals may result in findings which may require further evaluation, which could affect the risk-benefit evaluation of clinical development, or which may even lead the regulatory agencies to delay, prohibit the initiation of or halt clinical trials or delay or deny marketing authorization applications. Failure to adhere to the applicable GLP standards or misconduct during the course of the study may invalidate the study requiring repeat of the study.

        Clinical trials must be conducted in accordance with FDA, EMA and other applicable regulatory authorities' legal requirements, regulations or guidelines, including good clinical practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors. Clinical trials are further subject to oversight by these governmental agencies and Institutional Review Boards, or IRBs, at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of FP187 produced under current good manufacturing practices, or cGMP, and other requirements. Our clinical trials are conducted at multiple sites, including some sites in countries outside the U.S. and the EU, which may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-U.S. and non-EU clinical research organizations, as well as expose us to risks associated with clinical investigators who are unknown to the FDA or the European regulatory authorities, and with different standards of diagnosis, screening and medical care.

        To date, we have not completed all clinical trials required for the approval of FP187, which is currently being prepared for Phase 3 testing. The commencement and completion of clinical trials for

26


Table of Contents

FP187 may be delayed, suspended or terminated as a result of many factors, including but not limited to:

    negative or inconclusive results, which may require us to conduct additional pre-clinical or clinical trials or to abandon projects that we expect to be promising;

    safety or tolerability concerns could cause us to suspend or terminate a trial if we find that the participants are being exposed to unacceptable health risks;

    the delay or refusal of regulators or IRBs to authorize us to commence a clinical trial at a prospective trial site and changes in regulatory requirements, policies and guidelines;

    regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;

    delays or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;

    delays in patient enrollment and variability in the number and types of patients available for clinical trials;

    the inability to enroll a sufficient number of patients in trials to ensure adequate statistical power to detect statistically significant treatment effects;

    lower than anticipated retention rates of patients and volunteers in clinical trials;

    our third-party research and manufacturing contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;

    difficulty in maintaining contact with patients after treatment, resulting in incomplete data;

    delays in establishing the appropriate dosage levels;

    the quality or stability of FP187 falling below acceptable standards;

    the inability to produce or obtain sufficient quantities of FP187 to complete clinical trials; and

    exceeding budgeted costs due to difficulty in predicting accurately costs associated with clinical trials.

        Positive or timely results from pre-clinical studies and early stage clinical trials do not ensure positive or timely results in late stage clinical trials or product approval by the FDA, the EMA or other regulatory authorities.

        Products that show positive pre-clinical or early clinical results may not show sufficient safety or efficacy to obtain regulatory approvals and therefore fail in later stage clinical trials. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for FP187. Even if we believe the data collected from clinical trials of FP187 are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority.

        We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Monitoring Committee, or DMC, for such trial or by the FDA, the EMA or other regulatory authorities. We or such authorities may impose a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, the EMA or other regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using the drug, changes in governmental regulations or administrative actions or lack of adequate funding to

27


Table of Contents

continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of FP187, the commercial prospects of FP187 will be harmed, and our ability to generate product revenues from this product will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow the FP187 development and approval process and jeopardize our ability to commence product sales and generate revenues.

        Any of these occurrences could materially adversely affect our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of FP187. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize FP187 and impair our ability to commercialize FP187 and may harm our business and results of operations.

The FDA and/or the EMA/ EC may determine that our proposed single Phase 3 trial for the use of FP187 for the treatment of RRMS, including any EDSS and SAD data generated through the date of our NDA submission, is insufficient for approval of FP187, which would delay or could prevent the approval of FP187 and adversely affect our prospects.

        We filed our IND for FP187 as a drug to treat RRMS in the U.S. on April 30, 2014. On June 10, 2014, the FDA sent us a "may proceed" letter, indicating that the IND is active and that we may conduct studies in humans. In August 2013, we had held a pre-Investigational New Drug, or IND, Application meeting with the FDA, prior to which we submitted a briefing book including a proposal for a large, single Phase 3 trial. Approval by the FDA of a New Drug Application, or NDA, is dependent on a number of factors. A final decision as to whether the program we shared with the FDA at a high level in advance of our pre-IND meeting will be sufficient for approval (including the sufficiency of our proposed single Phase 3 trial and whether a favorable effect on SAD or other secondary endpoints will need to be demonstrated by us at the time of our NDA submission) can only be made by the FDA once it has reviewed our full NDA package.

        In addition, since we intend to rely on a single Phase 3 trial to demonstrate the effectiveness of FP187, the usual demonstration of the statistical significance of the superiority of FP187 to the active comparator drug in the primary efficacy endpoint (p<0.05) is unlikely to be sufficient to obtain approval. We currently expect that we will be required to demonstrate a two sided p<0.01 for our primary efficacy endpoint of ARR and two sided p<0.05 for the key secondary efficacy endpoint of SAD and/or other secondary endpoints (e.g., MRI scans) while retaining the primary efficacy advantage for FP187 through the full two year study. Importantly, during our pre-IND meeting, the FDA explained that although a low p-value may be one of the contributing factors for approval supported by a single study, such low p-value alone is not sufficient for approval, and that a final decision can only be made once the results from the study are reviewed. The FDA commented that consideration of an approval supported by a single study is based on many factors as described in "Guidance for Industry: Providing clinical evidence of effectiveness for human drug and biological products (May, 1998)".

        Overall, there can be no assurances that the FDA will ultimately accept the data from our single Phase 3 trial (including the SAD data we have generated at the time of submission or at a later date) as sufficient for approval when we file our NDA or at all, or that we will be able to timely file such an NDA. Similarly, in the EU, we may experience a delay in submitting our market authorization application to the EMA and can have no assurances that the EC ultimately will approve FP187 as a drug for the treatment of RRMS.

28


Table of Contents

If serious adverse, undesirable or unacceptable side effects are identified during the development or commercialization of FP187, we or our collaboration partners may need to abandon or limit development or commercialization of FP187.

        If FP187 or any other product candidate we develop is associated with serious adverse, undesirable or unacceptable side effects, we may need to abandon such candidate's development or limit development to certain uses or sub-populations in which such side effects are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in early-stage or clinical testing have later been found to cause side effects that prevented further development of the compound.

        Undesirable side effects caused by FP187 or another product candidate we develop could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EC or other comparable foreign authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA, EMA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. To date, seven Serious Adverse Events, or SAEs, have been reported in our clinical trials for FP187, which have included 318 treated subjects. Five cases were classified by the investigator as being unrelated to the use of FP187, while two cases were judged by the investigator as being possibly related to the use of FP187. One patient, who had hypertension and a family history of cardiovascular diseases experienced a transient ischemic attack, or TIA, while a second patient experienced severe abdominal pain over period of approximately 24 hours. The patient experiencing the TIA discontinued the treatment regimen but the patient experiencing abdominal pain continued the treatment regimen after being discharged from the hospital without additional drug-related AEs. These cases have been reported to the FDA and European regulatory authorities but have not resulted in any requests from the authorities. The occurrence of these or other serious adverse, undesirable or unacceptable side effects could materially adversely affect our business, financial condition and prospects.

        It is documented in the Tecfidera® labeling and through experience using Fumaderm® that the use of products containing DMF, the sole API in FP187, may cause a decrease in lymphocytes (white blood cells) in humans, thereby possibly increasing the potential for infection. To date, we are not aware of instances in which this side effect has prevented the FDA or the EC from approving RRMS drugs such as Tecfidera®, although it is expected that each of the FDA and the EMA will require us to monitor the incidence of this condition, known as lymphopenia and will evaluate whether FP187 increases the potential for infections during the review of our NDA in the U.S. and market authorization application in the EU.

        If FP187 or another product candidate we develop receives marketing approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including:

    regulatory authorities may withdraw approvals of such product;

    regulatory authorities may require additional warnings on the labeling;

    we or our collaboration partners may be required to create a medication guide or risk evaluation and mitigation strategies, or REMS, addressing the risks of such side effect;

    we or our collaboration partners could be sued and held liable for harm caused to patients; and

    our reputation may suffer.

29


Table of Contents

        Any of these events could prevent us from achieving or maintaining market acceptance of FP187 or any other product candidate, if approved, and could materially adversely affect our business, financial condition and prospects.

Positive results in previous clinical trials of FP187 may not be replicated in future clinical trials of FP187, which could result in development delays or a failure to obtain marketing approval.

        Positive results in previous clinical trials of FP187 may not be predictive of similar results in future clinical trials. In addition, interim results during a clinical trial do not necessarily predict final results. A number of companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stage development. Accordingly, the results from the completed pre-clinical studies and clinical trials for FP187 may not be predictive of the results we may obtain in later stage trials. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain FDA or EMA/EC approval for their products.

We depend on enrollment of patients in our clinical trials for FP187. If we are unable to enroll patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.

        Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. Patient enrollment depends on many factors, including the size of the patient population, eligibility criteria for the trial, the proximity of patients to clinical sites, the nature of the trial protocol, competing clinical trials and the availability of new drugs approved for the indication the clinical trial is investigating.

        With respect to our clinical development of FP187 in RRMS, our proposed Phase 3 trial is particularly ambitious, requiring the recruitment of up to 2,000 RRMS patients worldwide. We have no experience in managing a clinical trial of this scope, in centers throughout the world, and we will need to significantly increase our clinical development resources in order to successfully manage and oversee this process.

        Enrollment of a sufficient number of patients in the Phase 3 trial for RRMS, the size of which is, to our knowledge, unprecedented for drugs intended for the treatment of RRMS, will depend on our ability to convince physicians and patients at the trial sites of the clinical meaningfulness of our study, and the recent availability of oral therapies such as Gilenya® (fingolimod), Aubagio® (teriflunomide) and Tecfidera® (another DMF formulation) may cause patients to be less willing to participate in our clinical trial for an oral therapy in regions in which one of these alternative oral therapies has been approved. Since RRMS is a competitive market in certain regions, such as the U.S. and the EU, with a number of drug candidates in development, patients may have other choices with respect to potential clinical trial participation and we may have difficulty reaching our enrollment targets.

Instability in Russia and the CIS could adversely affect our planned European Phase 3 clinical trial for FP187 for the treatment of psoriasis.

        We are continuing advanced preparatory work for a placebo-controlled confirmative Phase 3 trial of FP187 for the treatment of psoriasis in Europe, as well as an additional placebo-controlled Phase 3 trial of FP187 for the treatment of psoriasis in the United States. Our planned Phase 3 trial in Europe would consist of approximately 60 clinical sites, of which 23 are in Russia and the Ukraine. The implementation of sanctions in Russia and/or the Ukraine, or the exacerbation of or continued political

30


Table of Contents

instability in the region could adversely impact our ability to perform studies in the region, or could increase the costs to us and our clinical research organizations, or CROs, in performing such studies. As a result, our ability to proceed or continue with sites in these countries could be adversely impacted.

We may become exposed to costly and damaging liability claims, either when testing FP187 or any other product candidates we develop in the clinic or at the commercial stage; and our product liability insurance may not cover all damages from such claims.

        We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently we have no products that have been approved for commercial sale; however, the current and future use of FP187 or other product candidates by us and our collaboration partners in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, our collaboration partners or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for FP187 or any prospects for commercialization of FP187.

        Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If FP187 were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use FP187.

        Although we maintain limited product liability insurance for FP187 (currently coverage is for $2 million), it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for FP187. However, we may be unable to obtain any insurance covering the sale of FP187, once commercialized, or may be unable to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.

        Should any of the events described above occur, this could have a material adverse effect on our business, financial condition and results of operations.

Our product candidate FP187 is subject to extensive regulation, compliance with which is costly and time consuming, may cause unanticipated delays, or prevent the receipt of the required approvals to commercialize our product candidate.

        We and our collaboration partners are not permitted to market our product candidate FP187 until we receive regulatory approval from regulatory authorities. The process of obtaining regulatory approval is expensive, often takes many years, and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target indications. Approval policies or regulations may change and regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit, or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.

31


Table of Contents

        The FDA, the EMA or other comparable foreign regulatory authorities can delay, limit, or deny approval of a product candidate for many reasons, including:

    such authorities may disagree with the design or implementation of our clinical trials or the adequacy of our pre-clinical studies;

    we may be unable to demonstrate to the satisfaction of the FDA, the EMA or other regulatory authorities that a product candidate is safe and effective for any indication;

    such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from the United States;

    we may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks; and

    such authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;

        In addition, competitors could attempt to use the regulatory process to attempt to delay or prevent approval of FP187. For example, a competitor could file a citizen petition with the FDA seeking a ruling from the FDA that the use of a single Phase 3 trial as a basis for approving FP187 is not appropriate. We believe that, if our proposed Phase 3 trial for FP187 is successful and the results meet our expectations, the FDA will have a proper basis for approving our NDA for FP187. However, the filing of a citizen petition could delay any approval of FP187 by the FDA, which would adversely affect our prospects. Should any of the events described above occur, this could have a material adverse effect on our business, financial condition and results of operations.

Even if FP187 obtains regulatory approval, it will be subject to continual regulatory review.

        If marketing authorization is obtained for FP187, it will remain subject to continual review and therefore authorization could be subsequently withdrawn or restricted. We and our collaboration partners will be subject to ongoing obligations and oversight by regulatory authorities, including Adverse Event, or AE, reporting requirements, marketing restrictions and, potentially, other post-marketing obligations, all of which may result in significant expense and limit our ability to commercialize FP187. We and our collaboration partners will also be subject to regulatory requirements covering the manufacturing of FP187, including maintaining compliance with cGMP, and our contract manufacturers will be subject to periodic inspections by regulatory authorities.

        If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our collaboration partners fails to comply with regulatory requirements, the regulators could take various actions. These include issuing warning and/or untitled letters to us, imposing fines on us, imposing restrictions on FP187 or its manufacture, requiring us to recall or remove the product from the market, entering an injunction against us, requiring us to enter into a consent decree, and pursuing criminal prosecution against us. The regulators could also suspend or withdraw our marketing authorizations or require us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations.

32


Table of Contents

Agencies like the FDA and national competition laws in Europe regulate the promotion and uses of drugs not consistent with approved product labeling requirements. If we are found to have improperly promoted FP187 for uses beyond those that are approved, we may become subject to significant liability.

        Regulatory authorities like the FDA and national competition laws in Europe (e.g., the German Heilmittelwerbegesetz) strictly regulate the promotional claims that may be made about prescription products, such as FP187, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA, the EMA or such other regulatory agencies as reflected in the product's approved labeling. For example, the FDA requires substantial evidence, which generally consists of two adequate and well-controlled head-to-head clinical trials, for a company to make a claim that its product is superior to another product in terms of safety or effectiveness. Unless we perform clinical trials comparing FP187 to Tecfidera®, we will not be able promote FP187 by making comparative claims to Tecfidera®. If we are found to have made such claims we may become subject to significant liability. In the U.S., the federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in improper promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.

Due to our limited resources and access to capital, we must decide to prioritize development of FP187 for certain indications and at certain doses; these decisions may prove to have been wrong and may materially adversely affect our business, financial condition, results of operations and prospects.

        Because we have limited resources and access to capital to fund our operations, we must decide which dosages and indications to pursue for the clinical development of FP187 and the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward dosages or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. If we make incorrect determinations regarding the market potential of FP187 or misread trends in the biopharmaceutical industry, our business, financial condition, results of operations and prospects could be materially adversely affected.

Because we are subject to environmental, health and safety laws and regulations, we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may disrupt or delay our production and development efforts and materially adversely affect our business, financial condition and results of operations.

        Our operations, including our research, development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of, and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.

        As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case our production and development efforts may be interrupted or delayed and our financial condition and results of operations may be materially adversely affected.

33


Table of Contents

Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.

        Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive.

Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize FP187 and may affect the prices we may set.

        In the U.S., the EU and some other foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system. These changes could prevent or delay marketing approval of FP187, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval.

        In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sale prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost-reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments from private payors.

        More recently, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, or ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Effective October 1, 2010, the ACA revised the definition of "average manufacturer price" for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the new law imposed a significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance have also been enacted, which may affect our business practices with health care practitioners. We will not know the full effects of the ACA until applicable federal and state agencies issue regulations or guidance under the new law. Although it is too early to determine the effect of the ACA, the new law appears likely to continue the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.

        Both in the U.S. and in the EU, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of FP187, if any, may be.

34


Table of Contents

Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

        Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable healthcare laws and regulations include the following:

    the U.S. healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under U.S. healthcare programs such as Medicare and Medicaid;

    the U.S. False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

    the U.S. Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

    the U.S. false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits items or services;

    the transparency requirements under the ACA require manufacturers of drugs, devices, biologics and medical supplies to report to the U.S. Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests; and

    analogous laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures.

        Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business with is found to be not in compliance with applicable laws,

35


Table of Contents

they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.

        The biopharmaceutical industry is highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in the U.S., the EU and other jurisdictions. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that compete with FP187.

        We believe that our key competitor in the commercialization of DMF for RRMS is Biogen, which has developed Tecfidera®, an oral treatment with RRMS. Tecfidera® has been approved in the U.S., Canada, Australia and the EU. The fact that Tecfidera® has been commercialized and is being marketed in the U.S. may render our development and discovery efforts in the area of DMF for the treatment of RRMS uncompetitive. Other companies are also developing alternative therapeutic approaches to the treatment of RRMS. These alternative therapeutic approaches may be used as complementary to the use of FP187 for the treatment of RRMS, but they could also be competitive.

        The highly competitive nature of and rapid technological changes in the pharmaceutical and biotechnological industries could render FP187 or our technology obsolete or non-competitive. Our competitors may, among other things:

    develop and commercialize products that are safer, more effective, less expensive, or more convenient or easier to administer;

    obtain quicker regulatory approval;

    establish superior proprietary positions;

    have access to more manufacturing capacity;

    implement more effective approaches to sales and marketing; or

    form more advantageous strategic alliances.

        Should any of these factors occur, our business, financial condition and results of operations could be materially adversely affected.

The successful commercialization of FP187 and any other products we develop will depend, in part, on the extent to which governmental authorities, health insurers and other third-party payors establish adequate reimbursement levels and pricing policies.

        The successful commercialization of FP187 and any other products we develop will depend, in part, on the extent to which third-party coverage and reimbursement for our product will be available from government and health administration authorities, private health insurers and other third-party payors.

        These bodies may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. Obtaining and maintaining

36


Table of Contents

reimbursement status is time-consuming and costly. Significant uncertainty exists as to the reimbursement status of newly approved medical products. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. In addition, many governments and health insurers are increasingly attempting to manage healthcare costs by limiting both coverage and the level of reimbursement of new products. As a result, they may not cover or provide adequate payment for our future products.

        These concerns are particularly present for drugs like FP187 that use an API that is already available in other, approved drugs. Public and private payors may only be willing to provide coverage for FP187 if we can demonstrate a significant clinical advantage, or offer the drug at a price resulting in a treatment cost lower than other available drugs. Public and private payors may not be willing to grant reimbursement prices in line with our expectations if they do not share our views concerning the advantages of our proprietary formulation technology, in particular if they do not give as much weight as we do to, for example, what we expect will be reductions in flushing as a side effect.

        The unavailability or inadequacy of third-party coverage and reimbursement could have a material adverse effect on the market acceptance of FP187 and the future revenues we may expect to receive from it. In addition, we are unable to predict what additional legislation or regulation relating to the healthcare industry or third-party coverage and reimbursement may be enacted in the future, or what effect such legislation or regulation would have on our business.

FP187 and any other products we develop may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially adversely affect our business, financial condition and results of operations.

        Even if the FDA, the EMA or any other regulatory authority approves the marketing of any products that we develop on our own or with a collaboration partner, physicians, healthcare providers, patients or the medical community may not accept or use them. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of FP187 will depend on a variety of factors, including:

    the timing of market introduction;

    the number and clinical profile of competing products;

    our ability to provide acceptable evidence of safety and efficacy;

    the prevalence and severity of any side effects;

    relative convenience and ease of administration;

    cost-effectiveness;

    patient diagnostics and screening infrastructure in each market;

    marketing and distribution support;

    availability of coverage, reimbursement and adequate payment from health maintenance organizations and other insurers, both public and private; and

    other potential advantages over alternative treatment methods.

        If FP187 or any other product we develop fails to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may not prove to be large enough to allow us to generate significant revenues.

37


Table of Contents

We have never commercialized a product candidate, and we currently have no marketing and sales organization. To the extent our product candidate FP187 is approved for marketing, if we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell FP187 or generate product revenue.

        We have never commercialized a product candidate, and we currently do not have a marketing or sales organization for the marketing, sales and distribution of FP187 and do not intend to create one. In order to commercialize any of our products that receive marketing approval, we would have to build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In the event of successful development of FP187, if we elect to build a targeted specialty sales force, such an effort would be expensive and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. With respect to FP187, we may choose to partner with third parties that have their own sales forces and established distribution systems, in lieu of or to augment any sales force and distribution systems we may create. If we are unable to enter into collaborations with third parties for the commercialization of approved products, if any, on acceptable terms or at all, or if any such partner does not devote sufficient resources to the commercialization of our product or otherwise fails in commercialization efforts, we may not be able to successfully commercialize FP187 if it receives regulatory approval. If we are not successful in commercializing FP187, either on our own or through collaborations with one or more third parties, our future revenue will be materially and adversely impacted.

Risks Related to our Financial Position and Capital Needs

We have a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. If we fail to obtain additional funding to conduct our planned research and development effort, we could be forced to delay, reduce or eliminate our product development programs or commercial development efforts.

        We incurred net losses of $15.7 million and $22.5 million for the years ended December 31, 2013 and 2012, respectively. As of December 31, 2013, we had an accumulated deficit of $51.9 million. We incurred net losses of $8.5 million for the six month period ended June 30, 2014 and we had an accumulated deficit of $58.9 million as of June 30, 2014. Our losses have resulted principally from expenses incurred in research and development of FP187, from general and administrative expenses that we have incurred while building our business infrastructure, and from fair value adjustments to net settlement obligations to shareholder warrants. We expect to continue to incur significant operating losses in the future as we continue our research and development efforts and seek to obtain regulatory approval and commercialization of FP187. In our fiscal year ending December 31, 2014, we expect to incur up to approximately $26.0 million of costs associated with research and development assuming successful consummation of this offering, subject to timing of our development activities.

        To date, we have financed our operations through private placements of equity securities, grants from governmental bodies, and debt financing arrangements. We have never generated any revenues from product sales. Based on our current plans, we do not expect to generate significant royalty or product revenues unless and until we obtain marketing approval for, and commercialize, FP187. We believe that the net proceeds of this offering, together with the bridge financings providing for the availability to us of €8.4 million we entered into on May 30, 2014 with NB FP Investment II K/S, or NBFPII, and $10.0 million we entered into on August 6, 2014, with BVF Forward Pharma L.P. (an affiliate of BVF Partners LP, which is itself affiliated with certain of our principal shareholders), or BVF Forward, and our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 24 months. We have based this

38


Table of Contents

estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.

        We will have to seek additional funding beyond the expected net proceeds from this offering to complete our Phase 3 clinical trials in RRMS and to commercialize any of our product candidates. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. In addition, we may not be able to obtain further funding from governmental bodies.

        Even if we do generate product royalties or product sales, we may never achieve or sustain profitability on a consistent basis or at all. Our failure to sustain profitability could depress the market price of our ordinary shares and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of our ordinary shares also could cause you to lose all or a part of your investment.

Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited consolidated financial statements included in this Prospectus.

        Our audited consolidated financial statements were prepared assuming that we will continue as a going concern. However, the report of our independent registered public accounting firm included elsewhere in this Prospectus contains an explanatory paragraph on our consolidated financial statements stating there is substantial doubt about our ability to continue as a going concern, meaning that we may not be able to continue in operation for the foreseeable future or be able to realize assets and discharge liabilities in the ordinary course of operations. Such an opinion could materially limit our ability to raise additional funds through the issuance of new debt or equity securities or otherwise. There is no assurance that sufficient financing will be available when needed to allow us to continue as a going concern. The perception that we may not be able to continue as a going concern may also make it more difficult to raise additional funds or operate our business due to concerns about our ability to meet our contractual obligations.

        Based on current operating plans, assuming successful completion of this offering, we believe that we have resources to fund our operations for at least the next twenty-four months, but will require further funds to finance our activities thereafter. In the event this offering is not consummated as expected we will need to consider alternative arrangements and such arrangements could have a potentially significant negative impact on our ability to continue our operations.

Raising additional capital may cause dilution to holders of our shares or the ADSs, including purchasers of the ADSs in this offering, restrict our operations or require us to relinquish rights to our technologies or products.

        Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of the net proceeds of this offering, together with our existing cash and cash equivalents and additional financings, if needed. In respect thereof, we entered into a bridge financing on May 30, 2014 with NBFPII providing for the availability to us of €8.4 million and an additional bridge financing on August 6, 2014 with BVF Forward providing for the availability to us of $10.0 million. In the event we need to seek additional funds, we may raise additional capital through the sale of equity or convertible debt securities. In such an event, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of the ADSs. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of the ADSs to decline. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability

39


Table of Contents

to take specific actions such as incurring additional debt, making capital expenditures or declaring dividends.

        If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or products or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market FP187 or other product candidates that we would otherwise prefer to develop and market ourselves.

Exchange rate fluctuations or abandonment of the Euro currency may materially affect our results of operations and financial condition.

        Due to the international scope of our operations, fluctuations in exchange rates, particularly between the DKK and the U.S. dollar, may adversely affect us. Although we are based in Denmark, we source research and development, manufacturing, consulting and other services from several countries. Further, potential future revenue may be derived from abroad, particularly from the United States. As a result, our business may be affected by fluctuations in foreign exchange rates between the Danish Kroner, the U.S. dollar, British Pounds or other currencies, which may also have a significant impact on our reported results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place and do not currently have plans to implement any hedging arrangements.

        In addition, the possible abandonment of the Euro by one or more members of the EU could materially affect our business in the future. Despite measures taken by the EU to provide funding to certain EU member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the Euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of individual currencies in one or more EU member states, or in more extreme circumstances, the dissolution of the EU. The effects on our business of a potential dissolution of the EU, the exit of one or more EU member states from the EU or the abandonment of the Euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations.

Related party transactions may be challenged by tax authorities.

        Many of the jurisdictions in which we conduct or will conduct business, and in particular Denmark and Germany, have detailed transfer pricing rules which require that all transactions with related parties be priced using arm's length pricing principles. Contemporaneous documentation must exist to support this pricing. The taxation authorities in these jurisdictions could challenge our arm's length related party transfer pricing policies. International transfer pricing is an area of taxation that depends heavily on the underlying facts and circumstances and generally involves a significant degree of judgment. Although we believe that our related-party transactions satisfy the substantive requirements of these transfer pricing rules, if any of these taxation authorities are successful in challenging our transfer pricing policies, our income tax expense may be adversely affected and we could also be subjected to interest and penalty charges. Any increase in our income tax expense and related interest and penalties could have a significant impact on our future earnings and future cash flows.

40


Table of Contents

Risks Related to Our Dependence on Third Parties

If we fail to enter into strategic relationships or collaborations our business, financial condition, commercialization prospects and results of operations may be materially adversely affected.

        Our product development programs and the potential commercialization of FP187 or any other product candidates we develop will require substantial additional cash to fund expenses. Therefore, in addition to financing the developments of FP187 or any other product candidates we develop through additional equity financings or through debt financings, we may decide to enter into collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of such products or product candidates.

        We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If that were to occur, we may have to curtail the development of a particular product, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring FP187 to market and generate product revenue. If we do enter into a new collaboration agreement, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects and financial condition:

    we may not be able to control the amount and timing of resources that the collaboration partner devotes to the product development program;

    the collaboration partner may experience financial difficulties and thus not commit sufficient financial resources to the product development program;

    we may be required to relinquish important rights such as marketing, distribution and intellectual property rights;

    a collaboration partner could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors; or

    business combinations or significant changes in a collaboration partner's business strategy may adversely affect our willingness to complete our obligations under any arrangement.

We currently rely on third-party suppliers and other third parties for production of FP187 and our dependence on these third parties may impair the advancement of our research and development programs and the development of FP187.

        We currently rely on and expect to continue to rely on third parties for the supply of raw materials and manufacture of drug supplies necessary. We have a single relationship with a manufacturer (a so-called contract manufacturing organization, or CMO) to purchase excipients (i.e., inactive substances formulated alongside DMF), and to develop and manufacture our DMF, which we do through periodic work orders instead of a formal contractual relationship. We also have a single relationship with another CMO for the formulation, development, manufacture, analysis, packaging and supply of our DMF tablets, which we also maintain through periodic work orders instead of a formal contractual relationship. We anticipate soon expanding beyond relying on just these two third parties.

        Our current reliance on just one CMO for each of the purchase of excipients, manufacturing of DMF and our delivery formulation may expose us to more risk than if we were to manufacture FP187

41


Table of Contents

or other products ourselves, or if we were now to have relationships with multiple or back-up third parties. Delays in production by either of these third parties could delay our clinical trials or have an adverse impact on any commercial activities. In addition, the fact that we are dependent on these two third parties for the manufacture of DMF and formulation of FP187, respectively, means that we are subject to the risk that the products may have manufacturing defects that we have limited ability to prevent or control. Although we oversee these activities to ensure compliance with our quality standards, budgets and timelines, we have had and will continue to have less control over the manufacturing of DMF than potentially would be the case if we were to manufacture FP187 ourselves, or have alternative CMOs to turn to in instances where batches of our FP187 did not meet required standards. Further, the CMOs we deal with could have staffing difficulties, might undergo changes in priorities or may become financially distressed, which would adversely affect the manufacturing of DMF and the production of our FP187 tablets. In addition, they could be acquired by, or enter into an exclusive arrangement with, one of our competitors, which would adversely affect our ability to access DMF in the form we require.

        We are obliged to work with CMOs and third-party suppliers that comply with EMA, FDA or other regulatory authorities' laws and regulations, including cGMPs, on an ongoing basis. Although we are ultimately responsible for ensuring compliance with these regulatory requirements, we do not have day-to-day control over a CMO or other third-party manufacturer's compliance with these laws, regulations and applicable cGMPs and other laws and regulations, such as those related to environmental health and safety matters. Any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of FP187 or that obtained approvals could be revoked, which would adversely affect our business and reputation. In addition, third-party providers, such as our CMOs, may elect not to continue to work with us due to factors beyond our control. They may also refuse to work with us because of their own financial difficulties, business priorities or other reasons, at a time that is costly or otherwise inconvenient for us. If we were unable to find adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed.

        The manufacture of DMF requires highly specialized safety procedures and equipment and is therefore carried out by a limited number of CMOs. Our Phase 3 trial for FP187 and commercialization of FP187, when and if initiated, will greatly increase our requirements for DMF. While we are currently searching for (and believe we have identified) alternative and/or supplementary sources of production, there can be no assurance that we will be able to locate such alternatives or that we will be able to agree on the commercial terms of any supply with such CMOs, which could impact negatively on our programs. The inability of our single third-party source of DMF to meet our requirements for DMF would have a material adverse impact on our business and prospects.

        Problems with the quality of the work of third parties, such as CMOs, may lead us to seek to terminate our working relationships and use alternative service providers. However, making this change may be costly and may delay the trials. In addition, it may be very challenging, and in some cases impossible, to find replacement service providers that can develop and manufacture the necessary DMF or tablets in an acceptable manner and at an acceptable cost and on a timely basis. The sale of products containing any defects or any delays in the supply of necessary services could adversely affect our business, financial condition and results of operations.

        Growth in the costs and expenses of components or raw materials may also adversely affect our business, financial condition and results of operations. Supply sources could be interrupted from time to time and, if interrupted, supplies may not be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all.

42


Table of Contents

If we fail to retain accounting and financial staff with appropriate experience, our ability to maintain the financial controls required of a public company may adversely affect our business.

        We currently rely on third-party accounting professionals to assist us with our financial accounting and compliance obligations. We are seeking financial professionals with appropriate experience to maintain our financial control and reporting obligations as a public company. If we are unable to identify and retain such qualified and experienced personnel, our business may be adversely impacted.

Risks Related to the Offering and Our Ordinary Shares and ADSs

You will not be directly holding our ordinary shares.

        As an ADS holder, you will not be treated as one of our shareholders and you will not have shareholder rights. Danish law governs shareholder rights. Our depositary, Bank of New York Mellon, will be the holder of the ordinary shares underlying your ADSs. As a holder of ADSs, you will have ADS holder rights. The deposit agreement among us, the depositary and you, as an ADS holder, and all other persons directly and indirectly holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary.

The price of the ADSs may be volatile and may fluctuate due to factors beyond our control.

        The price of equity securities of publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of the ADSs may fluctuate significantly due to a variety of factors, including:

    developments concerning proprietary rights, including patents and litigation matters;

    positive or negative results of testing and clinical trials by us, strategic partners, or competitors;

    delays in entering into strategic relationships with respect to development and/or commercialization of FP187 or entry into strategic relationships on terms that are not deemed to be favorable to us;

    technological innovations or commercial product introductions by us or competitors;

    changes in government regulations;

    public concern relating to the commercial value or safety of FP187;

    financing or other corporate transactions;

    publication of research reports or comments by securities or industry analysts;

    general market conditions in the pharmaceutical industry or in the economy as a whole; or

    other events and factors beyond our control.

        In addition, the stock market in general has recently experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of individual companies. Broad market and industry factors may materially affect the market price of companies' equity securities, including ours, regardless of actual operating performance.

There was no public market for the ADSs prior to this offering, and an active market in the ADSs may not develop in which investors can resell the ADSs.

        Prior to this offering there was no public market for our Class A shares or our Class B shares, each of which will be converted into ordinary shares prior to consummation of this offering. We cannot predict the extent to which an active market for the ADSs will develop or be sustained after this offering, or how the development of such a market might affect the market price for the ADSs. The

43


Table of Contents

initial public offering price of the ADSs in this offering was agreed between us and the underwriters based on a number of factors, including market conditions in effect at the time of this offering, which may not be indicative of the price at which the ADSs will trade following completion of this offering. Investors may not be able to sell their ADSs at or above the initial public offering price.

Our principal shareholders currently own, in the aggregate, almost all of our outstanding Class A shares and all of our outstanding Class B shares, and will own approximately 74% of our ordinary shares upon the closing of this offering. They will therefore be able to exert significant control over matters submitted to our shareholders for approval.

        After this offering, our shareholders who own more than 5% of our Class A shares and Class B shares before this offering will, in the aggregate, beneficially own approximately 74% of our ordinary shares (assuming no exercise of the underwriters' over-allotment option). These shareholders will be able to significantly influence or even unilaterally approve matters requiring approval by our shareholders, including the election of directors, certain decisions relating to our capital structure, amendments to our Articles of Association, and the approval of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests or the interests of our other shareholders or holders of the ADSs.

The Stock Lending Arrangements may result in the offering being characterized as a secondary offering.

        To facilitate the orderly closing of the sales of ADSs, the shares underlying the ADSs immediately prior to and concurrent with the consummation of the offering and the time of delivery of the ADSs will be shares (referred to as the Borrowed Shares) loaned by Nordic Biotech Opportunity Fund K/S, or NBOF, to the Company under the terms of a Stock Lending Agreement. In connection with the consummation of the offering and at or immediately after the delivery of the ADSs, newly issued ordinary shares of equal number of the Company will be exchanged for the Borrowed Shares held by the Depositary of the American Depositary Receipt Program and the Borrowed Shares underlying the ADSs will be returned to NBOF.

        All proceeds of the offering net of expenses are being paid to the Company. No proceeds are for the account of any shareholder. In the event the Company is unable to issue the newly issued shares as contemplated by the Stock Lending Agreement on a timely basis or if the Borrowed Shares are not returned to NBOF on a timely basis, then the offering may constitute a secondary offering.

        In such event, NBOF would have a cause of action against the Company or the underwriters for the return of the Borrowed Shares, the issuance of an equal number of newly issued shares or monetary damages. The Company has agreed to indemnify and hold harmless each of the underwriters and NBOF for any damages in connection with the Stock Lending Agreement and the transactions contemplated thereunder.

Our ordinary shares will be controlled by insiders, who could have significant influence over the outcome of corporate actions requiring board and shareholder approval.

        Our Chairman, Florian Schönharting, beneficially owns shares comprising approximately 71% of our voting power, and after the offering, will beneficially own approximately 56% of our ordinary shares (assuming that neither he nor his affiliates, purchase any ADSs in this offering). With such concentrated control, Mr. Schönharting will have influence over the outcome of corporate actions requiring board and shareholder approval, including the election of directors or any other significant corporate transaction. As a result, investors who acquire ADSs in the offering may have no effective voice in the management of our company.

44


Table of Contents

Our principal shareholders have entered into a shareholders' agreement under which they have agreed to take certain actions that may be adverse to your interests.

        Our principal shareholders have entered into a new shareholders' agreement in connection with this offering, under which they have agreed to take certain actions, including with respect to the ability of certain principal shareholders to nominate directors to the board of directors and the obligation to increase share capital in certain circumstances. The shareholders party to the shareholders' agreement will continue to control a majority of the beneficial voting power of our ordinary shares after completion of this offering, and the actions taken under or pursuant to the shareholders' agreement may conflict with your interests.

You may not be able to exercise your right to vote the ordinary shares underlying your ADSs.

        Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions of the deposit agreement and not as a direct shareholder in the Company. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (1) the notice of the meeting or solicitation of consent or proxy sent by us and (2) a statement as to the manner in which instructions may be given by the holders.

        You may instruct the depositary of your ADSs to vote the ordinary shares underlying your ADSs. Otherwise, you will not be able to exercise your right to vote, unless you withdraw the ordinary shares underlying the ADSs you hold. However, you may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for your instructions, the depositary, upon timely notice from us, will notify you of the upcoming vote and arrange to deliver our voting materials to you. We cannot guarantee you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the ordinary shares underlying your ADSs or to withdraw the ordinary shares underlying your ADSs so that you can vote them yourself. If the depositary does not receive timely voting instructions from you, it may give a proxy to a person designated by us to vote the ordinary shares underlying your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise any right to vote, and there may be nothing you can do if the ordinary shares underlying your ADSs are not voted as you requested.

Your right as a holder of ADSs to participate in any future preferential subscription rights or to elect to receive dividends in shares may be limited, which may cause dilution to your holdings.

        According to Danish Law, if we issue additional securities for cash, current shareholders will have preferential subscription rights for these securities on a pro rata basis unless (i) they waive those rights at a meeting of our shareholders (if issued at market value, by at least two-thirds of the votes cast and the share capital represented at such meeting), (ii) such rights are waived individually by each shareholder, or (iii) the additional securities are issued pursuant to an authorization granted to our board of directors including a waiver of preemptive rights. However, our ADS holders in the United States will not be entitled to exercise or sell such rights related to the ordinary shares which they represent unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary will not make rights available to you unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. Further, if we offer holders of our ordinary shares the option to receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the offer to holders of ADSs does not

45


Table of Contents

require registration of any securities under the Securities Act before making the option available to holders of ADSs. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights.

You may be subject to limitations on the transfer of your ADSs and the withdrawal of the underlying ordinary shares.

        Your ADSs, which may be evidenced by American Depositary Receipts, or ADRs, are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of your ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason subject to your right to cancel your ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders' meeting or we are paying a dividend on our ordinary shares. In addition, you may not be able to cancel your ADSs and withdraw the underlying ordinary shares when you owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. See the section of this Prospectus titled "Description of American Depositary Shares—Your Right to Receive the Ordinary Shares Underlying Your ADSs."

Future sales, or the perception of future sales, of a substantial number of our ordinary shares or ADSs could adversely affect the price of the ADSs, and actual sales of our equity will dilute shareholders and ADS holders.

        Future sales of a substantial number of our ordinary shares or ADSs, or the perception that such sales will occur, could cause a decline in the market price of the ADSs. Based on the number of Class A and Class B shares outstanding as of June 30, 2014 and following the Share Conversion, the Bridge Conversions, the Bonus Share Issuance, the exercise of 7,590 warrants by Morten Priskorn and the Share Split, we had 35,313,760 ordinary shares outstanding immediately prior to the consummation of this offering. Based on 10,500,000 ordinary shares being issued as part of the offering of ADSs, we will have 45,813,760 ordinary shares outstanding upon the completion of this offering (assuming no exercise of the underwriters' over-allotment option). This includes the shares underlying the ADSs offered in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Assuming the purchase in this offering of 952,381 of the ADSs by certain of our existing shareholders or their affiliates, the number of our ordinary shares beneficially owned by our existing shareholders will, in the aggregate, increase to 36,266,141 of our ordinary shares. A significant portion of these shares will be subject to the lock-up agreements described in the "Underwriting" section of this Prospectus. If, after the end of such lock-up agreements, these shareholders sell substantial amounts of shares or ADSs in the public market, or the market perceives that such sales may occur, the market price of the ADSs and our ability to raise capital through an issue of equity securities in the future could be adversely affected. We have entered into a registration rights agreement pursuant to which we have agreed under certain circumstances to file a registration statement to register the resale of the shares held by certain of our existing shareholders, as well as to

46


Table of Contents

cooperate in certain public offerings of such shares. In addition, we intend to register all ordinary shares that we may issue under our equity compensation plans. Once we register these ordinary shares, they can be freely sold in the public market or otherwise upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the "Underwriting" section of this Prospectus.

If you purchase ADSs in this offering, you will suffer immediate dilution of your investment.

        The initial public offering price of the ADSs is substantially higher than the pro forma net tangible book value per Class A share and Class B share (following the Share Split). Therefore, if you purchase ADSs in this offering, you will pay a price per ADS that substantially exceeds our pro forma net tangible book value per ADS after this offering. To the extent outstanding warrants are exercised or deferred shares are issued, you will incur further dilution. Based on the initial public offering price of $21.00 per ADS, you will experience immediate dilution, representing the difference between our pro forma net tangible book value per ADS after giving effect to this offering and the initial public offering price. In addition, purchasers of ADSs in this offering will have contributed approximately 72.6% of the aggregate price paid by all purchasers or subscribers of our ordinary shares but will own only ADSs representing approximately 22.9% of our ordinary shares outstanding after this offering. See "Dilution."

We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

        Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that ultimately do not improve our results of operations or enhance the value of our ordinary shares. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of the ADSs to decline and delay the development of FP187. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.

As required by the Framework Agreement, a nonrecurring preferential share issuance of Class A bonus shares was distributed immediately prior to this offering to our existing Class B shareholders, which resulted in a negative effect on the loss per share available to the holders of our ADSs immediately following this offering.

        As required by the Framework Agreement, described under "Related Party Transactions—Framework Agreement," a nonrecurring preferential share issuance of Class A shares was distributed to our existing Class B shareholders immediately prior to this offering. Due to such share issuance, the loss available to holders of our ADSs increased by the value of such share issuance and, as a result, there was a corresponding and equal negative effect on the loss per share available to the holders of our ADSs.

We do not expect to pay dividends in the foreseeable future.

        We have not paid any dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that any earnings will be reinvested in our business and that dividends will not be paid until we have an established revenue stream to support continuing dividends. Payment of future dividends will effectively be at the discretion of our board of directors, after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. In addition, payment of future dividends may be made only if our shareholders' equity exceeds the sum of our paid-in and called-up share capital plus the reserves required to be maintained by Danish law or by our Articles of Association. Accordingly, investors cannot rely on dividend income and any returns on an investment in the ADSs will likely depend entirely upon any future appreciation in the price of the ADSs.

47


Table of Contents

We are an "emerging growth company," and we cannot be certain if the reduced reporting requirements applicable to "emerging growth companies" will make our ordinary shares less attractive to investors.

        We are an "emerging growth company," as defined in the JOBS Act. For as long as we continue to be an "emerging growth company," we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies," including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an "emerging growth company" we are required to report only two years of financial results and selected financial data compared to three and five years, respectively, for comparable data reported by other public companies. We may take advantage of these exemptions until we are no longer an "emerging growth company." We could be an "emerging growth company" for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our equity securities held by non-affiliates exceeds $700 million as of any June 30 date (the end of our second fiscal quarter) before that time, in which case we would no longer be an "emerging growth company" as of the following December 31 (our fiscal year end). We cannot predict if investors will find the ADSs less attractive because we may rely on these exemptions. If some investors find the ADSs less attractive as a result, there may be a less active trading market for the ADSs and the price of the ADSs may be more volatile.

We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.

        As a foreign private issuer, we are not required to comply with all the periodic disclosure and current reporting requirements of the Exchange Act and related rules and regulations. The determination of foreign private issuer status is made annually on the last business day of an issuer's most recently completed second fiscal quarter. Accordingly, we will next make a determination with respect to our foreign private issuer status on June 30, 2015. There is a risk that we will lose our foreign private issuer status in the future.

        We would lose our foreign private issuer status if, for example, more than 50% of our assets are located in the United States and we continue to fail to meet additional requirements necessary to maintain our foreign private issuer status. As of June 30, 2014, an immaterial amount of our assets were located in the United States, although this may change if we expand our operations in the United States. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly greater than the costs we incur as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S. GAAP and modify certain of our policies to comply with corporate governance practices associated with U.S. domestic issuers. Such conversion and modifications would involve additional costs. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers, which could also increase our costs.

If we fail to establish and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of the ADSs.

        Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud.

48


Table of Contents

Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of the ADSs.

        We will be required to disclose changes made in our internal control over financial reporting and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an "emerging growth company" under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. We could be an "emerging growth company" for up to five years. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management's assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation.

If we are unable to successfully remediate material weaknesses in our internal control over financial reporting relating to inadequate financial statement preparation and review procedures, the accuracy and timing of our financial statements may be adversely affected. Further, these material weaknesses could impair our ability to comply with the accounting and reporting requirements within the International Financial Reporting Standards (IFRS) as issued by the IASB.

        In connection with the audits of our financial statements, our independent registered public accounting firm identified a material weakness related to our financial statement closing process, primarily related to the lack of sufficient skilled personnel with IFRS and SEC reporting knowledge for the purposes of timely and reliable financial reporting. Specifically, our independent registered public accounting firm determined that we lacked sufficient accounting and finance resources to and did not design and operate procedures and controls over the preparation of our financial statements, including insufficient financial statement close process and procedures including account reconciliations, the resolution of complex accounting issues involving significant judgment and estimates and overall review of the financial statements.

        Under standards established by the Public Company Accounting Oversight Board, a material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis.

        We concurred with the findings of our independent registered public accounting firm. We are working to remediate the material weakness and are taking numerous steps and plan to take additional steps to remediate the underlying causes of the material weakness. We recently engaged a full-time Chief Financial Officer, and plan to further develop and implement formal policies, processes and documentation procedures relating to the financial reporting of the Company. The actions that we are taking are subject to ongoing executive management review, and will also be subject to audit committee oversight. Although we plan to complete this remediation process as quickly as possible, we cannot at this time estimate how long it will take, and our initiatives may not prove to be successful in remediating the material weakness. If we are unable to successfully remediate the material weakness, and if we are unable to produce accurate and timely financial statements, the price of the ADSs may be adversely affected and we may be unable to comply with applicable stock exchange listing requirements.

49


Table of Contents

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price of the ADSs and our trading volume could decline.

        The trading market for the ADSs will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or too few securities or industry analysts commence coverage of our company, the trading price for our ordinary shares would likely be negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our ordinary shares or publish inaccurate or unfavorable research about our business, the price of our ordinary shares would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for the ADSs could decrease, which might cause the price of our ordinary shares and trading volume to decline.

We may be classified as a passive foreign investment company, or a PFIC, in 2014 or any future year. If we are a PFIC for any taxable year, this could result in adverse U.S. federal income tax consequences to U.S. Holders.

        Under the U.S. Internal Revenue Code of 1986, as amended, or Code, we will be a PFIC for any taxable year in which, after the application of certain "look-through" rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of "passive income," or (ii) 50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production of, "passive income." Passive income generally includes interest, dividends, rents, certain non-active royalties and capital gains. Whether we will be a PFIC in any year depends on the composition of our income and assets, and the relative fair market value of our assets from time to time, which we expect may vary substantially over time. Because (i) we currently own, and will own after the completion of this offering, a substantial amount of passive assets, including cash, and (ii) the values of our assets, including our intangible assets, that generate non-passive income for PFIC purposes, is uncertain and may vary substantially over time, it is uncertain whether we will be or will not be a PFIC in 2014 or any future year.

        If we are a PFIC for any taxable year during which a U.S. Holder (as defined below) holds ADSs, a U.S. Holder may be subject to adverse tax consequences, including (i) if a mark-to-market election or a qualified electing fund, or QEF, election has not been made with respect to its ADSs, a U.S. Holder may incur significant additional U.S. federal income taxes on income resulting from distributions on, or any gain from the disposition of, such ADSs, as such income generally would be allocated over the U.S. Holder's holding period for its ADSs and would be subject to tax at the highest rates of U.S. federal income taxation in effect for such years, with an interest charge then imposed on the resulting taxes in respect of such income, and (ii) dividends paid by us would not be eligible for preferential individual rates of U.S. federal income tax. In addition, U.S. Holders that own an interest in a PFIC are required to comply with certain reporting requirements.

        A U.S. Holder may in certain circumstances mitigate adverse tax consequences of the PFIC rules by filing an election to treat the PFIC as QEF, or, if shares of the PFIC are "marketable stock" for purposes of the PFIC rules, by making a mark-to-market election with respect to the shares of the PFIC. However, in the event that we are or become a PFIC, we do not intend to comply with the reporting requirements necessary to permit U.S. Holders to elect to treat us as a QEF. Furthermore, if a U.S. Holder were to make a mark-to-market election with respect to its ADSs, the U.S. Holder would be required to include annually in its U.S. federal taxable income an amount reflecting any year end increase in the value of its ADSs. For further discussion of the adverse U.S. federal income tax consequences of our classification as a PFIC, see "Taxation—U.S. federal income tax considerations for U.S. holders."

50


Table of Contents

Risks Related to Danish Law and Our Operations in Denmark

Preemptive rights may not be available to non-Danish shareholders, and any inability of non-Danish shareholders to exercise preemptive rights in respect of shares issued in any offering by us will cause their proportionate interests to be diluted.

        Under Danish law, existing shareholders will have preemptive rights to participate on the basis of their existing share ownership in the issuance of any new shares for cash consideration, unless those rights are waived by a resolution of the shareholders or the shares are issued pursuant to an authorization granted to the board of directors including a waiver of preemptive rights. The preemptive rights of the shareholders may be waived by a majority comprising at least two-thirds of the votes cast and of the share capital represented at the general meeting provided the capital increase is made at market price. Certain non-Danish shareholders may not be able to exercise preemptive rights for their shares due to restrictions included in securities laws of certain countries, including those applicable in the United States. To the extent that shareholders are not able to exercise their preemptive rights in respect of the shares in any offering by us, such shareholders' proportional interests will be diluted.

Upon the consummation of this offering, we will be a Danish company with limited liability. The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions.

        We are, and will upon the consummation of this offering be, a Danish company with limited liability. Our corporate affairs are governed by our Articles of Association and by the laws governing companies incorporated in Denmark. The rights of shareholders and the responsibilities of members of our board of directors may be different from the rights and obligations of shareholders and boards of directors in companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our board is required by Danish law to consider the interests of our company, its shareholders, its employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, the interests of our shareholders. See "Description of Share Capital and Articles of Association—Corporate Governance."

We are, as a foreign private issuer, not obligated to and do not comply with all the corporate governance requirements of NASDAQ. This may affect the rights of our shareholders.

        We will be a foreign private issuer for purposes of U.S. federal securities laws. As a result, in accordance with the listing requirements of NASDAQ, we will rely on home country governance requirements and certain exemptions thereunder rather than relying on the corporate governance requirements of NASDAQ. In accordance with Danish law and generally accepted business practices, our Articles of Association do not provide quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of NASDAQ Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting shares. Although we must provide shareholders with an agenda and other relevant documents in advance of a general meeting of shareholders, Danish law does not have an applicable regulatory regime for the solicitation of proxies, thus our practice will vary from the requirement of NASDAQ Listing Rule 5620(b). For an overview of our corporate governance principles, see "Description of Share Capital and Articles of Association—Corporate Governance." Accordingly, our shareholders may not have the same protections afforded to shareholders of companies that are subject to these NASDAQ requirements.

        As a Danish company we must comply with the Danish Companies Act, or DCA. The DCA contains binding provisions for the board of directors, shareholders and general meetings of shareholders; and financial reporting, auditors, disclosure, compliance and enforcement standards.

51


Table of Contents

Certain provisions apply to our board of directors (e.g., in relation to role, composition, conflicts of interest and independency requirements and remuneration), shareholders and the general meeting of shareholders (e.g., regarding our obligations to provide information to our shareholders). Further, certain sections of the DCA only apply to Danish companies listed on a regulated market with the EEA, and accordingly would not apply to us. See "Description of Share Capital and Articles of Association—Danish Corporate Governance." This may affect the rights of our shareholders.

We have historically filed our Danish tax returns on a standalone basis; however, due to certain changes to the ownership structure of the Company made at the start of 2013, as of January 2013, we must file our Danish tax returns as part of a Danish tax group controlled by Tech Growth Invest ApS, a Danish corporation ("Tech Growth").

        As of January 19, 2013, we became part of the tax group of Tech Growth for purposes of Danish law as a result of certain acquisitions made (see the table set forth in the section entitled "Principal Shareholders"). Danish law provides for joint income taxation for all Danish entities in the same tax group, with the result that losses by one entity would be offset by gains by another. However, Danish law requires entities in the same tax group to pay each other for the use of each other's tax losses. Therefore, any use of Forward Pharma's losses by other members of the Tech Growth tax group will result in compensation to Forward Pharma.

        All members of a Danish tax group are jointly and severally liable for the group's Danish tax liabilities. However, Danish law requires taxing authorities to look primarily to Tech Growth and its wholly owned entities to satisfy Danish tax liabilities and to look to partially owned entities (such as Forward Pharma) only on a secondary basis. While we do not believe Tech Growth to have any material Danish tax liabilities, there can be no assurance that they do not have any such material liabilities, that they will not incur such material liabilities in the future, or that they will fulfill any such obligations. If Tech Growth has material Danish tax liabilities that are not satisfied by Tech Growth and its wholly owned subsidiaries or if Tech Growth incurs any such liabilities in the future, we may be responsible for the payment of such taxes, which could have an adverse effect on our results of operations.

U.S. federal and/or state income tax may apply to us in the future.

        We are not currently subject to U.S. federal or state income tax. Our Chief Financial Officer Joel Sendek is employed by both Forward Pharma A/S and our wholly owned U.S. subsidiary, Forward Pharma USA, LLC, and our Vice President, Finance and Controller Thomas Carbone, and Director, Investor Relations Sharon Klahre, are both employed by Forward Pharma USA, LLC. Pursuant to the U.S. tax laws and the income tax treaty between Denmark and the United States, we will not be subject to U.S. tax in connection with any of such employees' activities unless there is a U.S. trade or business being conducted in connection with a permanent establishment. While we believe that the functions such employees fulfill do not give rise to U.S. tax liability for us, there can be no assurances that the U.S. tax authorities will agree with such position. In addition, if the functions of such employees are expanded in the future, and/or we engage additional personnel located in the United States whose functions are sufficiently broad, we may become subject to U.S. federal and/or state income tax, which might have a material adverse effect on us and our results of operations.

Claims of U.S. civil liabilities may not be enforceable against us.

        Forward Pharma A/S is incorporated under the laws of Denmark, and one of its wholly owned subsidiaries Forward Pharma GmbH, is incorporated under the laws of Germany. Substantially all of our assets are located outside the United States. On a combined basis, the majority of our directors and officers immediately following consummation of the offering reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon

52


Table of Contents

such persons or to enforce against them or us in U.S. courts, including judgments predicated upon the civil liability provisions of the federal securities laws of the United States.

        The United States does not have a treaty with Denmark or Germany providing for reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Accordingly, a final judgment for the payment of money rendered by a United States court based on civil liability will not be directly enforceable in Denmark or Germany. However, if the party in whose favor such final judgment is rendered brings a new lawsuit in a competent court in Denmark, that party may submit to the Danish court the final judgment that has been rendered in the United States. A judgment by a federal or state court in the United States will neither be recognized nor enforced by a Danish court but such judgment may serve as evidence in a similar action in such court. In addition, the final judgment of a United States court may be recognized and enforced in Germany in compliance with certain requirements including petitioning a German court to enforce such judgment.

We will be a foreign private issuer and, as a result, we will not be subject to U.S. proxy rules and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company.

        Upon consummation of this offering, we will report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although we intend to furnish quarterly financial information to the SEC, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i) the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii) the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iii) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, our shareholders may not have the same protections afforded to shareholders of companies that are not foreign private issuers.

53


Table of Contents


CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

        This Prospectus contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this Prospectus can be identified by the use of forward-looking words such as "anticipate," "believe," "could," "expect," "may," "should," "plan," "intend," "estimate," "will," "would," and "potential," among others.

        Forward-looking statements appear in a number of places in this Prospectus and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section entitled "Risk Factors" in this Prospectus. These risks and uncertainties include factors relating to:

    statements regarding the timing of initiation and completion of the trials and when results of the trials will be made public;

    the clinical utility of FP187;

    the timing or likelihood of regulatory filings and approvals;

    our expectations regarding our planned path for approval of FP187 to treat RRMS, including the possibility that the FDA may determine that a single Phase 3 trial is insufficient for the approval of FP187 for RRMS;

    our estimates regarding the market opportunity for other indications for FP187;

    our ability to establish sales, marketing and distribution capabilities;

    our ability to establish and maintain manufacturing arrangements for FP187;

    our ability to enter into strategic relationships or collaborations with respect to FP187;

    our intellectual property position;

    the intellectual property positions of third parties;

    our expectations regarding the use of proceeds from this offering;

    our estimates regarding expenses, future revenues, capital requirements and the need for additional financing;

    the impact of government laws and regulations;

    our competitive position;

    our ability to continue as a going concern; and

    other risk factors discussed under "Risk Factors."

        Forward-looking statements speak only as of the date they are made, and except as required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

54


Table of Contents


PRESENTATION OF FINANCIAL AND OTHER INFORMATION

        We prepare our consolidated financial statements in accordance with IFRS as issued by the IASB. None of the financial statements included in this Prospectus were prepared in accordance with generally accepted accounting principles in the United States.

        The audited consolidated financial statements as of December 31, 2013 and 2012 and January 1, 2012 and for each of the two years in the period then ended are the audited consolidated financial statements for Forward Pharma A/S. The unaudited condensed consolidated interim financial statements as of June 30, 2014 and for each of the six month periods ended June 30, 2014 and 2013 are the unaudited condensed consolidated interim financial statements for Forward Pharma A/S.

        The terms "$" and "USD" refer to U.S. dollars, the terms "DKK" and "Danish Kroner" refer to the legal currency of Denmark and the terms "€", "EUR" and "Euro" refer to the legal currency of the euro area.

55


Table of Contents


USE OF PROCEEDS

        We expect to receive total estimated net proceeds of approximately $198.8 million, based on the initial public offering price, after deducting estimated underwriting discounts and commissions and expenses of this offering that are payable by us. If the underwriters exercise their over-allotment option in full, we estimate that the net proceeds from this offering will be approximately $229.6 million, after deducting estimated underwriting discounts and commissions and expenses of this offering that are payable by us.

        As of June 30, 2014, we had cash and cash equivalents of approximately $244,000. We currently expect that we will use the net proceeds from this offering, together with a fully drawn down €8.4 million principal amount bridge financing we entered into on May 30, 2014 with NBFPII, a fully drawn down $10 million principal amount additional bridge financing we entered into on August 6, 2014 with BVF Forward (an affiliate of BVF Partners LP, which is itself affiliated with certain of our principal shareholders), and cash and cash equivalents on hand, as follows:

    approximately $80 million for the clinical development of FP187 for the treatment of RRMS;

    approximately $25 million to fund the exploitation and protection of our intellectual property rights (including in connection with oppositions and interference cases);

    approximately $22 million for the clinical development of FP187 for the treatment of psoriasis;

    approximately $12 million for execution of our pre-clinical program, for our manufacturing activities, and for related Phase 1 clinical trials; and

    the remainder for working capital and other general corporate purposes.

        Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition, where we expect to incur up to $26.0 million of costs associated with research and development in our fiscal year ending December 31, 2014, subject to timing of our development activities. As of the date of this Prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of net proceeds will vary depending on numerous factors, including our ability to obtain additional financing, the relative success and cost of our research, pre-clinical and clinical development programs, and whether we enter into collaborations with third parties in the future. As a result, management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds of this offering. In addition, we might decide to postpone or not pursue other clinical trials or pre-clinical activities if the net proceeds from this offering and our other sources of cash are less than expected.

        At present, we believe that the expected net proceeds of this offering, the bridge financings we entered into on May 30, 2014 and August 6, 2014, and our current cash and cash equivalents, will allow us to initiate a Phase 3 clinical trial program for FP187 in RRMS, including the opening of approximately 200 investigational sites and the enrolment of approximately 700 subjects. We further anticipate that the net proceeds would also enable us to complete the initial Phase 3 trial in psoriasis. However, we anticipate that we will require substantial additional capital to complete our development activities in RRMS and psoriasis. We also anticipate that the net proceeds would be insufficient to allow for the market authorization and commercialization of FP187. We further note that it is difficult to predict our future liquidity requirements given the uncertainty around the requirements associated with the development and commercialization of new drugs, and we could exhaust our capital resources earlier than we currently expect. For more information regarding these risks, see "Risk Factors".

        Pending their use, we plan to invest the net proceeds from this offering in short- and intermediate-term interest-bearing obligations and certificates of deposit.

56


Table of Contents


DIVIDEND POLICY

        We have never paid or declared any cash dividends on our Class A shares or Class B shares, and we do not anticipate paying any cash dividends on our Class A shares or Class B shares or, following the Share Conversion, our ordinary shares or ADSs, in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.

Legal and Regulatory Requirements

        In accordance with the Danish Companies Act, or DCA, dividends, if any, are declared with respect to a financial year at the annual general meeting of shareholders in the following year, where the statutory annual report (which includes the audited financial statements) for that financial year is approved. Further, our shareholders may resolve at a general meeting to distribute interim dividends and our board of directors may, pursuant to an authorization that will be granted to it by our shareholders prior to completion of this offering, resolve to distribute interim dividends. Any resolution to distribute interim dividends within six months after the date of the statement of financial position as set out in our latest adopted annual report must be accompanied by the statement of financial position from our latest annual report or an interim statement of financial position which must be reviewed by our auditor. If the decision to distribute interim dividends is passed more than six months after the date of the statement of financial position as set out in our latest adopted annual report, an interim statement of financial position must be prepared and reviewed by our auditor. The statement of financial position or the interim statement of financial position, as applicable, must show that sufficient funds are available for distribution. Dividends may not exceed the amount recommended by the board of directors for approval by the general meeting of shareholders. Moreover, dividends and interim dividends may only be made out of distributable reserves and may not exceed what is considered sound and adequate with regard to our financial condition or be to the detriment of our creditors and such other factors as the board of directors may deem relevant.

        In accordance with the DCA, share buybacks, if any, may only be carried out by the board of directors using funds that could have been distributed as dividends at the latest annual general meeting of shareholders. Any share buyback must be conducted in accordance with an authorization obtained at a general meeting of shareholders. The authorization must be granted for a defined period of time not exceeding five years. In addition, the authorization must specify the maximum permitted value of treasury shares as well as the minimum and maximum amount that we may pay as consideration for such shares. A decision by our board of directors to engage in share buybacks, if any, will be made in accordance with the factors applicable to dividend payments set forth above.

        Prior to our board of directors' approval of the offer price and the issuance of ADSs being offered by this Prospectus, it is expected that our board of directors will be authorized to purchase some of our shares to the extent that our holding of shares at no time exceeds a fixed percentage of our share capital. The purchase price will not be permitted to deviate by more than a fixed percentage from the ADSs' quoted price on NASDAQ at the time of the purchase. The authorization will be valid for a limited time period. The authorization can be utilized to (i) acquire our own shares directly, and/or (ii) acquire ADSs which can then be surrendered to the Bank of New York Mellon, enabling us to take delivery of the underlying shares represented by such ADSs and subsequently cancel the shares.

        In connection with the offering, certain of our shareholders have entered into a shareholders' agreement which provides that dividends are not intended to be paid prior to the occurrence of certain events constituting exit events, as further provided for in the shareholders' agreement. For more information regarding the shareholders' agreement, see "Related Party Transactions—New Shareholders' Agreement". See "Taxation" for a description of Danish withholding taxes and certain other Danish and U.S. federal income tax considerations relevant to the purchase or holding of shares and ADSs.

57


Table of Contents


CAPITALIZATION

        The table below sets forth our capitalization (defined as total debt and shareholders' equity) as of June 30, 2014 derived from our condensed consolidated financial statements included in this Prospectus:

    on an actual basis; and

    on a pro forma as adjusted basis, reflecting (a) the Share Conversion, (b) the Bridge Conversions, (c) the issuance of 7,590 Class A shares pursuant to an exercise of warrants to acquire Class A shares, at a price of DKK 70.06 per share on July 3, 2014, (d) the Bonus Share Issuance, (e) the Share Split, and (f) the issuance and sale of 10,500,000 ADSs, representing 10,500,000 ordinary shares, at the initial public offering price, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

        Investors should read this table in conjunction with our audited consolidated financial statements included in this Prospectus as well as "Use of Proceeds," "Selected Financial Information" and "Management's Discussion and Analysis of Financial Condition and Results of Operations."

 
  June 30, 2014  
(USD in thousands)
  Actual
(unaudited)
  Pro Forma
(as adjusted)(1)
 

Cash and cash equivalents(2)

    244     219,771  
           

Share capital

    314     790  

Share premium

    58,084     281,088  

Foreign currency translation reserve

    (1,319 )   (1,319 )

Accumulated deficit

    (58,889 )   (62,842 )
           

Total shareholders' equity (deficit)

    (1,810 )   217,717  
           

Total capitalization (deficit)

    (1,810 )   217,717  

(1)
The pro forma amounts do not include the effect of a nonrecurring preferential share issuance that was distributed to the Class B shareholders, resulting from the issuance of Class A bonus shares required by the Framework Agreement, as described under "Related Party Transactions—Framework Agreement." The preferential share issuance is valued at approximately $42.8 million (based on the initial public offering price of $21.00 per ADS) and when issued, increased the loss available to the holders of our ADSs by an equal amount and, therefore, had a negative effect on the loss per share available to such ADS holders.

(2)
Cash and cash equivalents are not a component of capitalization but are included here for the convenience of prospective investors in seeing the effects of this offering on the Company's cash position.

58


Table of Contents


DILUTION

        If you invest in our ordinary shares, your interest will be diluted to the extent of the difference between the initial public offering price per ADS and the pro forma net tangible book value per ADS after this offering. Net tangible book value represents the amount of our total tangible assets reduced by our total liabilities.

        At June 30, 2014, we had a net tangible book value of $18.9 million, corresponding to a net tangible book value of $0.53 per ADS, after giving pro forma effect to the Share Conversion, the Bridge Conversions, the Bonus Share Issuance, the Share Split, and the issuance of 7,590 Class A shares pursuant to an exercise of warrants. Net tangible book value per ADS represents the amount of our total assets less our total liabilities divided by 35,313,760, the total number of ADSs that would have been outstanding as of June 30, 2014 had each of the Share Conversion, the Bridge Conversions, the Bonus Share Issuance, the Share Split, and the issuance of 7,590 Class A shares pursuant to an excercise of warrants been effected on such date.

        After giving effect to the sale by us of the 10,500,000 ADSs offered by us in this offering, and given the initial public offering price of $21.00 per ADS, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma net tangible book value estimated at June 30, 2014 would have been approximately $217.7 million, representing $4.75 per ADS. This represents an immediate increase in net tangible book value of $4.22 per ADS to existing shareholders and an immediate dilution in net tangible book value of $16.25 per share to new investors purchasing ADSs in this offering. Dilution for this purpose represents the difference between the price per ADS paid by these purchasers and net tangible book value per ADS immediately after the completion of this offering.

        The following table illustrates this dilution to new investors purchasing ADSs in this offering.

 
  USD  

Net tangible book value per ADS at June 30, 2014, pro forma for the Share Conversion, the Bridge Conversions, the Share Split, the issuance of 7,590 Class A shares pursuant to an exercise of warrants, and the Bonus Share Issuance

    0.53  

Increase in net tangible book value per ADS attributable to new investors

    4.22  

Pro forma net tangible book value per ADS after the offering

    4.75  

Dilution per ADS to new investors

    16.25  

Percentage of dilution in net tangible book value per ADS for new investors to the amount paid per ADS by new investors

    77 %

        The following table sets forth, on a pro forma basis as of June 30, 2014, after giving effect to this offering at the initial public offering price of $21.00 per ADS, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and the Share Conversion, the Bridge Conversions, the Bonus Share Issuance, the Share Split, and the issuance of 7,590 Class A shares pursuant to an exercise of warrants, (A) the total number of (i) existing shares owned by existing shareholders and (ii) new shares to be issued in connection with this offering and represented by the ADSs, and (B) (i) the total consideration paid and the average price per share paid by our existing shareholders for existing shares and (ii) the total consideration to be paid by investors purchasing ADSs in this offering.

 
  Shares/ADSs
subscribed/purchased
   
   
   
 
 
  Total consideration    
 
 
  Average price
per share/ADS
 
 
  Number   Percent   Amount   Percent  

Existing shareholders

    35,313,760     77.1 % $ 83,029,760     27.4 % $ 2.35  

New investors

    10,500,000     22.9 % $ 220,500,000     72.6 % $ 21.00  

Total

    45,813,760     100 % $ 303,529,760     100 %      

59


Table of Contents

        The table above does not include:

    131,052 of our Class A shares issuable upon the exercise of warrants outstanding as of June 30, 2014 at a weighted average exercise price of DKK 156.4 per share, which will entitle the holders to subscribe for an aggregate of 229,383 ordinary shares of DKK 1 following the Share Conversion and the Bonus Share Issuance, but before the Share Split (based on the initial public offering price of $21.00 per ADS);

    31,895 Class A shares or 56,861 ordinary shares of DKK 1, following the Share Conversion and the Bonus Share Issuance, but before the Share Split (based on the initial public offering price of $21.00 per ADS) issuable pursuant to the deferred share award granted in August 2014 to Joel Sendek under the Share Plan (as defined below);

    47,038 ordinary shares of DKK 1, following the Share Conversion and the Bonus Share Issuance, but before the Share Split, issuable to Joel Sendek, Thomas Carbone and Sharon Klahre pursuant to non-qualified stock options granted under the Share Plan upon consummation of this offering (based on the initial public offering price of $21.00 per ADS);

    5,000 Class A shares or 8,914 ordinary shares of DKK 1, following the Share Conversion and the Bonus Share Issuance, but before the Share Split (based on the initial public offering price of $21.00 per ADS) issuable to Jan G. J. van de Winkel upon exercise of warrants issued in August 2014; and

    Exercise by the underwriters of their over-allotment option; if the over-allotment option is exercised in full, the following will occur:

    the percentage of our existing ordinary shares held by existing shareholders will decrease to approximately 74.5% of the total number of our ordinary shares outstanding after this offering; and

    the percentage of our ordinary shares issued in connection with this offering and represented by the ADSs will increase to approximately 25.5% of the total number of our ordinary shares outstanding after this offering.

60


Table of Contents


SELECTED FINANCIAL INFORMATION

        The summary statement of profit or loss and statement of financial position for the years ended and as of December 31, 2013 and 2012 of Forward Pharma A/S are derived from the audited consolidated financial statements included in this Prospectus. The summary statement of profit or loss and statement of financial position for the six month periods ended June 30, 2014 and 2013 and as of June 30, 2014 of Forward Pharma A/S are derived from the unaudited condensed consolidated interim financial statements included in this Prospectus. We prepare our consolidated financial statements in accordance with IFRS as issued by the IASB.

        This financial information should be read in conjunction with "Presentation of Financial and Other Information," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements, including the notes thereto, included in this Prospectus.

Consolidated statement of profit or loss data

 
  Year ended
December 31,
(Audited)
  Six months ended
June 30,
(Unaudited)
 
(USD in thousands, except share and per share data)
  2013   2012   2014   2013  

Research and development costs

    (8,018 )   (4,445 )   (4,821 )   (2,982 )

General and administrative costs

    (1,014 )   (928 )   (2,618 )   (385 )
                   

Operating loss

    (9,032 )   (5,373 )   (7,439 )   (3,367 )
                   

Fair value adjustment to net settlement obligations to shareholder warrants

    (6,676 )   (17,071 )   (1,005 )   2,084  

Other finance costs

    (84 )   (35 )   (108 )   (12 )
                   

Net loss before tax

    (15,792 )   (22,479 )   (8,552 )   (1,295 )
                   

Income tax

    96     0     57     87  
                   

Net loss for the period

    (15,696 )   (22,479 )   (8,495 )   (1,208 )
                   

Historical net loss per share

                         

Basic

    (9.53 )   (14.25 )   (4.91 )   (0.75 )

Diluted

    (9.53 )   (14.25 )   (4.91 )   (1.88 )

Weighted-average shares outstanding used to calculate net loss per share

                         

Basic

    1,599,000     1,577,000     1,678,000     1,599,000  

Diluted

    1,599,000     1,577,000     1,678,000     1,737,000  

Historical as adjusted net loss per share (unaudited)(1)

                         

Basic

    (0.95 )   (1.43 )   (0.49 )   (0.07 )

Diluted

    (0.95 )   (1.43 )   (0.49 )   (0.19 )

Historical as adjusted weighted-average shares outstanding used to calculate historical as adjusted net loss per share (unaudited)

                         

Basic

    15,990,000     15,770,000     16,780,000     15,990,000  

Diluted

    15,990,000     15,770,000     16,780,000     17,370,000  

(1)
The historical as adjusted net loss per share amounts and the historical as adjusted weighted-average shares outstanding have been computed to retroactively reflect the Share Split for all periods presented. The historical as adjusted share and per share amounts exclude the effect of the Bonus Share Issuance.

61


Table of Contents

Consolidated statement of financial position data

 
  As of December 31,
(Audited)
  As of June 30,
(Unaudited)
 
(USD in thousands)
  2013   2012   2014  

Cash and cash equivalents

    2,955     828     244  

Adjusted working capital (deficit)(1)

    2,317     213     (1,814 )

Total assets

    3,599     970     2,901  

Long-term debt, including current portion

    2,613     2,100     0  

Accumulated deficit

    (51,913 )   (36,796 )   (58,889 )

Total shareholders' deficit

    (26,415 )   (20,250 )   (1,810 )

(1)
We define adjusted working capital as current assets minus trade and other payables. We use adjusted working capital to, among other things, evaluate our short-term liquidity requirements. We find adjusted working capital a useful metric in evaluating our short-term liquidity requirements because it eliminates the impact of shareholder warrants.

        Adjusted working capital is not an IFRS measure, and our definition may vary from that used by others in our industry. Accordingly, our use of adjusted working capital has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our financial position as reported under IFRS.

62


Table of Contents


EXCHANGE RATE INFORMATION

        Our business is primarily conducted in Denmark and Germany. The functional currency of Forward Pharma A/S is the Danish Kroner, the functional currency of Forward Pharma GmbH is the Euro and the functional currency of Forward Pharma USA, LLC is the U.S. dollar. Forward Pharma A/S reports its consolidated financial statements in U.S. dollars. Certain information in this Prospectus is presented in Danish Kroner. On September 30, 2014, the period-end exchange rate was DKK 5.893 to $1.00.

        The following table presents information on the exchange rates between the Danish Kroner and the U.S. dollar for the periods indicated, as published by the Danish Central Bank.

 
  Period-end   Average
for Period
  Low   High  
 
  (DKK per USD)
 

Year Ended December 31:

                         

2009

    5.186     5.355     4.931     5.946  

2010

    5.555     5.625     5.115     6.234  

2011

    5.725     5.357     5.008     5.760  

2012

    5.659     5.794     5.523     6.156  

2013

    5.414     5.618     5.400     5.833  

Month Ended:

                         

March 2014

    5.417     5.398     5.359     5.434  

April 2014

    5.383     5.406     5.376     5.452  

May 2014

    5.469     5.435     5.357     5.489  

June 2014

    5.445     5.486     5.445     5.513  

July 2014

    5.572     5.509     5.451     5.574  

August 2014

    5.656     5.598     5.552     5.656  

September 2014

    5.893     5.770     5.656     5.893  

        The following table presents information on the exchange rates between the Euro and the U.S. dollar for the periods indicated, as published by WM/Reuters.

 
  Period-end   Average
for Period
  Low   High  
 
  (EUR per USD)
 

Year Ended December 31:

                         

2009

    0.697     0.719     0.663     0.798  

2010

    0.745     0.755     0.687     0.838  

2011

    0.770     0.719     0.672     0.774  

2012

    0.758     0.778     0.743     0.827  

2013

    0.726     0.753     0.724     0.782  

Month Ended:

                         

March 2014

    0.726     0.723     0.718     0.728  

April 2014

    0.721     0.724     0.720     0.730  

May 2014

    0.733     0.728     0.718     0.735  

June 2014

    0.730     0.736     0.730     0.739  

July 2014

    0.747     0.739     0.731     0.747  

August 2014

    0.759     0.751     0.745     0.759  

September 2014

    0.792     0.775     0.759     0.792  

63


Table of Contents


MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

        You should read the following discussion and analysis of our financial condition and results of operations together with the information under "Selected Financial Information" and our audited consolidated financial statements and unaudited condensed consolidated interim financial statements, including the notes thereto, included in this Prospectus. The following discussion is based on our consolidated financial information prepared in accordance with IFRS as issued by the IASB, which might differ in material respects from generally accepted accounting principles in other jurisdictions. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under "Risk Factors" and elsewhere in this Prospectus.

Overview

        Forward Pharma is a Danish biopharmaceutical company preparing to initiate a Phase 3 clinical trial using FP187, a proprietary formulation of dimethyl fumarate, or DMF, for the treatment of multiple sclerosis, or MS, patients. Since our founding in 2005, we have worked to advance unique formulations of DMF, an immune modulator, as a therapeutic to improve the health and well-being of patients with immune disorders including MS. FP187, our clinical candidate, is a DMF formulation in a delayed and slow release oral dose, which we plan to advance for the treatment of relapsing remitting MS, or RRMS, and other immune disorders, such as psoriasis.

        We are a company with a limited number of employees and outsource the majority of our activities to external consultants and suppliers. We are comprised of a Danish incorporated parent company, Forward Pharma A/S, and a wholly owned subsidiary incorporated in Germany, Forward Pharma GmbH, and a wholly owned subsidiary formed in the state of Delaware, Forward Pharma USA, LLC.

    Trend Information

        We do not currently have any commercialized products on the market. Accordingly, any trends within the markets in which we operate are expected to have more direct impact on our business in the event that we are successful in commercializing our clinical candidate FP187.

        Over the past few years, there has been increasing pressure to reduce drug prices in the developed markets as a consequence of political initiatives and regulations aiming to curb continuous increases in healthcare spending. Any revenue we earn in the future may be negatively affected by such political initiatives and regulations. The recent financial crisis and the increased burden of healthcare costs have led to an increased focus on reducing costs and, therefore, have further increased the pressure to lower drug prices. We expect this trend to continue in the years ahead. However, we believe spending in the healthcare industry, as compared to many other industries, is less linked to economic trends. Furthermore, while falling drug prices in the mature drug markets such as the U.S. and the EU are having a negative impact on general sales growth levels for the biopharmaceutical industry as a whole in those markets, we expect such sales growth to continue at higher levels in emerging markets. We also expect that demographic developments, increased treatment penetration, especially in newly established drug markets, and better diagnostic tools to enable the tailoring of drugs to specific needs, will result in continuing growth in overall global drug sales.

        There are unmet medical needs both in the RRMS and psoriasis areas. In particular, products with positive long-term safety profiles are needed. Controlling side effects associated with many such drugs is also important. Improvements have been seen in biological treatments for both RRMS and psoriasis, but there remains a need for safe oral treatments for both indications for long-term chronic administration. We believe that DMF has the potential to fulfill such unmet needs.

64


Table of Contents

Financial Operations Overview

    Revenue

        To date, we have not generated any operating revenue as we do not have any commercialized products and we have not out-licensed our clinical candidate FP187 to any third-party.

    Research and development costs

        Historical research and development costs relate primarily to development of FP187 for the treatment of psoriasis and only to a very limited extent to MS development, and they consist primarily of:

    salaries for research and development staff and fees to consultants, as well as expenses incurred by all such personnel; expenses related to share-based compensation to employees and others; the costs of our extensive use of external third-party expert and advisory firms and personnel (e.g., consultants for the RRMS indication) for our product development efforts; and the outsourcing of specific development tasks to contract manufacturing organizations, or CMOs;

    costs for formulation, development and production of FP187 tablets in new doses for use in clinical trials; and production of DMF by our current external single-source CMO, including the costs of testing related to increasing the batch sizes and manufacturing capability of this CMO in order for us to be able to scale to anticipated commercial production levels of psoriasis tablets and the costs of limited initial testing of new tablet strengths and forms for the treatment of RRMS;

    fees and other costs paid to clinical research organizations, or CROs, in connection with additional pre-clinical testing, formulation and product testing of FP187; and the fees and costs associated with the performance of clinical trials in RRMS and psoriasis, which will be outsourced as full service projects to CROs, that will plan and run the clinical trials for us, and help us to gather and maintain all required clinical data for regulatory purposes; and

    preparation and filing of patent applications and other intellectual property claims, responding to patent office actions, and conducting patent opposition and interference proceedings and other activities to secure the intellectual property estate.

        All of our operational activities are initiated, conducted and overseen by staff at our German subsidiary in Leipzig and, as a result, the majority of our development costs are incurred by our German subsidiary.

        We expect that our total research and development costs in 2014 will be approximately $26.0 million, assuming successful consummation of this offering, subject to timing of our development activities. The estimated 2014 costs will be allocated to funding the development of our MS and psoriasis programs. Our research and development costs are expected to increase significantly and relate primarily to the following key programs:

    development of our FP187 program for RRMS, including the preparation of a Phase 3 clinical trial protocol, establishment of related databases and data capturing systems, and preparation of regulatory submissions, all of which is being coordinated for us by a CRO and is planned for initiation in the second half of 2014;

    the launch of a Phase 3 clinical trial program for FP187 in psoriasis, with the expected initiation of patient dosing in Europe by early 2015 and preparation for the U.S. Phase 3 clinical trial, along with further related Phase 1 clinical trials;

    continuation of a pre-clinical test program for FP187 including short reproduction studies and long term carcinogenicity tests;

65


Table of Contents

    development of new tablet strengths and formulations of FP187 for RRMS and psoriasis, and working with our CMOs to increase DMF production processes and FP187 batch size levels and related manufacturing capability in order for us to be able to scale to anticipated commercial production levels;

    technology transfer in connection with our efforts to secure secondary CMO partners for DMF and FP187 production;

    follow up on our IND submission for RRMS and any FDA-related requests involving such IND;

    Phase 3 clinical trial protocol development and discussions with CROs and clinical advisers for the RRMS indication, and submission of the protocol following our IND filing with the FDA; and

    preparation and filing of patent application and other intellectual property claims, responding to patent office actions, and conducting patent opposition proceedings (including running any laboratory or clinical testing required thereof), interference proceedings and other activities aimed at securing our intellectual property estate.

        In 2013 and 2012, we spent an aggregate of approximately $8.0 million and $4.4 million, respectively, on research and development, of which $1.35 million and $682,800, respectively, were costs related to patent matters. There was a very limited amount of cost associated directly with development for the treatment of MS such as approximately $35,000 related to agency meetings and consultations, $28,000 for the IND submission, and $68,000 related to the initial testing of new MS tablets and dose strengths; all other costs were related to development for the treatment of psoriasis. Our research and development costs may vary substantially from period to period based on the timing of our research and development activities, including timing of regulatory approvals and enrollment of patients in clinical trials, and the preparation, submission and registration of patents in the U.S. and Europe. Assuming successful completion of this offering, research and development costs are expected to increase as we advance the clinical development of FP187 into Phase 3 for RRMS and psoriasis. The successful development of FP187 is highly uncertain. At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which we may begin to recognize revenues from FP187. This is due to numerous risks and uncertainties associated with developing drugs, including the uncertainty of the scope, rate of progress and expense of:

    our research and development activities;

    clinical trial approvals, securing sufficient clinical trial sites, recruitment of subjects for our clinical trials in a timely manner, and completion of the clinical trials;

    regulatory activities, including agency meetings, dossier preparations and submissions;

    any further pre-clinical or clinical studies that we may initiate; and

    prosecuting and defending patent claims and other intellectual property rights (including patent opposition and interference proceedings, which we consider part of our research and development costs to the extent they are conducted by patent registry offices).

        A change in the outcome of any of these factors with respect to the development of FP187 or any other product that we may develop could result in a significant change in the costs and timing associated with the development of FP187 or such other products.

        Similarly, the preparation of the Phase 3 trial of FP187 for the treatment of RRMS is a major effort and will require substantial internal resources and cooperation with a global CRO. We are in the early stages of such planning and further development depends on the positive outcome of this offering.

66


Table of Contents

        If litigation with respect to our intellectual property rights were to commence, or if we were to become subject to other types of litigation, the magnitude and timing of our estimated costs could materially change.

    General and administrative costs

        Our general and administrative costs consist primarily of:

    salaries and expenses for employees other than research and development staff, as well as expenses related to share-based compensation awards granted to certain employees;

    professional fees for auditors and other consulting expenses not related to research and development activities;

    cost of facilities, communication and office expenses;

    information technology, or IT, related expenses; and

    expenses associated with intellectual property-related activities carried out in the courts to protect, defend and re-enforce patent rights granted against third parties (not residing within patent offices).

        We expect that our general and administrative costs will increase in the future as our business expands and we incur additional costs associated with operating as a public company. This will include costs related to retaining personnel to establish a finance department and upgrading our financial and financial reporting processes in Germany, the U.S. and Denmark, as well as engaging investor relations firms for both the U.S. and the EU. The impact of us becoming a public company will also include increased costs related to new personnel we will need to retain in connection with both administrative and operational activities, legal compliance fees, accounting and audit fees, board of directors and board of managers' liability insurance premiums, and costs related to general investor relations. In addition, we may incur costs in dealing with potential patent litigation that we may enter into or that may be brought against us, as well as costs associated with granting share-based compensation awards to key management personnel and other employees and consultants after this offering.

    Finance cost (net)

        Components of our finance cost (net) during 2013 and 2012 consisted primarily of:

    fair value gains / losses on net settlement obligations related to shareholder warrants; and

    interest expense on debt obligations (consisting of a convertible debt instrument, which has now converted into equity).

67


Table of Contents

Results of Operations

Comparison of the six month periods ended June 30, 2014 and 2013

 
  Six month period ended
June 30,
(Unaudited)
 
 
  2014   2013   Change
%
 
 
  (USD in thousands)
 

Total revenue

    0     0     0  

Research and development costs

    (4,821 )   (2,982 )   61.7  

General and administrative costs

    (2,618 )   (385 )   580.0  

Operating loss

    (7,439 )   (3,367 )   120.9  

Fair value adjustment to net settlement obligations to shareholder warrants

    (1,005 )   2,084     (148.2 )

Other finance costs

    (108 )   (12 )   800.0  

Finance cost (net)

    (1,113 )   2,072     (153.7 )

Net loss before tax

    (8,552 )   (1,295 )   (560.4 )

    Research and development costs for the six month periods ended June 30, 2014 and 2013

        The research and development related costs for the six month periods ended June 30 were $4.8 million and $3.0 million in 2014 and 2013, respectively. This change resulted primarily from an increase in fees to patent advisers and other patent-related costs incurred to register our intellectual property and to prepare for the possible interference case with the USPTO involving Biogen's U.S. Patent No. 8,399,514, as well as opposition proceedings with the EPO in Europe, that increased from $217,000 in 2013 to $1.2 million in 2014. In addition, share-based compensation increased from $146,000 in the first half of 2013 to $1.5 million in the first half of 2014, resulting from grants made during 2014. Other development costs mainly involved pharmaceutical development to prepare for our Phase 3 programs planned for RRMS and psoriasis, although these costs have been lower for the first half of 2014 than they were in the comparable period in 2013 since we are now awaiting expected funds from the proposed offering before moving forward with our development plan.

    General and administrative costs for the six month periods ended June 30, 2014 and 2013

        The general and administrative costs for the six month period ended June 30 increased substantially from $0.4 million in 2013 to $2.6 million in 2014 primarily because of the services related to the offering process initiated in the first quarter of 2014. During 2014, we incurred costs related to the preparation of this offering in the amount of $1.8 million.

    Finance costs for the six month periods ended June 30, 2014 and 2013

        Finance costs related to the fair value adjustment to net settlement obligations of our shareholder warrants were $1.0 million for the first six months of 2014, compared to a gain of $2.1 million for the same period in 2013. This increase was primarily due to the fact that the underlying share price increased from December 31, 2013 to March 17, 2014 (the settlement date) while it did not change during the first six months of 2013. Although the share price did not change during the first six months of 2013, the expected term of the shareholder warrants was reduced resulting in a gain during this period. Finance costs associated with the shareholder warrants are calculated by using an OPM, described in the section below "Valuation of net settlement obligations to shareholder warrants".

        Other finance costs consisted of interest on convertible debt (which has now converted to equity) and other financial expenses, and amounted to $108,000 in the first six months of 2014 and $12,000 in the first six months of 2013. The increased cost is primarily caused by the convertible debt being

68


Table of Contents

outstanding for a longer period in the first six months of 2014 than in the first six months of 2013. In 2013, the conversion took place on January 19, while in 2014, the conversion took place on March 17.

Comparison of the years ended December 31, 2013 and 2012

 
  Year ended December 31,
(Audited)
 
 
  2013   2012   Change
%
 
 
  (USD in thousands)
 

Total revenue

    0     0     0  

Research and development costs

    (8,018 )   (4,445 )   80.4  

General and administrative costs

    (1,014 )   (928 )   9.3  

Operating loss

    (9,032 )   (5,373 )   68.1  

Fair value adjustment to net settlement obligations to shareholder warrants

    (6,676 )   (17,071 )   (60.9 )

Other finance costs

    (84 )   (35 )   140.0  

Finance cost (net)

    (6,760 )   (17,106 )   (60.5 )

Net loss before tax

    (15,792 )   (22,479 )   (29.7 )

    Research and development costs for the years ended December 31, 2013 and 2012

        Research and development costs increased 80.4% to approximately $8.0 million in the year ended December 31, 2013 from approximately $4.4 million in the year ended December 31, 2012. Our research and development costs are highly dependent on the development phases of our projects and therefore fluctuate significantly from year to year.

        The increase in research and development costs from 2012 to 2013 related to the re-initiation in 2013 of a number of activities within both pharmaceutical and clinical development. The direct costs related to pharmaceutical development and production activities in 2013 and 2012, respectively, were $1.9 million and $1.7 million. The direct costs related to clinical development in 2013 and 2012, respectively, were $4.3 million and $1.7 million. Included in these figures were, among others, costs for production of new batches of DMF and validation of the production, development activities related to the production of FP187 tablets, placebo tablet production for the Phase 3 clinical program in psoriasis, the closure of the Phase 2 trial program and the submission of clinical trial documents to governmental agencies and ethical committees or Institutional Review Boards, or IRBs, in connection with, and preparation for, our planned Phase 3 psoriasis clinical trial program. We expect that our total research and development costs in 2014 will be approximately $26.0 million, assuming successful consummation of this offering. The increase in such costs is expected to be primarily the result of pursuing the Phase 3 trial for FP187 for the treatment of RRMS, but also includes significant costs related to the Phase 3 trial program for FP187 for the treatment of psoriasis.

    General and administrative costs for the years ended December 31, 2013 and 2012

        General and administrative costs increased to $1.0 million in the year ended December 31, 2013 from $928,000 in the year ended December 31, 2012, due to business development initiatives and costs related to managing and maintaining our intellectual property, as well as increased travel by our employees. We anticipate that our general and administrative costs will increase in the future as we continue to pursue our clinical development program and we incur additional costs associated with operating as a public company, including the addition of an expanded finance team. We also anticipate our administrative costs will increase due to significant upgrades in our IT systems and IT security associated with our becoming a public company.

69


Table of Contents

    Finance costs for the years ended December 31, 2013 and 2012

        Finance costs related to the fair value adjustment to net settlement obligations of our shareholder warrants decreased to $6.7 million in 2013, from $17.1 million in 2012. This decrease was due primarily to the fact that the underlying share price increased substantially more in 2012 than it did in 2013. Finance costs associated with the shareholder warrants are calculated by us using an Option Pricing Model, or OPM, described in the section below entitled "Valuation of net settlement obligations to shareholder warrants".

        Other finance costs consisted of interest on convertible debt (which has now converted to equity) and other financial expenses, and amounted to $84,000 in 2013 and $35,000 in 2012.

Liquidity and Capital Resources

Cash flows

Comparison of the six month periods ended June 30, 2014 and 2013

        Our cash and cash equivalents as of June 30, 2014 were $0.2 million. The table below summarizes our consolidated statement of cash flows for each of the six month periods ended June 30, 2014 and 2013:

 
  Six month
period ended
June 30,
(Unaudited)
 
 
  2014   2013  
 
  (USD in thousands)
 

Net cash flows used in operating activities

    (4,616 )   (3,003 )

Net cash flows from financing activities

    1,910     2,527  

Net decrease in cash and cash equivalents

    (2,706 )   (476 )

Net foreign exchange differences

    (5 )   (14 )

Cash and cash equivalents at June 30

    244     338  

        Net cash flows used in operating activities increased to $4.6 million in the six month period ended June 30, 2014, from $3.0 million in the six month period ended June 30, 2013, primarily due to an increase in research and development costs as described in the section above entitled "Research and development costs for the six month periods ended June 30, 2014 and 2013" and costs related to the preparation of our public offering as described in the section above entitled "General and administrative costs for the six month periods ended June 30, 2014 and 2013".

        Net cash flows from financing activities decreased to $1.9 million in the six month period ended June 30, 2014 from $2.5 million in the six month period ended June 30, 2013. This decrease was primarily due to lower proceeds on issuance of shares.

70


Table of Contents

Comparison of the years ended December 31, 2013 and 2012

        Our cash and cash equivalents as of December 31, 2013 were $3.0 million. The table below summarizes our consolidated statement of cash flows for each of the years ended December 31, 2013 and 2012:

 
  Year ended
December 31,
(Audited)
 
 
  2013   2012  
 
  (USD in thousands)
 

Net cash flows used in operating activities

    (8,373 )   (3,494 )

Net cash flows used in investing activities

    0     (5 )

Net cash flows from financing activities

    10,397     3,885  

Net increase in cash and cash equivalents

    2,024     386  

Net foreign exchange differences

    103     15  

Cash and cash equivalents at December 31

    2,955     828  

        Net cash flows used in operating activities increased to $8.4 million in the year ended December 31, 2013, from $3.5 million in the year ended December 31, 2012, primarily due to an increase in research and development costs as described in the section above entitled "Research and development costs for the years ended December 31, 2013 and 2012."

        The net cash flows used in investing activities decreased to zero in the year ended December 31, 2013, from $5,000 in the year ended December 31, 2012.

        Net cash flows from financing activities increased by 167.6% to $10.4 million in the year ended December 31, 2013, from $3.9 million in the year ended December 31, 2012. This increase was due primarily to our issuance of 37,874 Class B shares in 2013 for net proceeds of $8.0 million in cash.

Cash and funding sources

        The table below summarizes our sources of financing and related cash proceeds for the six month period ended June 30, 2014 and the years ended December 31, 2013 and 2012.

 
  Six month
period ended
June 30,
  Year ended
December 31,
 
 
  2014   2013   2012  
 
  (USD in thousands)
 

Equity capital

    1,910     7,951     1,864  

Shareholder loans

    0     2,456     2,030  

        Cash proceeds are also received by us at the time our shareholder warrants are settled by the holders of such shareholder warrants, at which times their fair values as of such date are reclassified from liabilities to share premium. As of June 30, 2014, the net settlement obligations to our shareholder warrants were zero. As of the years ended December 31, 2013 and 2012, respectively, the net settlement obligations to our shareholders warrants were $26.1 million and $18.4 million, respectively.

        In 2013, we issued a convertible loan to one of our shareholders with a principal value of $2.5 million, which was converted into shares in March 2014. In 2012, we also issued a convertible loan to one of our shareholders, which was converted into share capital in January 2013.

        In the first six months of 2014, we issued to one of our shareholders 8,841 Class B shares for $1.9 million in cash. In 2013, we issued to one of our existing shareholders 37,874 Class B shares for

71


Table of Contents

$8.0 million in cash. In 2012, we issued to two of our shareholders a total of 71,618 Class A shares for $1.9 million in cash.

        The shareholder warrants were exercised on March 17, 2014 resulting in a transfer from liabilities to share premium in the amount of $27.0 million.

        We entered into a bridge financing on May 30, 2014 with NBFPII providing for the availability to us of €8.4 million. As of the date of this Prospectus, we have drawn down the full €8.4 million available under the bridge financing. The loan bears interest at a rate of 10% per annum and becomes due on December 31, 2018. Interest accrues until maturity. The principal together with accrued interest is mandatorily convertible into ordinary shares in connection with an initial public offering on or before December 31, 2014, at the public offering price less a 15% discount. If an initial public offering has not been completed by the end of 2014, NBFPII has the right to convert the principal together with accrued interest into a share class with the same distribution preference as the current Class B shares at a fixed price of DKK 1,177.35 per share.

        We entered into an additional bridge financing on August 6, 2014 with BVF Forward (an affiliate of BVF Partners LP, which is itself affiliated with certain of our principal shareholders) providing for the availability to us of $10.0 million. As of the date of this Prospectus, we have drawn down the full $10.0 million available under the bridge financing. The loan bears interest at a rate of 10% per annum and becomes due December 31, 2018. Interest accrues until maturity. The principal together with accrued interest is mandatorily convertible into ordinary shares in connection with an initial public offering on or before December 31, 2014, at the public offering price less a 15% discount. If an initial public offering has not been completed by the end of December 31, 2014, BVF Forward has the right to convert the principal together with accrued interest into a share class with the same distribution preference as the current Class B shares at a fixed price of DKK 1,177.35 per share.

        Please refer to the sections below on "Funding requirements" and "Borrowings" for a discussion of the significant assumptions underlying our going concern assumption.

Funding requirements

        We believe that the net proceeds from this offering, together with our recent bridge financings and our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 24 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Other than the bridge financings, we have no ongoing material financial commitments, such as lines of credit or guarantees, which are expected to affect our liquidity over the next five years, other than office rental leases, which we consider immaterial.

        Our present and future funding requirements will depend on many factors, including, among other things:

    our product development and increasing production capacity to commercial scale;

    technology transfer in connection with our efforts to identify additional CMOs;

    the scope and timing of our pre-clinical and clinical testing programs;

    successful planning and implementation of the required clinical development programs for FP187, particularly for the RRMS indication, but also for the planned psoriasis indication;

    our establishment of an internal organization and structure needed for a public company, including the hiring of additional personnel and developing appropriate policies and procedures; and

    our ability to continue as a going concern.

72


Table of Contents

        In the event we are unable to consummate this offering on the terms we currently anticipate or at all, we will have to limit our research and development activities until we are able to obtain alternative funding sources.

Capital Expenditures

        Our capital expenditures were zero for the year ended December 31, 2013, and $5,000 for the year ended December 31, 2012.

        We had zero capital expenditures for each of the six month periods ended June 30, 2013 and 2014.

        We do not have any significant capital expenditures planned for 2014.

Contractual obligations and commitments

        The table below sets forth our contractual obligations and commercial commitments as of December 31, 2013.

 
  Payments due by period  
 
  Less than
1 year
  Between 1
and 2 years
  Between 2
and 5 years
  More than
5 years
  Total  
 
  (USD in thousands)
 

Debt obligations(1)

  $ 2,613   $ 0   $ 0   $ 0   $ 2,613  

Operating lease obligations(2)

  $ 21   $ 0   $ 0   $ 0   $ 21  

Total

  $ 2,634   $ 0   $ 0   $ 0   $ 2,634  

(1)
Debt obligations as of December 31, 2013 consisted of a convertible loan note dated October 1, 2013, by and between Forward Pharma, as debtor, and NBOF, as creditor, for a principal amount of $2.5 million, which was cancelled in March 2014 (in connection with which the principal amount was used to offset the exercise price of warrants to subscribe for an aggregate of 137,750 Class A shares at an exercise price of DKK 100 per share). The loan was to mature on October 31, 2018 and had an annual interest rate of 20% as of December 31, 2013.

(2)
Operating lease obligations consist of a rental property agreement.

Off-Balance Sheet Arrangements

        In 2004, a private Swedish company Aditech Pharma AB (collectively with its successor-in-interest, a Swiss company Aditech Pharma AG, or Aditech), controlled by Nordic Biotech General Partner ApS (an affiliate of one of our largest shareholders), began developing and filing patents for, among other things, an innovative delayed and slow release formulation for DMF. In 2005 we entered into a patent license agreement with Aditech to license this patent family from Aditech, and in 2010 we acquired this patent family from Aditech pursuant to a patent transfer agreement. Under our agreements with Aditech, we obtained, among other things, Aditech's patents and associated know-how related to DMF formulations and delivery systems, subject to both diligence and minimum annual expenditure (€1.0 million per year) obligations on our part (with an option for Aditech to receive back, for no consideration, all of our DMF related assets should we fail to satisfy these obligations), as well as a payment by us to Aditech of up to 2% of net sales generated from our DMF products and processes. Further, our agreement with Aditech gives Aditech a 90-day right of first offer to acquire non-DMF related intellectual property assets we might choose to sell.

        As noted above, the agreement with Aditech is technically a patent transfer agreement, not a license agreement. This means that we have acquired exclusive and perpetual ownership to Aditech's patents and related rights. Aditech can terminate the agreement (in which event Aditech has an option

73


Table of Contents

to receive back, for no consideration, all of our DMF related assets) due to any of the following reasons:

    We seek a liquidation, dissolution or winding up of our business or assets, we become insolvent or we make any general assignment for the benefit of our creditors;

    A petition is filed by or against us, or any proceeding is initiated by or against us, or any proceeding is initiated against us as a debtor, under any bankruptcy or insolvency law, unless such petition or proceeding is held to be unfounded;

    A receiver, trustee or any similar officer is appointed to take possession, custody or control of all or any part of our assets or property;

    Upon the material breach by us of any material term or material condition of our agreement with Aditech, if such breach continues for 30 calendar days after the receipt of written notice thereof from Aditech; or

    If we do not meet applicable requirements in respect of the development and commercialization of the patent rights.

        While we have exclusive ownership of the patents, the duration of our obligation to make payments to Aditech lasts until (on a country by country basis) the latest to occur of the expiration of the registered patent rights or applicable data exclusivity.

        A German government grant of approximately $5.2 million received by Forward Pharma GmbH as compensation for development costs it incurred must be repaid should SAB determine that the grant was not, or not entirely, used for the specific purpose of the project for which it was given. In June 2012, SAB concluded the proceedings of proof of correct use, retaining, however, a right to initiate further proceedings. Further, if a production site has not been established by Forward Pharma GmbH in Saxony by May 31, 2017, this grant shall be repaid with a share in the income generated by Forward Pharma GmbH from the exploitation of the results, pro rata, up to a maximum of the grant amount, plus interest, if applicable. Should Forward Pharma GmbH not comply with this obligation, it will be required to grant SAB rights of use regarding the results of the funded research. As of June 30, 2014, we had not decided whether to establish production facilities in Saxony. Further, we believe that as of June 30, 2014, there is uncertainty in respect of both future revenue from the development project and the possible proceeds from a sale of all or certain of our intellectual property rights if we were to cease development. On this basis, we have determined that it is currently appropriate not to recognize as a contingent liability the repayment of this German government grant.

Quantitative and Qualitative Disclosures about Market Risk

        We are exposed to a variety of financial risks: market risk (including foreign exchange risk and interest rate risk), credit risk and liquidity risk.

Market risk

        We are exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the U.S. dollar, or USD, British pound sterling, or GBP, and the Euro.

        Forward Pharma A/S' functional currency is the Danish Kroner, or DKK, our wholly owned subsidiary Forward Pharma GmbH's functional currency is the Euro, and our wholly owned subsidiary Forward Pharma USA, LLC's (which was formed on July 25, 2014) functional currency is the U.S. dollar. We anticipate that a substantial portion of any revenue earned as sales of goods or royalty payments following the commercialization of FP187 will be denominated in either USD or Euro. Our expenses to date have been largely been denominated in GBP, USD, DKK, and in Euro.

74


Table of Contents

        In accordance with IFRS, at period end all of Forward Pharma A/S', Forward Pharma GmbH's, and Forward Pharma USA, LLC's assets and liabilities denominated in foreign currencies are recorded in the financial statements in DKK, Euro and U.S. dollar respectively, using exchange rates in effect at the applicable balance sheet date. During the year, transactions in foreign currencies are recorded in DKK and Euro respectively at the applicable exchange rates on the date of the relevant transactions.

        We do not believe there is currently a need to enter into specific contracts to reduce the exposure to changes in foreign exchange rates, such as by entering into options or forward contracts. We may in the future consider using options or forward contracts to manage currency transaction exposures. To date, we have had no material financial impact as a result of foreign currency changes.

        Up until May 30, 2014, our borrowings were denominated in DKK. Because our borrowings were at fixed interest rates and we maintain only limited cash balances, a change in interest rates would not have had a material effect on our results of operations. On May 30, 2014, we obtained a bridge loan financing denominated in EUR, and we obtained an additional bridge loan financing denominated in USD on August 6, 2014. These two loans also bear a fixed interest rate and, as a result, our exposure to interest rate risk is not affected.

Credit Risk

        We manage credit risk on a group basis.

        Our cash and cash equivalents are invested primarily in saving and deposit accounts with original maturities of three months or less. Saving and deposit accounts generate a small amount of interest income. We only engage in such transactions with banks and financial institutions that have an independent credit agency rating of "A" or greater.

Liquidity Risk

        We believe that the net proceeds from this offering, together with net proceeds from our bridge financing and our cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least the next twenty-four months. See "Use of Proceeds".

Government, Economic, Fiscal, Monetary or Political Initiatives That May Materially Affect Our Operations

        We have not identified any current government, economic, fiscal, monetary or political initiatives that would be expected to materially affect our operations.

Critical Accounting Policies

        Our management's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with IFRS as issued by the International Accounting Standards Board. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

        While our significant accounting policies are more fully described in the notes to our audited consolidated financial statements appearing elsewhere in this Prospectus, we believe that the following accounting policies are the most critical to aid you in understanding and evaluating our financial condition and results of operations.

75


Table of Contents

Research and development costs

        Research expenses are recognized when expenses are incurred. Costs incurred on development projects will be recognized as intangible assets as of the date that it can be established that it is probable that we will recognize future economic benefits attributable to the relevant project, considering factors including the technological and commercial feasibility of the project. Specifically, intangible assets arising from our development projects will be recognized on our balance sheet if all of the following criteria are met:

    the development project is clearly defined and identifiable,

    the attributable costs can be measured reliably during the development period;

    the technological feasibility, adequate resources to complete and a market for the product or an internal use of the product can be demonstrated; and

    management has the intent to produce and market the product or otherwise utilize it.

        Development costs incurred are capitalized as of the date when these criteria are met. In other words, until such criteria are met, development costs incurred are recognized as an expense.

        A development project involves a single product candidate undergoing a high number of tests to illustrate its safety profile and the effect on humans prior to obtaining the necessary final approval of the product from the appropriate authorities. The future economic benefits associated with our individual development projects are dependent on obtaining such approval. Considering the significant risk and duration of the development period related to the development of biological products, management has concluded that the future economic benefits associated with FP187 in late-stage clinical development in RRMS and psoriasis individual projects cannot be estimated with sufficient certainty until the projects have been finalized and the necessary regulatory final approvals have been obtained. Accordingly, given the current stage of the development of FP187, no development expenditures have yet been capitalized.

        Intellectual property-related costs for patents are included in expenses for our research and development projects. Therefore, associated registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.

Share-based compensation

        The fair value of warrants (the share-based compensation arrangement we have historically used) issued to our employees and consultants in connection with their services provided to us is recognized by us as compensation expenses over the applicable warrant vesting periods.

        Determination of the initial fair value and subsequent compensation expenses for our warrants are subject to significant estimation uncertainty. For publicly traded entities, such fair value determinations are often calculated using an OPM, which relies on the publicly traded price of such public entity's shares and its expected volatility based in part on historical share price volatility. As a private company, this is not a valuation model that is easy for us to employ. Historically, we have been governed by a shareholders' agreement, which provided different liquidation preferences rights among our share classes and restricted the trading of our shares, resulting in no observable share volatility.

        To enable us to use the OPM to determine fair value, for warrants granted through December 30, 2012 we established our share price at the date of each grant by assuming that we might be sold at a specified price per share, which was equivalent to the price per share paid in a financing round prior to the warrant grant date. Beginning on December 31, 2012, as a short time after that date we issued Class B shares with preferential rights, it was no longer possible to establish a price at which the

76


Table of Contents

Class A shares underlying our employee and consultant warrants would have been issued had we granted them on the same or near the same date as the Class B shares. Accordingly, starting on December 31, 2012, we determined our price per share using an estimation methodology. See "Valuation of shares" below.

        Volatility of share price for a non-public company, like ours, was difficult to estimate. As a result, we opted to employ a Black-Scholes formula model, in which we assessed the volatility of the share prices of what we identified as a peer group of currently public biopharmaceutical companies.

Valuation of net settlement obligations to shareholder warrants

        In 2011 we granted one of our shareholders warrants to acquire our Class A shares in connection with a capital increase made by such shareholder. These warrants provide that the holder can elect to partially exercise the warrants by net share settlement (also commonly referred to as a "cashless" exercise method) in which the warrant holder forfeits some of the warrants against a corresponding decrease of the exercise price on the remaining warrants, based on the fair value of the underlying Class A shares.

        Determination of fair value of our net settlement obligations to shareholder warrants is subject to significant estimation uncertainty. As discussed earlier, for publicly listed companies, fair value is generally calculated using an OPM based on the trading price of the shares and expected volatility based in part on historical volatility of share prices. Because our shares are not traded in an active market, there is no observable market data to support our valuation. We applied the valuation approach described under "Share-based compensation" above. As of December 31, 2013 and 2012, respectively, the exercise price of our shareholder warrants was significantly lower than the underlying share price as of each such date and, consequently, fair value of the warrants is most sensitive to changes in the underlying share price. It should be noted that once the ADSs begin trading publicly, there will no longer be a requirement for these types of estimations of fair value.

Valuation of shares

        As of December 31, 2012, we have calculated our valuation based on an internal model we developed that considered each of what we believe to be our key value drivers, including intellectual property advancement, development stage of FP187 both in terms of manufacturing and regulatory advances, and commercialization prospects for FP187. Such estimates are inherently complex and highly subjective. Specifically, we considered numerous objective and subjective factors to determine our best estimate of the fair value of our shares as of each grant date, including the following:

    status of our intellectual property;

    progress of our research and development programs;

    costs necessary to complete Phase 3 programs for both RRMS and psoriasis;

    likelihood of successful completion of our Phase 3 programs for RRMS and psoriasis;

    likelihood of obtaining regulatory approvals for FP187 to treat each of RRMS and psoriasis;

    potential of commercial success taking into account the risk of competition from other market participants;

    market penetration and price structure in the markets where we expect to sell FP187;

    costs to establish a production site for FP187;

    the relative rights and preferences of our capital shares; and

    external market and economic conditions impacting our industry sector.

77


Table of Contents

        Our fair value as of December 31, 2012 has been determined by us through employing a discounted cash flow, or DCF, model. DCF is an estimate of the present value of the future monetary benefits expected to flow to the owners of a business. It requires a projection of the cash flow that the business is expected to generate. This cash flow is converted to present value by means of discounting, using a rate of return that accounts for the time value of money and the appropriate degree of risks inherent in the business. The discount rate in the DCF analysis is based upon a weighted average cost of capital, or WACC, calculated at each valuation date. The WACC is a method that market participants commonly use to price securities and is derived by using the Capital Asset Pricing Model and inputs such as the risk-free rate, beta coefficient, equity risk premiums and the size of the company. For our valuation as of December 31, 2013, a discount rate (WACC) of 12% has been applied, and for the valuation as of December 31, 2012, a rate of 10.9% has been applied.

        Through December 30, 2012, we had only issued Class A shares, and the value of one share was determined with reference to the above described fair value of the Company divided by the number of outstanding shares, taking into account the dilutive effect of outstanding warrants, resulting in a price per share amount of $150.

        On January 19, 2013, we issued shares with liquidation preference. Our fair value calculated as of this point in time was allocated to the preferred shares and ordinary shares using the current value method, or CVM, and taking into account the dilutive effect of outstanding warrants. The CVM assumes an immediate exit of the company and allocates value to our preferred shares based on the liquidation preferences and the residual value to the remaining shares. Due to a limited absolute liquidation preference compared to the total value of the Company as of the respective valuation dates subsequent to issuance of preference shares, we did not apply an OPM. The OPM treats ordinary shares and preferred shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company's securities changes.

        Equity was allocated using the CVM, resulting in a value per share of $137 as of January 19, 2013, and $208 as of December 31, 2013. We determined that there had been no events intervening between the respective valuation dates and therefore the analysis and inputs remained the same.

Additional Debt and Equity Issuances

        Subsequent to December 31, 2013, the following equity issuances have been made:

    On March 13, 2014, NBFPI subscribed for 8,841 of our Class B shares at a subscription price of DKK 1,177.35 per share, for a total payment of DKK 10,408,951.

    On March 17, 2014, NBOF cancelled its shareholder loan with a principal value of DKK 13,775,000, which amount was used to offset the exercise price on an aggregate of 137,750 warrants to subscribe for Class A shares held by it at an exercise price of DKK 100 per share.

    On March 17, 2014, NBOF subscribed for 260 Class A shares by way of exercise of 260 warrants, at a subscription price of DKK 100 per share, for a total payment of DKK 26,000.

    On June 20, 2014, 4,997 warrants were issued to one of our consultants which, subject to certain terms and conditions, give the consultant a right to subscribe for 4,997 Class A shares at a subscription price of DKK 70.06 per share.

    On July 3, 2014, Morten Priskorn subscribed for 7,590 Class A shares by way of exercise of 7,590 warrants at a subscription price of DKK 70.06 per share.

    On August 12, 2014, Joel Sendek was granted a deferred share award with respect to 31,895 deferred Class A shares, and upon consummation of this offering, Mr. Sendek was granted a non-qualified stock option to subscribe for such number of ordinary shares as are equal to

78


Table of Contents

      21,284 Class A shares at an exercise price equal to the price of one ordinary share sold to the public pursuant to this offering.

    On August 13, 2014, upon his election as a director of the Company, Jan G. J. van de Winkel received a stock option to subscribe for 5,000 Class A shares of nominal DKK 1 at an exercise price of DKK 1,158 per share.

    Upon consummation of this offering, Thomas Carbone was granted a non-qualified stock option to subscribe for such number of ordinary shares as are equal to 4,500 Class A shares at an exercise price equal to the price of one ordinary share sold to the public pursuant to this offering.

    Upon consummation of this offering, Sharon Klahre, our Director, Investor Relations, was granted a non-qualified stock option to subscribe for such number of ordinary shares as are equal to 600 Class A shares at an exercise price equal to the price of an ordinary share sold to the public pursuant to this offering.

        On May 30, 2014, NBFPII entered into a bridge financing with us for an aggregate availability of €8.4 million which together with accrued interest, is convertible into our ordinary shares at the public offering price, less a discount of 15%.

        On August 6, 2014, BVF Forward (an affiliate of BVF Partners LP, which is itself affiliated with certain of our principal shareholders) entered into a bridge financing with us for an aggregate availability of $10.0 million which together with accrued interest, is convertible into our ordinary shares at the public offering price, less a discount of 15%.

Offering price versus last valuation

        On October 14, 2014, we and our underwriters determined the initial public offering price. The initial public offering price is $21.00 per ADS, representing one underlying ordinary share. In comparison, our estimate of the fair value of our Class A and Class B shares was $212 per share as of June 30, 2014 (not taking into account the Share Conversion, the Bridge Conversions, the Bonus Share Issuance, the Share Split, and the issuance of 7,590 Class A shares pursuant to an exercise of warrants). We note that, as is typical in initial public offerings, the initial public offering price for this offering was not derived using a formal determination of fair value, but was determined by negotiation between us and the underwriters. Among the factors that were considered in setting this price were our prospects and the history of and prospects for our industry, the general condition of the securities markets and the recent market prices of, and the demand for, publicly traded securities of generally comparable companies. Specifically, we believe that the difference between the fair value of our Class A and Class B shares as of June 30, 2014 and the initial public offering price for this offering is primarily due to advances we have made in connection with our intellectual property, manufacturing and regulatory development, and commercialization prospects.

Income taxes

        We are subject to income taxes in Denmark, Germany and the U.S. Significant judgment is required in determining the use of net operating loss carry forwards and, were it to be applicable in our case, taxation of upfront and milestone payments (related to possible out-licensing transactions we might consider) for income tax purposes. There are many transactions and calculations for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current and deferred income tax assets and liabilities in the period in which such determination is made.

        We recognize deferred tax assets, including the tax base of tax loss carry forwards, if our management assesses that these taxes can be offset against positive taxable income within a foreseeable

79


Table of Contents

future. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits together with future tax planning strategies. Such a judgment will be made on an ongoing basis and is based on budgets and business plans for the coming years, including planned commercial initiatives.

        The creation and development of therapeutic products, such as our product candidate FP187, is subject to considerable risks and uncertainties. Since our inception, we have reported significant losses and as a consequence, we have unused tax losses.

        Our management has concluded that deferred tax assets should not be recognized as of June 30, 2014, December 31, 2013 or December 31, 2012 in accordance with IAS 12, "Income Taxes." Our tax assets are currently not deemed to meet the criteria for recognition as our management is not able to provide any convincing positive evidence that deferred tax assets should be recognized.

        We had unused tax loss carry forwards of $10.5 million in Denmark and $17.8 million in Germany as of December 31, 2013. The tax losses can be carried forward indefinitely in time. We note that only the first DKK 7.5 million of taxable income on a Danish consolidated level may be fully offset by tax loss carry forwards whereas income exceeding DKK 7.5 million may only be reduced by 60% by tax loss carry forwards.

        Forward Pharma A/S is currently subject to group taxation in Denmark. For more, see "Risk Factors—Risks Related to Danish Law and Our Operations in Denmark". Forward Pharma A/S has historically filed Danish tax returns on a standalone basis; however, due to certain acquisitions made at the start of 2013, as of January 2013, Forward Pharma A/S must file its Danish tax returns as part of a Danish tax group controlled by Tech Growth Invest ApS, a Danish private limited liability company ("Tech Growth").

Borrowings

        As of December 31, 2013, our borrowings consisted of a convertible shareholder loan with a principal value of DKK 13.8 million ($2.5 million), which was scheduled to mature on October 31, 2018. The loan was cancelled in March 2014 in connection with a transaction in which the principal amount outstanding was used to offset the exercise price of warrants to subscribe for an aggregate of 137,750 Class A shares at an exercise price of DKK 100 per share.

        On May 30, 2014, we entered into a bridge financing with NBFPII providing for the availability to us of €8.4 million. On August 6, 2014, we entered into an additional bridge financing with BVF Forward (an affiliate of BVF Partners LP, which is itself affiliated with certain of our principal shareholders) providing for the availability to us of $10 million. As of the date of this Prospectus, we have drawn down the full €8.4 million and $10 million under the bridge financings with NBFPII and BVF Forward, respectively. Pursuant to both agreements, the amounts drawn under the financing, together with accrued unpaid interest, were converted into ordinary shares at the public offering price, less a discount of 15%, immediately prior to this offering. Together with the assumptions disclosed in the section above entitled "Funding requirements", the bridge financings form a part of the basis for the going concern assumption reflected in this Prospectus.

Recent Accounting Pronouncements

        There are no IFRS standards as issued by the IASB or interpretations issued by the IFRS interpretations committee that are effective for the first time for the financial year beginning on or after January 1, 2014 that would be expected to have a material impact on our financial position.

80


Table of Contents

Internal control over financial reporting

        In connection with the audits of our 2013 and 2012 financial statements which were completed concurrently, our independent registered public accounting firm identified a material weakness related to our financial statement close process, primarily related to the lack of sufficient skilled personnel with IFRS and SEC reporting knowledge for the purposes of timely and reliable financial reporting. Specifically, our independent registered public accounting firm determined that we did not have adequate procedures and controls to ensure that accurate financial statements could have been prepared and reviewed on a timely basis for annual and interim reporting purposes, including insufficient financial statement close process and procedures including account reconciliations, the resolution of complex accounting issues involving significant judgment and estimates and overall review of the financial statements.

        Under standards established by the Public Company Accounting Oversight Board, a material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis.

        We are working to remediate the material weakness and are taking numerous steps and plan to take additional steps to remediate the underlying causes of the material weakness. We recently engaged a full-time Chief Financial Officer, and plan to recruit additional finance support personnel and further develop and implement formal policies, processes and documentation procedures relating to our financial reporting. The actions that we are taking are subject to ongoing executive management review, and will also be subject to audit committee oversight. Although we plan to complete this process as quickly as possible, we cannot at this time estimate how long it will take, and our initiatives may not prove to be successful in addressing the material weakness. If we are unable to successfully address the material weakness, and if we are unable to produce accurate and timely financial statements, our share price and the ADS price may be adversely affected and we may be unable to comply with applicable stock exchange listing requirements.

JOBS Act Exemptions

        On April 5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." As an emerging growth company, we are electing to take advantage of the following exemptions:

    including two years of audited financial statements as opposed to three years;

    not providing an auditor attestation report on our internal control over financial reporting; and

    not providing all of the compensation disclosure that is required of non-emerging growth public companies under the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.

        The JOBS Act permits an "emerging growth company" such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to "opt out" of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act is irrevocable.

        These exemptions will apply for a period of five years following the completion of our initial public offering or until we no longer meet the requirements of being an "emerging growth company," whichever is earlier. We would cease to be an emerging growth company if we have more than $1.0 billion in annual revenue, have more than $700 million in market value of our ordinary shares held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a three-year period.

81


Table of Contents


BUSINESS

Our Company

        Forward Pharma is a Danish biopharmaceutical company preparing to initiate a Phase 3 clinical trial using FP187, a proprietary formulation of dimethyl fumarate, or DMF, for the treatment of multiple sclerosis, or MS, patients. Since our founding in 2005, we have worked to advance unique formulations of DMF, an immune modulator, as a therapeutic to improve the health and well-being of patients with immune disorders including MS. FP187, our clinical candidate, is a DMF formulation in a delayed and slow release oral dose, which we plan to advance for the treatment of relapsing remitting MS, or RRMS, and other immune disorders, such as psoriasis.

Our Focus on DMF

        Oral drugs employing DMF as an active pharmaceutical ingredient, or API, have been in use for over half a century. Today, DMF is the API found in Tecfidera®, which Biogen Idec Inc., or Biogen, began selling for the treatment of RRMS following approval by the U.S. Food and Drug Administration, or FDA, in March 2013 (and approval by the European Commission, or EC, in February 2014). Tecfidera®, which is an oral dose of 480 mg of DMF daily (240 mg twice daily), generated global sales from launch in April 2013 through June 30, 2014 of $2.08 billion. DMF is also an API found in Fumaderm®, which has been sold for the treatment of psoriasis since 1994 in Germany.

        In 2004, a private Swedish company Aditech Pharma AB (collectively with its successor-in-interest, a Swiss company Aditech Pharma AG, or Aditech), controlled by Nordic Biotech General Partner ApS (an affiliate of one of our largest shareholders), assessed the potential for DMF to become a significant global product. Aditech specifically focused on the development of an innovative delayed and slow release formulation of DMF, with the goal of limiting side effects typically associated with DMF treatment.

        We were founded in 2005 for the purpose of exploiting a patent family Aditech filed relating to, among other things, its delayed and slow release formulation for DMF, and in 2010 we acquired this patent family from Aditech. Under our agreements with Aditech, we obtained, among other things, Aditech's patents and associated know-how related to DMF formulations. See "Related Party Transactions—Aditech Agreement."

        The patent family that we acquired from Aditech included an international patent application filed in 2005, disclosing, among other things, formulations of DMF that provide for its slow release in the small intestine, where we believe that DMF has its immunomodulatory impact. This international application became the basis for a family of national patent applications which were subsequently filed relating to DMF. Two European patents, one from the original Aditech patent family and one from a patent family of ours (involving erosion matrix formulations of DMF with a thin enteric coating) have been granted and both are now the subject of opposition proceedings (i.e., special proceedings heard by the European Patent Office, or EPO, where one or more third parties request that the patent, or a part thereof, be revoked) which have been instigated by multiple third parties. In the U.S., our Erosion Matrix Patent application has been allowed and we have pending patent applications that we believe will soon be allowed (i.e., will meet the statutory requirements of patentability), one of which claims particular up-titration schedules (e.g., increasing the dose over a specified number of weeks) of using DMF to treat MS, and the other of which claims treating MS using particular compositions containing DMF and that also specifies levels of a DMF metabolite called mono methyl fumarate, or MMF, in the bloodstream. These claims are substantially the same as the respective claims in two other applications that the U.S. Patent and Trademark Office, or USPTO, Examiner recently found allowable but which we elected to abandon (i.e., voluntarily requested to be irrevocably removed from the USPTO docket of active patent applications). In another of our patent applications, U.S. Patent Application

82


Table of Contents

No. 11/576,871, the USPTO Examiner has found our claims directed to methods of treating MS using a 480 mg dose of DMF to be allowable and has recommended that an interference be declared against Biogen's U.S. Patent No. 8,399,514 and a USPTO official has indicated that we will be designated as the so-called senior party. An interference is an administrative proceeding at the USPTO that is used to determine which party is the first to invent a common invention claimed by the parties. The party with the earliest effective filing date to the common invention is designated "senior party" and is entitled to the presumption that it is the first inventor. Once an interference has been suggested, a supervisory Examiner refers the suggested interference to the Patent Trial and Appeal Board, or PTAB. An administrative patent judge at the PTAB declares the interference and administers the proceeding. During the interference, each party can dispute the patentability of the other parties' claims, challenge the senior party designation and present proof of dates of invention prior to the effective filing date. In an initial motions phase, a three judge panel at the PTAB decides the patentability and senior party issues raised and, if that decision does not resolve the interference, then after priority proofs are submitted in a second priority phase, enters final judgment on priority (i.e., who is first to invent).

        On August 22, 2014, an administrative law judge at the PTAB returned our U.S. Application No. 11/576,871 to the patent examining group within the USPTO, or the Examining Group, in which our USPTO Examiner is assigned. Based on an earlier discussion with a USPTO official, we believe the return is to address formal matters. However, we do not know whether the return has any accompanying communication to the Examining Group and we cannot rule out the possibility that the return was made for substantive reasons, which may adversely affect, delay or prevent our planned interference proceeding. For more, see "Risk Factors—Risks Related to Intellectual Property."

        In order to assess FP187's safety profile for human use, we have performed 28 pre-clinical studies on DMF since 2006, gathering data through animal testing (and in certain cases in vitro testing of DMF in cells) on its pharmacological activity, toxicity profile, and on dosing level effects. All pre-clinical studies apply to both MS and psoriasis development. Beginning in 2007, we commenced a set of Phase 1 clinical trials followed by a Phase 2 clinical trial to investigate, among other things, safety and dosing tolerability of FP187. We have successfully completed all of these clinical studies, collectively involving over 300 psoriasis patients and healthy volunteers, and gathering substantial positive safety and dosing data. Importantly, as of the date hereof we have conducted no clinical trials involving patients with MS.

        To advance FP187 for use as a drug to treat RRMS in the U.S., we held a pre-Investigational New Drug, or IND, application meeting with the FDA in August 2013. Prior to this pre-IND meeting, we submitted a briefing book to the FDA, which included our high-level description of a proposed 48-week Phase 3 trial, which we expect will include up to 2,000 RRMS patients. We intend to compare FP187 to an active beta interferon, or IFNb, comparator drug. The primary efficacy endpoint for the proposed Phase 3 trial will be the Annualized Relapse Rate, or ARR. The key secondary efficacy endpoint will be the Sustained Accumulation of Disability, or SAD, based on repeated assessments of the Expanded Disability Status Scale, or EDSS. Further secondary endpoints are based on magnetic resonance imaging, or MRI, markers.

        EDSS has been recognized by the EMA as the most widely used and known scale to assess disability in RRMS patients. EDSS scores are measured periodically (generally in intervals of three to six months) based on a standard neurological examination of seven major functional systems and observations concerning gait and use of assistive devices. EDSS is reported using a scale ranging from 0 to 10 in 0.5 unit increments that each represent higher levels of disability. SAD is defined as a specified increase from baseline in EDSS that persists for at least 12 weeks.

        Consistent with our pre-IND meeting and submissions, we filed our IND for RRMS on April 30, 2014 and expect to be able to submit the protocol and draft Statistical Analysis Plan, or SAP, for our Phase 3 study in the fourth quarter of 2014.

83


Table of Contents

        Following completion of our planned Phase 3 trial, we intend to submit our NDA for FP187 to treat RRMS. Approval by the FDA of a New Drug Application, or NDA, is dependent on a number of factors. A final decision as to whether the program we shared with the FDA in advance of our pre-IND meeting is sufficient for approval (including the sufficiency of our proposed single Phase 3 trial and whether a favorable effect on SAD or other secondary endpoints will need to be demonstrated by us at the time of our NDA submission) can only be made by the FDA once it has reviewed our full NDA package.

        We expect that patient enrollment for the Phase 3 trial we are contemplating will take at least 18 months, with completion of the final patient's initial 48-week treatment period after a total of 30 months. When the last patient dosed has completed the 48-week treatment period, we expect that we will have a substantial number of patients with two years of data, which we believe will allow us to complete an analysis of the effects of FP187 on SAD which can be provided to the FDA when we submit our NDA. As a result, we believe that any requirement by the FDA for data on EDSS/SAD will not delay a decision on whether to approve FP187 for the treatment of RRMS.

        We intend to submit our NDA for FP187 to treat RRMS under Section 505(b)(1) of the U.S. Federal Food, Drug, and Cosmetic Act, or FDC Act, based on pre-clinical and clinical data we have and will have developed and independently own. Section 505(b)(1) of the FDC Act prescribes how a product may be submitted for approval by the FDA as a new drug based on clinical trial data and other information independently developed and owned by the party making the NDA submission, or obtained from a third-party with a right of reference.

        In Europe, we have held preliminary discussions concerning marketing authorization for FP187 in moderate to severe psoriasis with the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, or BfArM) in Germany, and more recently in November 2013 held a scientific consultation on FP187 for the treatment of MS with the European Medicines Agency, or EMA. We expect to apply for a European Union, or EU, marketing authorization for FP187 to treat RRMS.

        We also intend to pursue the development of FP187 for the treatment of psoriasis, and expect to commence a Phase 3 clinical trial program for psoriasis, including the commencement of dosing of patients, by early 2015.

History of DMF

        A German pharmacist discovered in the late 1950s that fumaric acid derivatives were useful for the treatment of psoriasis. Over the following years, various blends of fumaric acid derivatives, including DMF, were tested and used in different doses throughout Germany and, later, in other parts of Europe. Pharmacies in Germany often made their own compounded versions for the treatment of psoriasis.

        In 1994, Fumapharm AG (acquired by Biogen in 2006) received approval in Germany to market Fumaderm®, which contains DMF and three ethyl fumarate salts, for the treatment of psoriasis. DMF is also the API in Biogen's Tecfidera®. Fumaderm® has not been approved outside of Germany, but it is nonetheless available throughout Europe as a prescription drug sourced from German pharmacies. Tecfidera® is sold in both the U.S. and Europe. We estimate that there have been well over 150,000 patient years of exposure to drugs containing DMF.

Our Intellectual Property

        We divide our intellectual property portfolios primarily into two basic patent families, which we refer to as our "Core Composition Patent" family and our "Erosion Matrix Patent" family. Our Core Composition Patent family, based on international application PCT/DK2005/000648, filed by Aditech on

84


Table of Contents

October 7, 2005, discloses, we believe, among other things, a broad range of controlled release pharmaceutical compositions of DMF, including the use of a dose of about 480 mg of DMF per day to treat MS. Our Erosion Matrix Patent family, based on international application PCT/EP2010/050172, filed in 2010, covers our delayed and slow release formulations of DMF in FP187 as used in our set of Phase 1 clinical trials and Phase 2 clinical trial.

Core Composition Patent family

        A patent from our Core Composition Patent family, EP2316430, has been granted by the EPO. EP2316430 covers DMF formulations with certain in vitro dissolution profiles. In the U.S., we have pending patent applications that we believe will soon be allowed.

        Pending U.S. Application No. 14/213,399 claims the use of delayed release formulations of DMF to treat MS according to an up-titration schedule (e.g., increasing the relevant dose over a specified number of weeks) that reaches a total daily dose of 480 mg. Pending U.S. Application No. 14/212,503 claims a method of treating an MS subject with 480 mg of DMF per day, using delayed release formulations containing from 120 mg to 240 mg of DMF which, following administration, result in certain levels of MMF in the bloodstream. These claims are substantially the same as the respective claims in two other applications that the U.S. Patent and Trademark Office, or USPTO, Examiner recently found allowable (U.S. Application Nos. 13/957,117 and 13/957,220) but which we elected to abandon (i.e., voluntarily requested to be irrevocably removed from the USPTO docket of active patent applications).

        Two third-party pre-issuance submissions were filed with the USPTO, questioning the patentability of the claims in each of the two U.S. patent applications from our Core Composition Patent family that had been allowed but were subsequently abandoned by us. We believed that these third-party submissions were defective. It is possible that similar third-party pre-issuance submissions may also be filed if our currently pending patent applications (having substantially the same claims as our earlier allowed but now abandoned applications) are allowed.

        We were recently informed by the USPTO Examiner that she believes the claims in another of our patent applications in the Core Composition Patent family, U.S. Application No. 11/576,871, to be allowable and in consultation with her supervisor and a patent interference specialist, has recommended that an interference be declared against Biogen's U.S. Patent No. 8,399,514, whose claims also cover a method of treating MS using about a 480 mg daily dose of DMF, and a USPTO official has indicated that we will be designated as the so-called senior party.

        The USPTO website indicates that the Examiner has prepared a memorandum in support of an interference, which will be reviewed by an administrative patent judge. Such interference, if declared, will give us the opportunity to prove to the USPTO that we were the first to invent the method of treating MS using about a 480 mg daily dose of DMF.

        On August 22, 2014, an administrative law judge at the PTAB returned our U.S. Application No. 11/576,871 to the Examining Group. Based on an earlier discussion with a USPTO official, we believe the return is to address formal matters. However, we do not know whether the return has any accompanying communication to the Examining Group and we cannot rule out the possibility that the return was made for substantive reasons, which may adversely affect, delay or prevent our planned interference proceeding. For more, see "Risk Factors—Risks Related to Intellectual Property."

        Multiple third parties, including Biogen, are opposing our patent EP2316430 (covering DMF formulations) before the European Patent Office, or EPO. In view of the publication of WO2006/037342, the international application in the Core Composition Patent Family, on April 13, 2006, prior to Biogen's February 8, 2007 priority date for its EP2137537 B1 patent, we (along with

85


Table of Contents

multiple other parties) have filed an opposition against that patent which has claims directed to the use of the 480 mg daily dose of DMF to treat MS.

Erosion Matrix Patent family

        A patent from our Erosion Matrix Patent family, EP2379063 (covering matrix formulations with a thin enteric coating), has been granted by the EPO. Multiple third parties, including Biogen, are opposing this patent before the EPO. The U.S. counterpart, U.S. Application No. 13/143,498, was allowed by the USPTO but withdrawn from allowance to permit the USPTO Examiner to consider the opposition papers in EP2379063. On July 11, 2014, the USPTO has again allowed the application following its review of the European oppositions.

Other patent families

        Beyond our Core Composition Patent and Erosion Matrix Patent families, our other patent families include PCT/EP2013/066285, PCT/EP2014/068094 (not yet published) and PCT/EP2014/068095 (not yet published), mainly directed to dosing regimens of DMF. We believe that our overall patent portfolio, if matured, should position FP187 competitively in the key markets of the U.S. and the EU.

Our Business Strategy

        We have focused on DMF's potential as an immune-modulating drug to improve the health and well-being of patients with immune disorders for approximately the past 10 years, during which time we have assembled and continue to develop our intellectual property portfolio and regulatory strategy. We believe our intellectual property portfolio, combined with the clinical data we have and will have independently obtained and the discussions we have had with the FDA, BfArM and EMA, provide us with the opportunity to pursue the development of FP187 for the treatment of RRMS in the U.S. and the EU. We intend to use the net proceeds from this offering to, among other things, pursue a Phase 3 clinical trial of FP187 for the treatment of RRMS which we believe, if successful, would (in combination with other data on FP187 we have and are obtaining) allow us to submit an NDA in the U.S. and a separate marketing authorization application in the EU for FP187 to treat RRMS. We intend to also pursue the development of FP187 for the treatment of psoriasis, including commencing a Phase 3 clinical trial program by early 2015. In addition, we intend to use part of the net proceeds from this offering to commence the remaining studies in our pre-clinical program.

        Components of our business strategy include:

    Successfully develop FP187 for the treatment of Relapsing Remitting Multiple Sclerosis.  We plan to pursue approval from the FDA and the EC of FP187 for the treatment of RRMS. We believe that, if approved, FP187 could become an important therapeutic in the multi-billion dollar MS drug market.

    Successfully develop FP187 for the treatment of psoriasis.  We plan to pursue FP187 for the treatment of psoriasis. We believe that, if approved, FP187 could become a compelling treatment option for patients with psoriasis.

    Exploit and defend our intellectual property rights.  We believe our patents and patent applications related to, among other things, our proprietary formulation technology, combined with our patents and patent applications claiming dosing levels of DMF, are critical assets of our company. We intend to exploit our intellectual property by continuing to pursue our patent applications, and to defend our patent rights as we deem necessary for our business.

    Obtain marketing exclusivity in the U.S. and the EU for FP187.  In addition to patent protection, if and when an NDA is approved, we will be eligible for up to three and one-half

86


Table of Contents

      years of marketing exclusivity against generic versions of FP187 in the U.S. In the EU, we will be entitled to up to 11 years of exclusivity from the first date of authorization in the EU.

    Potentially partner FP187 with third parties.  We may opportunistically seek commercial partners for FP187 to offset risk and preserve capital, if appropriate, although we intend to retain key development and commercialization rights. We believe retaining this strategic flexibility will help us to maximize shareholder value.

    Continue to explore, and potentially develop, FP187 and other DMF-related formulations for the treatment of other immune disorders.  We intend to continue to explore and potentially develop FP187 and other DMF-related formulations for the treatment of other immune disorder indications, if we determine that such development could be commercially viable.

Mode of Action of DMF and our Proprietary Formulation

Mode of action

        While the exact mode of action of DMF is not fully understood, we believe that some of its therapeutic effects are mediated via modulation of the immune system. From studying scientific literature on immune cells in vitro and Company-sponsored research, we believe that DMF can rapidly form adducts by combining with the antioxidant molecule glutathione, or GSH, leading to the functional depletion of GSH, followed by the modulation of various cellular pathways. We believe that one important downstream event of intracellular GSH depletion is the increased expression of the anti-inflammatory stress protein HO-1, with subsequent induction of type II dendritic cells leading to a reduction of inflammatory responses. We also believe that the depletion of GSH can induce apoptosis or cell death in different cell types including activated T cells, reducing inflammatory responses. Other pre-clinical data, we believe, have indicated that DMF can also protect cells, including neuronal cells, against oxidative stress.

        In animal models described in scientific literature and from Company-sponsored research, GSH/DMF adducts have been found in the gastrointestinal, or GI, mucosa and in the portal vein blood, but not in organs like the heart, brain and liver, which suggests to us that the clinical effects of DMF may be mediated at least in part by DMF exerting its action within the tissues in the intestine or pre-systemic circulation. Such a mode of action of DMF is also supported, we believe, by the fact that DMF has not been directly detected in the bloodstream.

        Some proportion of DMF is thought by us to be metabolized by esterases (enzymes ubiquitous in the GI tract) to produce MMF. In contrast to DMF, MMF can be measured in the bloodstream, but the extent to which it may contribute to clinical efficacy is currently unclear to us. However, recent pre-clinical research suggests to us that sudden plasma peaks of MMF may contribute to the side effect of flushing via interaction with nicotinic acid receptors. Flushing is the visible reddening of the skin and is often accompanied by a sensation of heat and prickling or itching of the skin.

Formulation and clinical profile of FP187

        Our proprietary DMF formulation, FP187, employs two strategies which we believe improve the release of DMF by reducing the peaks of MMF in the bloodstream while maintaining overall DMF exposure levels, which, in turn, may control DMF's side effects. FP187 uses an enteric coating material, which forms a polymeric barrier around each DMF-containing core tablet for the purpose of inhibiting the release of DMF in the stomach and allowing for release in the small intestine. Due to the enteric coating, the FP187 tablet remains intact in acid conditions like those found in the stomach but dissolves in a less acidic environment like the one found in the small intestine. The enteric coating employed by FP187 is thinner than the coating used by the other DMF products, which we believe results in the earlier onset of release of DMF in the small intestine. In addition, the DMF in FP187 is embedded in

87


Table of Contents

a slow eroding interior structure, which we call our erosion matrix formulation, resulting in what we believe to be a slower release of DMF in the small intestine after the enteric coating has dissolved.

        We believe that all currently available products containing DMF have an enteric coat that controls and inhibits the undesired release of DMF in the stomach and permits the release only in the more neutral environment of the small intestine. Once the enteric coat is dissolved in the small intestine, DMF-containing products such as Tecfidera® or Fumaderm® that are formulated with an immediate release technology and not an erosion matrix formulation or other rate-controlling release technology may result in DMF being released in a more concentrated and immediate burst. We believe that the slow rate of release of DMF permitted by FP187's erosion matrix formulation greatly reduces, or may even eliminate, the peaks of MMF in the bloodstream observed with formulations in which the DMF is not incorporated into a rate-controlling release formulation, while ensuring that a therapeutically effective dose of DMF is administered, potentially producing fewer and less severe flushing episodes. In addition, we believe that the rate-controlled release of DMF from the erosion matrix formulation, together with the earlier start of release in the small intestine, may allow absorption of DMF over a larger area of GI mucosa, potentially leading to lower local GI concentrations and therefore, we believe, potentially less severe GI-specific side effects.

        In the clinical trials we performed with FP187, flushing, GI complaints (primarily diarrhea and abdominal pain) and changes in white blood cell counts occurred. All of these side effects resolved or the white blood cell counts returned to their pre-treatment values during the treatment period (without any change in the treatment regime) or during the follow up period or were deemed to not be clinically relevant at the end of the study. Despite the white blood cell count changes, no increase in infections was observed. In our Phase 2 study of FP187, seven Serious Adverse Events, or SAEs, were reported. Five cases were classified by the investigator as being unrelated to the use of FP187, while two cases were judged by the investigator as being possibly related to the use of FP187. One patient was hospitalized with severe GI pain but was discharged the next day, after receiving intravenous fluid overnight, and continued on with the study until its conclusion without further complaints. The second patient had a transient ischemic attack, or TIA. This patient had hypertension prior to participating in the trial and a family history for cardiovascular diseases. Based on our review of the German spontaneous reporting system (a database maintained by BfArM for drug-related Adverse Events, or AEs) covering an estimated patient exposure for Fumaderm® of more than 150,000 patient years, and the recent FDA approval of Tecfidera® in the U.S., we do not believe there is any evidence of an increased risk for cardiovascular related AEs.

Overview of MS

        MS is a chronic disorder of the central nervous system, or CNS, involving brain, spinal cord and optic nerves, and is characterized clinically by recurring episodes of neurological dysfunction. MS is immune-mediated, driven by autoreactive lymphocytes that attack the covering surrounding nerve cells, or myelin sheath. This autoimmune response results in destruction of the myelin sheath, termed demyelination, and nerve damage. The CNS destruction caused by autoreactive lymphocytes can lead to debilitating clinical symptoms such as numbness, difficulty walking, visual loss, loss of coordination and muscle weakness.

        The Multiple Sclerosis International Foundation recently estimated that approximately 2.3 million people suffer from MS worldwide. It is estimated that between 60 and 65% of MS patients have what is referred to as relapsing remitting multiple sclerosis, or RRMS, characterized by recurrent acute exacerbations of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses, which would mean approximately 1.5 million people worldwide suffer from RRMS. The majority of patients are diagnosed with MS between the ages of 20 and 40. Almost half of relapses result in incomplete recovery of neurological function and leave permanent disability and impairment

88


Table of Contents

that accumulates over time. Owing to the complications of chronic disability, life span for patients with MS is typically shortened by approximately ten years.

        The early onset and progressive nature of RRMS highlights the need for treatment options that are effective, convenient and tolerable. This unmet need is particularly important for sufferers in the workforce or those raising families. The inevitability of both relapse and disease progression also results in the prescription of the newest medications that offer increased levels of efficacy and differing risk/benefit profiles. As new efficacious and safe treatments are approved, RRMS patients will have more options for treatment in earlier stages of the disease.

Clinical Development Summary

        Our clinical development strategy has been designed with a view towards satisfying marketing approval requirements in both the United States and the EU, while allowing us to create an electronic common technical document that we can use for marketing authorization applications in other jurisdictions. We have conducted an extensive pre-clinical program and have completed several Phase 1 and Phase 2 clinical trials. We further plan to conduct additional Phase 1 clinical trials and a Phase 2 clinical trial in psoriatic arthritis, and are in the process of planning Phase 3 clinical trials of FP187 in RRMS and in psoriasis. Our planned Phase 3 clinical trial of FP187 in RRMS is particularly large, with up to 2,000 RRMS patients to be enrolled.

89


Table of Contents

Completed clinical trials

        The following table sets forth information regarding completed clinical trials involving FP187:

Study
  Phase   Total
Patients
Enrolled
  Trial Design   Status   Dates
FP187-101   Phase 1     24   Randomized, single dose (240 mg) three way crossover PK study in healthy volunteers carried out in one clinical trial center in Germany.   Completed   January 15, 2007 — April 28, 2008

FP187-102

 

Phase 1

 

 

20

 

Randomized, single dose (240 mg) four way crossover PK study in healthy volunteers carried out in one clinical trial center in Germany.

 

Completed

 

November 11, 2008 — April 17, 2009

FP187-103

 

Phase 1

 

 

18

 

Randomized, single dose (240 mg) three way crossover PK study in healthy volunteers carried out in one clinical trial center in Germany.

 

Completed

 

February 4, 2009 — July 28, 2009

FP187-201

 

Phase 2
(Psoriasis)

 

 

252

 

Randomized, double-blind, placebo-controlled, 20 week treatment period study with three FP187 dose groups with two dosage levels and an open, flexible up-titration group carried out in 17 clinical trial centers in Germany.

 

Completed

 

September 7, 2010 — January 9, 2012

        Our extensive pre-clinical data, combined with our positive Phase 1 and 2 clinical trial results, has enabled us to now consider developing DMF for RRMS, psoriasis and potentially other immune disorders.

Pre-clinical studies

        To assess FP187's safety profile for human use, we have performed 28 pre-clinical studies on DMF since 2006, gathering data on its pharmacological activity, toxicity profile, and on dosing level effects through animal testing and in vitro testing of DMF. This pre-clinical program consisted of seven safety pharmacology studies, three single and multiple dose toxicokinetic studies, four studies on metabolism and drug interaction, two distribution studies, four acute toxicity studies, three dose-range repeat studies, two 28 day repeat dose toxicity studies, two 13 week repeat dose toxicity studies, and a four-part genotoxicity study.

        In Europe, the EMA and BfArM do not require further pre-clinical testing other than short-term reproductive toxicology studies that we plan to perform. No additional long-term toxicology or carcinogenicity studies will be required for our marketing authorization application in Europe.

90


Table of Contents

        In the U.S., carcinogenicity, chronic toxicity and other short-term studies will be required and such studies are included in our development plan. We have recently received recommendations on our plans to perform pre-clinical carcinogenicity studies on DMF from the FDA's Executive Carcinogenicity Assessment Committee, or CAC, and we have taken these recommendations into account in the design of our planned studies.

Initial Phase 1 and 2 clinical trials

        In 2007, we commenced our clinical trial program in Germany in coordination with BfArM. We conducted a set of Phase 1 clinical trials, followed by a Phase 2 clinical trial. These trials included over 300 subjects consisting of psoriasis patients and healthy volunteers, and investigated, among other things, safety and dosing tolerability of FP187. We have successfully completed all of these clinical trials, gathering substantial positive safety and dosing data.

Phase 1 trials

        We conducted three Phase 1 clinical trials of FP187, which tested seven delayed and slow release formulations and dosing regimens of DMF. In two of these clinical trials, we compared a 240 mg dose of FP187 with Fumaderm®, which includes 240 mg of DMF in an enteric-coated tablet. Since DMF is not quantifiable in the bloodstream after oral administration, we measured level of MMF, the main metabolite of DMF. The primary objectives of these trials were:

    the determination of the pharmacokinetic, or PK, properties of MMF, with a secondary objective of the evaluation of safety and tolerability (FP187-101 involving 24 healthy male volunteers);

    the determination of the PK properties of MMF, with secondary objectives of comparing bioavailability of the formulations with Fumaderm® and evaluating the safety and tolerability of FP187 (FP187-102 involving 20 healthy male volunteers); and

    the determination of PK properties of MMF with secondary objectives of comparing bioavailability of the formulations with Fumaderm® and to evaluate the safety and tolerability of FP-187 (FP187-103 involving 18 healthy male volunteers).

Phase 2 trial

        After completion of our Phase 1 trials, we continued the clinical development of FP187 with a randomized, placebo-controlled, double-blind, parallel-group Phase 2 trial in patients with psoriasis (FP187-201, clinicaltrials.gov identifier: NCT01230138). The trial was conducted in 17 centers in Germany.

    Trial design

        The primary endpoint was to analyze the effect of FP187 daily doses of 500 mg (given as 250 mg twice daily, or BID) and 750 mg (given as 375 mg BID or 250 mg thrice daily, or TID) and of placebo on the proportion of patients achieving a PASI75 response (reduction in Psoriasis Area and Severity Index, or PASI, of at least 75% from baseline) after 20 weeks of treatment.

        Secondary endpoints were to evaluate the efficacy and safety as assessed by PASI, static Physician's Global Assessment, or sPGA, patient global assessment, or PaGA, patients' disease-related quality of life score, patient assessed pruritus, Adverse Events, or AE, and Serious Adverse Events, or SAEs.

        Included were male and female patients at least 18 years of age, with a clinical diagnosis of psoriasis with a body surface area of no less than 10% and at least a PASI of 10, and with stable disease for at least 6 months prior to study start. Exclusion criteria included prior discontinuation of treatment with other DMF containing products as a result of lack of efficacy or due to side effects.

91


Table of Contents

        The trial design included an up-titration schedule of two weeks to the 500 mg dose and three weeks to the 750 mg dose. A separate open-label flexible up-titration treatment arm (target dose 750 mg) was added to the study to investigate impact on tolerability of a more flexible and longer up-titration period.

    Statistical analysis

        The primary efficacy analysis was performed based on the full analysis (FA) set (randomized patients receiving at least one dose of trial drug) and the per protocol (PP) set (patients of the FA set without major protocol violations and a PASI evaluated at week 8 or later). For the primary endpoint to be met, both the PP and FA analysis sets individually needed to be significant. The two 750 mg dose groups were pooled, as per the prospectively defined analysis strategy.

    Patient disposition

        In the blinded patient arms, 199 patients were randomized. Out of these, 192 patients received study medication at least once, and 92 patients discontinued prematurely. The discontinuation rate was higher in the placebo group (56%) than in the active treatment groups (40% and 48% for 500 mg and pooled 750 mg, respectively).

    Efficacy

        The primary endpoint was met for the 500 mg dose group at week 20 and was statistically significantly (i.e., p was less than 0.05) higher compared to placebo in both the FA set (PASI75 responder rate 31.3% vs. 10.4%; p=0.01) and the PP set (PASI75 responder rate 45.5% vs. 13.5%; p<0.01).

        For the pooled 750 mg dose group, the responder rate at week 20 was statistically significantly higher compared to placebo for the PP set (PASI75 responder rate 35.1% vs. 13.5%; p=0.01) but not for the FA set (PASI75 responder rate 20.8% vs. 10.4%; p=0.12).

        The efficacy results from the blinded study were supported by those of the open flexible up-titration arm, with PASI75 responder rates for FP187 vs. placebo of 41.5% vs. 10.4% in the FA population (p<0.01) and of 57.9% vs. 13.5% in the PP population (p<0.01).

    Safety

        Seven SAEs were reported in the FP187 treatment groups, each of which only occurred once. Five cases were classified by the investigator as being unrelated to the use of FP187, while two cases were judged by the investigator as being possibly related to the use of FP187. One patient, who had hypertension and a family history of cardiovascular diseases experienced a transient ischemic attack, or TIA, while a second patient experienced severe abdominal pain over period of approximately 24 hours. The patient experiencing the TIA discontinued the treatment regimen but the patient experiencing abdominal pain continued the treatment regimen after being discharged from the hospital without additional drug-related AEs. These cases have been reported to the FDA and European regulatory authorities but have not resulted in any requests from such authorities. No deaths were reported in the trial. No notable difference between active and placebo arms was seen for the frequency of infections, change in pulse, blood pressure or weight, change in triglycerides, cholesterol, HDL-C or LDL-C, change in liver enzymes, creatinine, or creatinine clearance (Cockcroft-Gault-Formula). A mild eosinophilia (i.e., increase in eosinophil blood cell count) was observed in all treatment groups, including the placebo group, whereas moderate and severe eosinophilia occurred only in FP187 treatment groups. Similarly, a mild lymphopenia (i.e., decrease in lymphocyte blood cell count) was observed in all treatment groups, including the placebo group, whereas moderate and severe lymphopenia occurred only in FP187 treatment groups. All returned to pre-treatment values during the

92


Table of Contents

course of the study or were considered by the investigator to be not clinically relevant at the end of the study. Both eosinophilia and lymphopenia are well documented AEs of fumaric acid ester therapy. No increased rate of infection was observed among patients with either eosinophilia or lymphopenia.

    Tolerability

        Gastrointestinal, or GI, AE and flushing are well-known side effects for fumaric acid ester treatments.

        While the majority of patients treated with FP187 reported at least one GI tolerability event, such as diarrhea or abdominal pain, the median number of GI events per patient in the 500 mg and 750 mg groups was only two, and 92% of events were mild or moderate. Flushing was reported by 4%, 17%, and 13%, for the placebo, 500 mg, and 750 mg groups, respectively. The median number of flushing events per patient in the 500 mg and 750 mg groups was 1, and 100% of events were mild or moderate. GI-related events and flushing mainly occurred within the first four weeks of the study, as has been reported for other fumaric acid ester therapies. The overall discontinuation rate in our trial was lower in all active therapy arms than in the placebo arm. Flushing events appeared to be recorded at a lower rate in the 500 mg and 750 mg doses of FP187 than the rate seen in most clinical trials with DMF-containing products, but this has not been confirmed by a head-to-head study.

Planned clinical trials and market authorization application strategy

        To advance FP187 for use as a drug to treat RRMS in the U.S., we held a pre-Investigational New Drug, or IND, application meeting with the FDA in August 2013. Prior to this pre-IND meeting, we submitted a briefing book to the FDA, which included our high-level description of a proposed 48-week Phase 3 trial, which we expect will include up to 2,000 RRMS patients. We intend to compare FP187 to an active beta interferon, or IFNb, comparator drug. The primary efficacy endpoint for the proposed Phase 3 trial will be the Annualized Relapse Rate, or ARR. The key secondary efficacy endpoint will be the Sustained Accumulation of Disability, or SAD, based on repeated assessments of the Expanded Disability Status Scale, or EDSS. Further secondary endpoints are based on magnetic resonance imaging, or MRI, markers. We filed our IND for RRMS on April 30, 2014. On June 10, 2014, the FDA sent us a "may proceed" letter, indicating that the IND is active and that we may conduct studies in humans. We expect to be able to submit the protocol for our Phase 3 study in the fourth quarter of 2014.

        Following completion of our planned Phase 3 trial, we intend to submit our NDA for FP187 to treat RRMS. Approval by the FDA of a New Drug Application, or NDA, is dependent on a number of factors. A final decision as to whether the program we shared with the FDA in advance of our pre-IND meeting is sufficient for approval (including the sufficiency of our proposed single Phase 3 trial and whether a favorable effect on SAD or other secondary endpoints will need to be demonstrated by us at the time of our NDA submission) can only be made by the FDA once it has reviewed our full NDA package. We will also be required to provide information in our NDA on adequate dose exploration of FP187 in patients with MS.

        We intend to submit the same pre-clinical and clinical data package to the EMA following our RRMS NDA submission to the FDA.

        We also intend to pursue the development of FP187 for the treatment of psoriasis, and expect to commence a Phase 3 clinical trial program, including the commencement of dosing of patients, for psoriasis by early 2015.

93


Table of Contents


Phase 1 and Phase 2 trial(s)

        We intend to conduct the following additional Phase 1 trials to further investigate the safety profile of FP187 for human use:

    PK fasting/fed trial: This will be a 3-way randomized cross over trial investigating the effect of food on the pharmacokinetics of MMF. The study will include 30 healthy volunteers (males and females) and involve kinetic blood sampling over 24 hours after each administration of FP187 (250 mg as a single dose), or the comparator (Tecfidera® 240 mg as a single dose) with standard laboratory evaluations and AE and tolerability reporting.

    QT/QTc study: This is a standard study to be carried out for FP187 and overseen by a specialized clinical research organization.

    We may be required to conduct bridging studies in order to reference data from previous pharmacokinetic investigations. We will perform pharmacokinetic investigations of our tablets for the RRMS indication prior to initiation of Phase 3 trials in order to investigate and document the pharmacokinetic profile of FP187 in these new tablets. Similarly, a new 250 mg dose tablet for psoriasis treatment will be tested in a Phase 1 trial. These will be standard Phase 1 trials.

        In addition, a human mass-balance/metabolic profile study and an alcohol dumping study in humans may need to be performed.

        We are in advanced planning for a proof of concept Phase 2 clinical trial of FP187 in psoriatic arthritis. This clinical trial, if it is conducted, would be a randomized, double-blind and placebo-controlled trial, with 30 patients initially, in a 1:1 randomization. The primary endpoint would be the proportion of patients with an improvement of ACR 20 (American College of Rheumatology 20% improvement response criteria) and a secondary set of endpoints evaluating ACR 50 and ACR 70, as well as LEI (Leeds enthesitis index) and standard safety and tolerability. The planned treatment dose is 500 mg/day (250 mg BID) and the planned treatment time is 24 weeks. Patients who respond to ACR 20 will be offered an opportunity to continue on an open-label 500 mg daily dose, and be followed for an additional 28 weeks to obtain long term efficacy and safety results. There will be an initial tolerability testing period and patients who do not tolerate the DMF treatment after four weeks will be excluded from the trial.

Phase 3 trials

    Phase 3 clinical trial of FP187 in RRMS

        We currently intend to conduct a single double-blind, double-dummy 48-week active comparator Phase 3 trial of FP187 in RRMS. We intend to compare two dosing levels of FP187 (400 mg daily (200 mg BID), and 480 mg daily (240 mg BID)) to an IFNb RRMS drug. The 480 mg/day dose is the labeled DMF dose for Tecfidera®, and the lower dose is being tested to explore its safety and efficacy.

        The primary efficacy endpoint of this trial will be ARR at week 48. The secondary endpoints consist of: new and total Gadolinium- enhanced, or GdE, lesions on magnetic resource imaging, or MRI, scans at week 24, 36, and 48; new or enlarging T2-hyperintensive lesions at week 24, 36, and 48; new T1-hyperintense lesions at week 24, 36, and 48; proportion of relapse-free patients at week 48; brain volume at week 48; and proportion of patients with confirmed progression of Expanded Disability Status Score, or EDSS, a measure of SAD (a key secondary endpoint). While the primary efficacy data will be based on 48-week data, patients will continue treatment for 96 weeks, after which patients can continue on FP187 until the product is available for commercial use.

        We plan to design this trial to detect a 30% reduction in ARR compared to the IFNb comparator drug with 90% power, which we estimate will require up to approximately 600 patients in each of the two FP187 dosing regimen arms and up to approximately 800 patients in the comparator drug arm; a

94


Table of Contents

combined total of up to 2,000 RRMS patients. We intend to design the trial to include an interim look at the data to assess, among other things, futility, sample size and probability of achieving a two-sided p-value of less than 0.01. We expect patient recruitment to take up to 18 months, with the last patient completing his or her 48-week study period approximately 30 months after the first patient is enrolled.

        The safety and tolerability assessment will be based on full laboratory evaluation at every visit, and detailed collection of AE information including GI, flushing and infection AEs.

    Phase 3 clinical trial of FP187 in psoriasis

        We are continuing advanced preparatory work for a placebo-controlled confirmative Phase 3 trial of FP187 for the treatment of psoriasis in Europe, which we expect to include approximately 650 psoriasis patients, as well as an additional placebo-controlled Phase 3 trial of FP187 for the treatment of psoriasis in the United States, which we expect will include approximately 700 psoriasis patients. We anticipate that, by early 2015, the first patient dosing in the European Phase 3 trial will occur and we will continue preparation for the U.S. Phase 3 clinical trial. We believe that Phase 3 trials of FP187 for the treatment of psoriasis could provide important long-term safety data concerning the use of FP187 in a large population at doses similar to those we plan to test for use in RRMS.

        In the United States, an IND for the use of FP187 for the treatment of psoriasis was opened in 2008. The FDA has been updated on all activities and results through the filing of annual reports with the FDA. A meeting to discuss Phase 2 results and obtain feedback for the Phase 3 requirements was held with the FDA in 2012.

        The European Phase 3 trial is planned for five countries with a total of approximately 60 sites, of which approximately 23 sites are in Russia and the Ukraine. If political instability in Russia and the Ukraine worsens or if sanctions are implemented, our ability to proceed or continue with sites in these countries could be adversely impacted. See "Risk Factors—Risks Related to the Development, Clinical Testing, Regulatory Approval and Commercialization of FP187—Instability in Russia and the CIS could adversely affect our planned Phase 3 clinical trials for FP187 for the treatment of psoriasis."

Exclusivity

Exclusivity in the U.S

        We intend to submit our NDA for FP187 to treat RRMS under Section 505(b)(1) of the FDC Act, based on pre-clinical and clinical data we have and will have developed and independently own. Approval of an NDA submitted under Section 505(b)(1) of the FDC Act for a single active ingredient product that does not include a new chemical entity, but which contains reports of new clinical investigations that were essential for approval, should entitle us to three years of marketing exclusivity against generic versions of FP187, with the potential to extend the exclusivity by six months if we perform a pediatric clinical trial that meets the study requirements provided for in an FDA-issued written request. If we perform additional clinical trials essential for approval of other indications, we could also obtain three years of marketing exclusivity for those new indications.

European approach and exclusivity

        We have discussed our European regulatory strategy for the approval of FP187 for the treatment of subjects with RRMS with the BfArM in Germany and more recently in a scientific consultation we had in November 2013 with the European Medicines Agency, or EMA. We expect to apply for an EU-wide marketing authorization to be granted by the European Commission under the so-called "centralized" procedure (Regulation EC 726/2004). See "Government Regulation—European Union—Marketing authorization applicable and available authorization procedures." We plan to be able to

95


Table of Contents

file a full clinical package, on the basis of our planned Phase 3 clinical trial, our planned/completed pre-clinical studies, and materials to be prepared for the NDA submission in the U.S.

        For a psoriasis indication, we may use a "full-mixed" application in Europe, allowing use of bibliographical references that include, among other things, references pertaining to public clinical and pre-clinical trial papers and the clinical use of Fumaderm® in Germany and other European countries.

        In Europe, the marketing authorizations we receive will entitle us to receive eight years of data exclusivity and an additional two years of market protection from FP187's first date of authorization in the EU. For more, see "Government Regulation—European Union—Regulatory data protection". Should we advance a second indication for FP187, one more year could be added to the market protection period, leading to a total protection of 11 years from the first date of authorization.

Intellectual Property Summary

        We seek to protect the intellectual property and proprietary technology that we believe is important to our business, including pursuing and maintaining patents intended to cover FP187, and any other inventions that are commercially important to the development of our business.

        Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, to exploit and defend our patents, to preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties. For more information, please see "Risk Factors—Risks Related to Our Intellectual Property and Information Technology."

        As of the date of this Prospectus, we owned 13 U.S. utility patent applications, and one U.S. provisional patent application relating to our DMF program.

        We divide our intellectual property portfolios primarily into two basic patent families, which we refer to as our "Core Composition Patent" family and our "Erosion Matrix Patent" family.

The following table highlights key aspects of the current status of our Core Composition and Erosion Matrix Patent families:

Patent / Application
  Patent Family   Status
EP2316430   Core Composition   Granted and validated in AT, BE, CH, CY, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, NL, PL, PT, SE and SI. Subject of EPO opposition by Biogen and others.

EP05789026.1

 

Core Composition

 

Pending (parent application of EP 2 316 430 and other divisional applications; contains claims directed to a pharmaceutical composition containing one or more fumaric acid esters, wherein the composition consists of a controlled-release dosage form adapted to release the fumaric acid ester(s) according to a particular in vitro dissolution profile). A third party observation has been filed on behalf of a non-identified party.

EP14172390.8

 

Core Composition

 

Pending (contains claims directed to treatment of MS by administering a daily dose of 480 mg of DMF using a controlled release composition that is adapted to release DMF according to a particular in vitro dissolution profile).

96


Table of Contents

Patent / Application
  Patent Family   Status
EP14172396.5   Core Composition   Pending (contains claims directed to treatment of MS by administering a daily dose of 480 mg of DMF using a controlled release composition).

EP14172398.1

 

Core Composition

 

Pending (contains claims directed to treatment of MS by administering a daily dose of 480 mg of DMF wherein the compositions have an enteric coat).

DE202005022112.0

 

Core Composition

 

Registered utility model in Germany (includes claims similar to US 11/576,871 and 14/213,399).

U.S. App. 14,213,399

 

Core Composition

 

Pending (contains claims substantially similar to claims in U.S. App. 13/957,117, which was allowed by the USPTO but voluntarily abandoned by us).

U.S. App. 14,212,503

 

Core Composition

 

Pending (contains claims substantially similar to claims in U.S. App. 13/957,220, which was allowed by the USPTO but voluntarily abandoned by us).

U.S. App. 13/957,117

 

Core Composition

 

Abandoned.

U.S. App. 13/957,220

 

Core Composition

 

Abandoned.

U.S. App. 11/576,871

 

Core Composition

 

Interference recommended by Patent Examiner. Decision by the USPTO Administrative Law Judge to proceed with interference is pending.(1)

EP2379063

 

Erosion Matrix

 

Granted and validated in AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM and TR. Subject of EPO opposition by Biogen and others.

EP12193798.1

 

Erosion Matrix

 

Pending (contains claims directed to a pharmaceutical formulation in the form of an erosion matrix tablet having a particular composition).

U.S. App. 13/143,498

 

Erosion Matrix

 

Allowed in the U.S. Request for continued examination to be filed to permit the USPTO Examiner to consider the opposition papers in EP2379063. Re-allowed in July 2014 following the USPTO's review of the EU opposition papers.

(1)
On August 22, 2014, an administrative law judge at the PTAB returned our U.S. Application No. 11/576,871 to the patent examining group within the USPTO, or the Examining Group, in which our USPTO Examiner is assigned. Based on an earlier discussion with a USPTO official, we believe the return is to address formal matters. However, we do not know whether the return has any accompanying communication to the Examining Group and we cannot rule out the possibility that the return was made for substantive reasons, which may adversely affect, delay or prevent our planned interference case. For more, see "Risk Factors—Risks Related to Intellectual Property."

        As we have described above, Biogen has patents and is also prosecuting a number of additional patent applications that could adversely impact our commercial efforts if our marketing of FP187 once approved by the FDA for treatment of RRMS and/or psoriasis were ultimately found to infringe any valid claim arising from any of these patents or applications. Biogen and/or other competitors may

97


Table of Contents

initiate legal proceedings against us alleging infringement of their intellectual property rights. While we would vigorously contest such claims, the outcome of such potential proceedings would be unpredictable and we could be prevented from commercializing or continuing to commercialize our product candidates. If we market FP187 and are later found to infringe one or more patents of Biogen or other competitors, we could also be required to pay substantial damages.

        Any patents issued from patent applications in our Core Composition Patent family based on PCT/DK2005/00648 will expire on October 7, 2025 at the latest, subject to patent term adjustments in the U.S. Any patents issued from patent applications in our Erosion Matrix Patent family based on PCT/EP2010/050172 will expire on January 8, 2030 at the latest, subject to patent term adjustments in the U.S. The German utility model will expire on October 7, 2015 at the latest.

        The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent's term may be shortened if a patent is terminally disclaimed over another patent, and a patent's term may be lengthened, among other things, by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in granting a patent. The patent term of a European patent is 20 years from its filing date, which, unlike in the U.S., is not subject to adjustment.

Other Opportunities for FP187

        We have explored performing clinical studies in other indication areas, including psoriatic arthritis (an immune disorder characterized by inflammation of the joints alone or in both skin and joints which occurs in about 15% of psoriasis patients) and other immune mediated diseases, including for many disease indications that we believe would entitle us to submit for Orphan Drug status.

Manufacturing

        FP187 for the treatment of psoriasis is a round tablet, 8 mm in diameter and 5 mm in height, that contains DMF in an erosion matrix; each erosion matrix tablet core is covered by a thin enteric coating. A new, elongated tablet is being developed for FP187 for the treatment of RRMS. The tablet will also use an erosion matrix and will be covered by the same thin enteric coating.

        Currently, a single contract manufacturing organization, or CMO, provides us with our DMF, which is our API for FP187. Production procedures and facilities operated by this CMO have been validated for the current batch size in 2013, and we are planning to validate an increased batch size during 2014 or 2015.

        Formulation and finishing for our FP187 tablets is currently completed by another single CMO. Production procedures and facilities for this CMO have been validated by us for the current batch size, and we are planning to validate an increased batch size in 2015. Currently 16 batches have consistently been produced under GMP conditions for use in our Phase 3 trial for psoriasis.

        The CMOs supply us with DMF and FP187 tablets pursuant to individual work orders, and we are currently in the process of entering into framework agreements with each such manufacturer to cover the manufacture of DMF and FP187 tablets, respectively.

        We are actively reviewing alternative secondary suppliers of both DMF and our formulated and finished FP187 tablets.

98


Table of Contents

Material Agreements

Aditech agreements

        In 2004, a private Swedish company Aditech Pharma AB (collectively with its successor-in-interest, a Swiss company Aditech Pharma AG, or Aditech), controlled by Nordic Biotech General Partner ApS (an affiliate of one of our largest shareholders), began developing and filing patents for, among other things, an innovative delayed and slow release formulation for DMF. In 2005 we entered into a patent license agreement with Aditech to license this patent family from Aditech, and in 2010 we acquired this patent family from Aditech pursuant to a patent transfer agreement. Under our agreements with Aditech, we obtained, among other things, Aditech's patents and associated know-how related to DMF formulations and delivery systems, subject to both diligence and minimum annual expenditure (€1.0 million per year) obligations on our part (with an option for Aditech to receive back, for no consideration, all of our DMF related assets should we fail to satisfy these obligations), as well as a payment by us to Aditech of up to 2% of net sales generated from our DMF products and processes. Further, our agreement with Aditech gives Aditech a 90-day right of first offer to acquire non-DMF related intellectual property assets we might choose to sell.

        As noted above, the agreement with Aditech is technically a patent transfer agreement, not a license agreement. This means that we have acquired exclusive and perpetual ownership to Aditech's patents and related rights. Aditech can terminate the agreement (in which event Aditech has an option to receive back, for no consideration, all of our DMF related assets) due to any of the following reasons:

    We seek a liquidation, dissolution or winding up of our business or assets, we become insolvent or we make any general assignment for the benefit of our creditors;

    A petition is filed by or against us, or any proceeding is initiated by or against us, or any proceeding is initiated against us as a debtor, under any bankruptcy or insolvency law, unless such petition or proceeding is held to be unfounded;

    A receiver, trustee or any similar officer is appointed to take possession, custody or control of all or any part of our assets or property;

    Upon the material breach by us of any material term or material condition of our agreement with Aditech, if such breach continues for 30 calendar days after the receipt of written notice thereof from Aditech; or

    If we do not meet applicable requirements in respect of the development and commercialization of the patent rights.

        While we have exclusive ownership of the patents, the duration of our obligation to make payments to Aditech lasts until (on a country by country basis) the latest to occur of the expiration of the registered patent rights or applicable data exclusivity.

Framework Agreement

        Our principal shareholders, Nordic Biotech K/S, NBOF, BML Healthcare I, L.P. and NBFPI, as well as our EUR-denominated bridge loan lender, NBFPII, have entered into a Framework Agreement dated July 11, 2014. Our USD-denominated bridge loan lender, BVF Forward, entered into an adherence agreement pursuant to which it joined as party to the Framework Agreement on August 5, 2014. Morten Priskorn also entered into an adherence agreement pursuant to which he became party to the Framework Agreement on August 6, 2014. Pursuant to the Framework Agreement, the following corporate actions occurred prior to the consummation of this offering:

    our board of directors and shareholders adopted our 2014 Omnibus Equity Incentive Compensation Plan, or the Share Plan, and our shareholders, at an extraordinary general

99


Table of Contents

      meeting held on October 14, 2014, in order to ensure that there would be a sufficient amount of shares authorized under the Share Plan to account for the Bonus Share Issuance, authorized our board of directors to issue (i) up to 2,140,000 warrants, each to subscribe for one ordinary share, and (ii) 2,140,000 ordinary shares of DKK 0.10, to our employees, consultants and members of our board of directors and management;

    we held an extraordinary general meeting on October 14, 2014 pursuant to which our shareholders authorized our board of directors to issue new shares without preemptive rights for our existing shareholders. Such shares are to be issued in connection with the initial public offering and underlie the ADSs offered by this Prospectus;

    our board of directors approved the employment of a Chief Financial Officer and the negotiation of an employment agreement with the Chief Financial Officer and the issuance of warrants and granting of a right to deferred shares under the Share Plan to the Chief Financial Officer;

    our board of directors approved (i) the rules of procedure for the board, (ii) our internal rules on inside information, (iii) indemnification agreements with members of the board of directors and executive management, and (iv) our liability and director and officer insurance; and

    prior to our board of directors' approval of the offer price and the issuance of ADSs offered by this Prospectus, we held an extraordinary general meeting on October 14, 2014 pursuant to which we performed the following:

    (i)
    We issued additional Class A bonus shares to the holders of Class B shares. Since Class B shares had a distribution preference of at least DKK 4,419.48 per share, or at least 375.375% of the amount paid by the Class B shareholders upon the subscription of the Class B shares, we issued to the holders of Class B shares, in order to account for such distribution preference and in lieu of cash, an additional 114,309 Class A bonus shares based on the initial public offering price of $21.00 per ADS. As a result of this issuance of additional Class A bonus shares, the holders of Class B shares received a return of approximately $42.8 million, in the aggregate, on their Class B shares, and the holders of Class A shares suffered dilution in an equivalent aggregate amount, prior to the consummation of this offering.

    (ii)
    Following the issuance of additional Class A bonus shares to the holders of Class B shares described above, all of our outstanding Class A shares and Class B shares were converted into a single class of ordinary shares on a 1:1 basis.

    (iii)
    Our bridge loans (including all principal and accrued interest) obtained from NBFPII and BVF Forward, respectively, were converted into ordinary shares, at the initial public offering price less a discount of 15%, and the holders of the ordinary shares suffered dilution in an equivalent aggregate amount, prior to the consummation of this offering.

    (iv)
    In order to achieve a fixed number of issued and outstanding ordinary shares prior to the consummation of this offering, and due to the fact that the exact number of Class A bonus shares issued to the holders of Class B shares was variable based on the price per share in the offering, we issued in the aggregate 1,550,540 additional ordinary shares based on the initial public offering price of $21.00 per ADS, in the form of bonus shares to all existing shareholders on a pro rata basis.

    (v)
    We underwent a share split, pursuant to which existing shareholders received ten (10) shares in exchange for each share they owned to such extent that the undiluted share capital was set to equal 35,313,760 issued and outstanding ordinary shares immediately prior to the consummation of the offering.

100


Table of Contents

    (vi)
    Our board of directors was authorized to (a) resolve to distribute extraordinary dividends, (b) have Forward Pharma A/S acquire its own shares, (c) issue new shares without preemptive rights for existing shareholders, and (d) adopt certain other amendments to our Articles of Association.

        We have decided to postpone the hiring of a new Chief Executive Officer at this time, and instead elevated our Chief Operating Officer Peder Møller Andersen to the position of Chief Executive Officer and Chief Operating Officer. In August 2014, we hired Joel Sendek to be our Chief Financial Officer.

Competition

        We are engaged in segments of the pharmaceutical and biotechnological industries that are highly competitive and rapidly changing. Large pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are commercializing or pursuing the development of products that target immune disorders, including the same diseases we are targeting. If FP187 is approved for the treatment of RRMS, we expect it will face intense and increasing competition as new products enter the RRMS markets and advanced technologies become available. FP187 will face competition based on its safety and effectiveness, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent position and other factors. Our competitors may succeed in developing competing products before we do, obtaining regulatory approval for products or gaining broader acceptance in the MS market we are targeting.

        We believe that our key competitor in the DMF space is Biogen. Biogen's Tecfidera® was approved by the FDA for the treatment of RRMS on March 27, 2103. Tecfidera® generated global sales of $2.08 billion from launch in April 2013 through June 30, 2014.

        Other companies have also developed alternative therapeutic approaches for the treatment of RRMS. These include Novartis AG whose Gilenya® is a once daily oral dose drug to treat RRMS approved in September 2010, and Genzyme Corporation (a subsidiary of Sanofi S.A.), which developed Aubagio®, a RRMS drug approved in September 2012.

        We also face competition from potential new entrants into the RRMS market. For example, Receptos Inc. has a product candidate, RPC1063, in Phase 2/3 testing which, if successfully approved and launched would be a once daily oral treatment for RRMS.

        As we pursue the development of and FP187 is approved for the treatment of psoriasis, we will similarly face intense competition in the psoriasis market. This will include competition from products which have already been commercialized and have gained market acceptance, as well as from products based on new and advanced technologies.

Government Regulation

        Our business is subject to extensive government regulation. Regulation by governmental authorities in the U.S., the EU and other jurisdictions is a significant factor in the development, manufacture and marketing of any drugs and in ongoing research and development activities. All of our products are subject to rigorous pre-clinical and clinical trials and other pre-marketing approval requirements by the FDA, the EMA and other regulatory authorities in the U.S., the EU and in other jurisdictions.

United States

        In the U.S., the FDA regulates drugs under the FDC Act, and regulations implemented by the agency. If we fail to comply with the applicable United States requirements at any time during the product development process, including non-clinical testing, clinical testing, the approval process or after approval, we may become subject to administrative or judicial sanctions. These sanctions could

101


Table of Contents

include, but are not limited to, the FDA's refusal to allow us to proceed with clinical testing, refusal to approve pending applications, withdrawal of an approval, warning or untitled letters, adverse publicity, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.

Approval of drugs

        The process required by the FDA before a drug may be marketed in the United States generally involves satisfactorily completing each of the following:

    pre-clinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA's Good Laboratory Practice, or GLP, and current Good Manufacturing Practice, or cGMP, regulations, as applicable;

    submission to the FDA of an investigational new drug, or IND, application for human clinical testing, which must become effective before human clinical trials involving testing on U.S. patients may begin;

    performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication;

    submission of data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labeling;

    submission to the FDA of an NDA;

    satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMPs;

    potential FDA audit of the non-clinical and clinical trial sites that generated the data in support of the NDA; and

    FDA review and approval of the NDA before any commercial marketing, sale or shipment of the product.

        Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based on the type, complexity and novelty of the product or disease.

Pre-clinical studies and Investigational New Drug application

        Pre-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in order to assess the potential safety and efficacy of the product. The conduct of the pre-clinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the pre-clinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND, application. The IND becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin. Submission of the IND may result in the FDA not allowing the trials to commence, either on the terms originally specified in the IND, or at all. If the FDA raises concerns or questions either during this initial 30 day period or at any time during the IND process, they may choose to impose a partial or complete clinical hold. This order issued by the FDA would delay either a proposed clinical study or cause suspension of an ongoing study, until all outstanding concerns have been adequately addressed and the FDA have

102


Table of Contents

notified the company that investigations may proceed. This could cause significant delays or difficulties in completing planned clinical studies in a timely manner.

Clinical trials

        Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators. Clinical trials are conducted in accordance with federal regulations and under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. An independent Institutional Review Board, or IRB, must also review and approve the clinical trial before it can begin and monitor the study until it is completed. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, and the safety of human subjects. The FDA, the IRB or the sponsor may suspend or discontinue a clinical trial at any time or impose sanctions for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or the subjects are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive Good Clinical Practice rules, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors, including the requirements for informed consent.

        Clinical trials typically are conducted in three sequential phases, but the phases may overlap. Additional studies may be required after approval.

            Phase 1 clinical trials are initially conducted in a limited population to test the product for safety, dose tolerance, absorption, metabolism, distribution and excretion in healthy humans or, on occasion, in patients, such as cancer patients.

            Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, determine the efficacy of the product for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trial.

            Phase 3 clinical trials proceed if the Phase 2 clinical trials provide evidence that a dose range of the product is effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken in large patient populations to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically relevant Phase 3 trial may be designed to deliver the data that the regulatory authorities will use to decide whether or not to approve a drug: such Phase 3 studies are referred to as "pivotal." In most cases FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be sufficient in instances where the study is a large multicenter trial demonstrating internal consistency and a statistically persuasive finding of a clinically meaningful effect.

        In some cases, the FDA may approve an NDA for a product with the sponsor's agreement to conduct additional clinical trials to further assess the drug's safety and effectiveness after NDA approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement. Failure to promptly conduct Phase 4 clinical trials could result in withdrawal of approval for products.

103


Table of Contents

New Drug Application

        The results of product development, pre-clinical testing and clinical trials are submitted to the FDA as part of an NDA, submitted under Sections 505(b)(1) or 505(b)(2) of the FDC Act. The NDA also must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. The application fee currently exceeds $2,169,000, and the manufacturer and/or sponsor under an approved new drug application are also subject to annual product and establishment user fees, currently exceeding $104,000 per product and $554,000 per establishment. These fees are typically increased annually. Once the submission has been accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under the most recent iteration of the Prescription Drug User Fee Act, or the PDUFA, the FDA has ten to twelve months in which to review a standard NDA and respond to the applicant, and six to eight months for a priority NDA. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs. The review process is often significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by three months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA may also refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of the advisory committee, but it generally follows such recommendations. The FDA may deny approval of an NDA if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or an additional pivotal Phase 3 clinical trial. Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.

        Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. FDA will not approve the product unless compliance with cGMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.

        At the conclusion of the FDA's review it will issue an action letter. If the FDA's evaluations of the NDA and the clinical and manufacturing procedures and facilities are favorable and there are no outstanding issues, the FDA will issue an approval letter. If the application is not approved, the FDA will issue a complete response letter, which will contain the conditions that must be met in order to secure final approval of the NDA, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a complete response letter may submit to the FDA information that represents a complete response to the issues identified by the FDA. If, or when, those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included..Once issued, the FDA may withdraw a drug approval if ongoing regulatory requirements are not met or if safety problems occur after the drug reaches the market. In addition, the FDA may require further testing, including Phase 4 clinical trials, and surveillance programs to monitor the effect of approved drugs which have been commercialized.

        As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug.

104


Table of Contents

        The FDA has the power to prevent or limit further marketing of a drug based on the results of these post-marketing programs. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved label. Further, if there are any modifications to a drug, including changes in indications, labeling or manufacturing processes or facilities, we may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require us to develop additional data or conduct additional pre-clinical studies and clinical trials. We cannot be sure that any additional approval for new indications for any product will be approved on a timely basis, if at all.

        The FDA has several programs that are intended to facilitate and expedite development and review of new drugs to address unmet medical need in the treatment of serious or life-threatening conditions. These programs are intended to help ensure that therapies for serous conditions are available as soon as it can be concluded that the therapies benefits justify their risks. These programs include breakthrough therapy designation, fast track designation, priority review and accelerated approval.

Hatch-Waxman Act and Orange Book listing

        In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant's product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants ordinarily are not required to conduct, or submit results of, pre-clinical or clinical tests to prove the safety or effectiveness of their drug product.

        The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA's Orange Book. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.

        A certification that the new product will not infringe the already approved product's listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the lawsuit that is favorable to the ANDA applicant.

        The ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired.

105


Table of Contents


Section 505(b)(2) New Drug Applications

        Most drug products obtain FDA marketing approval pursuant to an NDA or an ANDA. A third alternative is a special type of NDA, commonly referred to as a Section 505(b)(2) NDA, which enables the applicant to rely, in part, on FDA's previous approval of a similar product, or published literature, in support of its application.

        Section 505(b)(2) NDAs often provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance on FDA's previous approval is scientifically appropriate, it may eliminate the need to conduct certain pre-clinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new product candidate for all, or some, of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.

        To the extent that the Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. Thus approval of a Section 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant.

Exclusivity

        Upon NDA approval of a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which the FDA cannot receive any ANDA seeking approval of a generic version of that drug, or a Section 505(b)(2) NDA that references the drug. Certain changes to a drug that require a clinical trial to support the FDA approval, such as the addition of a new indication to the package insert, are associated with a three-year period of exclusivity during which the FDA cannot approve an ANDA or Section 505(b)(2) NDA for a drug that includes the change.

        An ANDA or Section 505(b)(2) NDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the NCE exclusivity period.

Post-approval regulation

        If regulatory approval for marketing of a product or new indication for an existing product is obtained, we will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process.

        For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.

106


Table of Contents

        We will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon drug manufacturers. Accordingly, we and our third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. Discovery of problems with a product after approval for marketing may result in restrictions on a product, manufacturer, or holder of an approved NDA, including withdrawal of the product from the market.

Pediatric information

        Under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.

Orphan drugs

        Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition—generally a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.

Disclosure of clinical trial information

        Sponsors of clinical trials of FDA regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.

107


Table of Contents

European Union

        The process regarding approval of medicinal products in the EU follows roughly the same lines as in the United States and likewise generally involves satisfactorily completing each of the following:

    pre-clinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU Good Laboratory Practice regulations;

    submission to the relevant national authorities of a clinical trial application, or CTA, which must be approved before human clinical trials may begin;

    performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication;

    submission to the relevant competent authorities of a marketing authorization application, or MAA, which includes the data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labeling;

    satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities, including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMPs;

    potential audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and

    review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the product.

Pre-clinical studies

        Pre-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in order to assess the potential safety and efficacy of the product. The conduct of the pre-clinical tests and formulation of the compounds for testing must comply with the relevant EU regulations and requirements. The results of the pre-clinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.

Clinical trial approval

        Pursuant to the Clinical Trials Directive 2001/20/EC, as amended, a system for the approval of clinical trials in the EU has been implemented through national legislation of the member states. Under this system, approval must be obtained from the competent national authority of an EU member state in which a study is planned to be conducted. To this end, a CTA is submitted, which must be supported by an investigational medicinal product dossier, or IMPD, and further supporting information prescribed by the Clinical Trials Directive and other applicable guidance documents. Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical trial application in that country.

        Clinical drug development is often described as consisting of four temporal phases (Phase 1-4), see for example EMA's note for guidance on general considerations for clinical trials (CPMP/ICH/291/95).

    Phase 1 (Most typical kind of study: Human Pharmacology);

    Phase 2 (Most typical kind of study: Therapeutic Exploratory);

    Phase 3 (Most typical kind of study: Therapeutic Confirmatory); and

    Phase 4 (Variety of studies: Therapeutic Use).

108


Table of Contents

        Studies in Phase 4 are all studies (other than routine surveillance) performed after drug approval and related to the approved indication.

        The phase of development provides an inadequate basis for classification of clinical trials because one type of trial may occur in several phases. The phase concept is a description, not a set of requirements. The temporal phases do not imply a fixed order of studies since for some drugs in a development plan the typical sequence will not be appropriate or necessary.

        Manufacturing of investigational products is subject to the holding of authorization and must be carried out in accordance with cGMPs.

Pediatric Investigation Plans

        Regulation (EC) 1901/2006, which came into force on January 26, 2007, has as its primary purpose the improvement of the health of children without subjecting children to unnecessary trials, or delaying the authorization of medicinal products for use in adults.

        The regulation established the Pediatric Committee, or PDCO, which is responsible for coordinating the EMA's activities regarding medicines for children. The PDCO's main role is to determine all the studies that applicants need to do in the pediatric population as part of the so-called Pediatric Investigation Plans, or PIPs.

        All applications for marketing authorization for new medicines that were not authorized in the EU before January 26, 2007 have to include the results of studies carried out in children of different ages. As indicated, the PDCO determines what these studies entail and describes them in a PIP. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The PDCO can grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults, and can also grant waivers when development of a medicine in children is not needed or appropriate, such as for diseases that only effect the elderly population.

        Regulation (EC) 1901/2006 also provides for several incentives for the development of medicines for children, among others:

    scientific advice and protocol assistance at the EMA are free of charge for questions relating to the development of medicines for children; and

    medicines developed specifically for children that are already authorized but are not protected by a patent or supplementary protection certificate, can apply for a pediatric use marketing authorization, or PUMA. If a PUMA is granted, the product will benefit from 10 years of market protection as an incentive.

Marketing authorization application and available authorization procedures

        Authorization to market a product in the EU member states proceeds under one of four procedures: a centralized authorization procedure, a mutual recognition procedure, a decentralized procedure or a national procedure.

    Centralized authorization procedure.  A marketing authorization for certain drugs must be obtained through the centralized authorization procedure for marketing authorization, which, if granted, is automatically valid in all EU member states plus the EEA (including Norway, Iceland and Lichtenstein). The EMA and the EC administer the centralized authorization procedure.

109


Table of Contents

        Pursuant to Regulation 726/2004, this procedure is mandatory for:

    a)
    medicinal products developed by means of one of the following biotechnological processes:

    recombinant DNA technology;

    controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes, including transformed mammalian cells; and

    hybridoma and monoclonal antibody methods;

    b)
    advanced therapy medicinal products as defined in Article 2 of Regulation 1394/2007 on advanced therapy medicinal products;

    c)
    medicinal products for human use containing a new active substance which, on the date of entry into force of this Regulation, was not authorized in the EU, for which the therapeutic indication is the treatment of any of the following diseases:

    acquired immune deficiency syndrome;

    cancer;

    neurodegenerative disorder;

    diabetes;

    auto-immune diseases and other immune dysfunctions; and

    viral diseases; and

    d)
    medicinal products that are designated as orphan medicinal products pursuant to Regulation 141/2000.

        RRMS is considered as an auto-immune disease. We have built our regulatory plan on the understanding that use of the centralized authorization procedure will be mandatory for FP187 for use in RRMS, if this is the lead indication.

        The centralized authorization procedure is optional for other medicinal products if they contain a new active substance or if the applicant shows that the medicinal product concerned constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization is in the interest of patients at a European Community level.

        Under the centralized authorization procedure, the CHMP serves as the scientific committee that renders opinions about the safety, efficacy and quality of human products on behalf of the EMA. The CHMP is composed of experts nominated by each member state's national drug authority, with one of them appointed to act as Rapporteur for the coordination of the evaluation with the possible assistance of a further member of the Committee acting as a Co-Rapporteur. After approval, the Rapporteur(s) continue to monitor the product throughout its life cycle. The CHMP has 210 days, to adopt an opinion as to whether a marketing authorization should be granted; the process usually takes longer as additional information is requested, which triggers delays in the procedural timelines. The process is complex and involves extensive consultation with the regulatory authorities of member states and a number of experts. Once the procedure is completed, a European Public Assessment Report, or EPAR, is produced. If the opinion is negative, information is given as to the grounds on which this conclusion was reached. The opinion produced by the CHMP is sent to the European Commission and used in reaching the final decision on a marketing authorization application by the EC.

110


Table of Contents

        In general, if the centralized procedure is not followed, there are three alternative procedures:

    Mutual recognition procedure.  If an authorization has been granted by one member state, or the reference member state, an application may be made for mutual recognition in one or more other member states, or the concerned member state(s).

    Decentralized procedure.  The third option is the decentralized procedure, or DCP. The DCP may be used to obtain a marketing authorization in several European member states when the applicant does not yet have a marketing authorization in any country.

    National procedure.  Applicants following the national procedure will be granted a marketing authorization that is valid only in a single member state. Furthermore, this marketing authorization is not based on recognition of another marketing authorization for the same product awarded by an assessment authority of another member state. The national procedure can also serve as the first phase of a mutual recognition procedure.

        It is not always possible for applicants to follow the DCP or the national procedure. In the case of medicinal products in the category for which the centralized authorization procedure is mandatory, that procedure must be followed. In addition, the national procedure is not available in the case of medicinal product dossiers where the same applicant has already obtained marketing authorization in one of the other EU member states or has already submitted an application for marketing authorization in one of the other member states and the application is under consideration. In the latter case, applicants must follow a mutual recognition procedure.

        In the event that we are not required to use the centralized procedure for FP187, we would consider using the DCP, as we believe it would afford us a faster pathway to approval. EU regulations allow for other approval procedures, some of which can shorten and simplify the approval process, but we have not included them in our regulatory planning, as we do not believe that they will be available for FP187.

        After a drug has been authorized and launched, it is a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be kept under review. Sanctions may be imposed for failure to adhere to the conditions of the marketing authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the product from sale.

Period of authorization and renewals

        Marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state(s). To this end, the marketing authorization provides the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization shall cease to be valid (the so-called sunset clause) if no reasons are being provided by the applicant and accepted by the competent authority prior to the end of the three-year period.

111


Table of Contents

Regulatory data protection

        Without prejudice to the law on the protection of industrial and commercial property, all applications for marketing authorization with a full dossier (including "full-mixed applications") and not falling under a global marketing authorization receive an 8+2+1 protection regime.

        This regime consists of a regulatory data exclusivity period of eight years plus an additional market protection of two years plus a further market protection of one more year if, during the first eight years of those ten years, the marketing approval holder obtains an approval for one or more new therapeutic indications which, during the scientific evaluation prior to their approval, are determined to bring a significant clinical benefit in comparison with existing therapies. Under the current rules, a third-party may reference the pre-clinical and clinical data of the original sponsor beginning eight years after first approval, but the third-party may market a generic version after only ten (or eleven) years have lapsed.

        As indicated, additional data protection can be applied for when an applicant has complied with all requirements as set forth in an approved PIP.

Manufacturing

        The manufacturing of authorized drugs, for which a separate manufacturer's license is mandatory, must be conducted in strict compliance with the GMP requirements and comparable requirements of other regulatory bodies, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. The EC (via EMA and national authorities) enforces its GMP requirements through mandatory registration of facilities and inspections of those facilities. The EMA may have a coordinating role for these inspections while the responsibility for carrying them out rests with the member states competent authority under whose responsibility the manufacturer falls. Failure to comply with these requirements could interrupt supply and result in delays, unanticipated costs and lost revenues, and could subject the applicant to potential legal or regulatory action, including but not limited to warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil and criminal penalties.

Marketing and promotion

        The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Community notably under Directive 2001/83 in the European Community code relating to medicinal products for human use as amended by Directive 2004/27. The applicable regulation aims to ensure that information provided by holders of marketing authorizations regarding their products is truthful, balanced and accurately reflects the safety and efficacy claims authorized by the EMA or by the competent authority of the authorizing member state. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.

Pharmaceutical Pricing and Reimbursement

        Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. Sales of FP187, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on

112


Table of Contents

an approved list, or formulary, which might not include all of the approved drugs for a particular indication.

        In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. FP187 may not be considered medically necessary or cost-effective. A payor's decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development.

        The containment of healthcare costs has become a priority of governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. The U.S. government, state legislatures and non-U.S. governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as the product that we are developing and could adversely affect our net revenue and results.

        Pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product to currently available therapies. For example, the EU provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing arrangements for any of our products.

        The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular, the Patient Protection and Affordable Care Act was enacted in the United States in March 2010 and contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies' share of sales to federal health care programs. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

113


Table of Contents

Environmental, Health and Safety

        Our operations are subject to a number of environmental acts and regulations. We believe that we are materially in compliance with all applicable environmental laws and regulations. Currently, there are no pending environmental issues that could have a material adverse effect on our business, financial position, results of operations and future growth prospects.

        We consider it important to maintain a good working environment and comply with the regulatory requirements regarding working environment. This consists of the physical and psychological working environment, including heating, ventilation, air conditioning and air circulation and exhaust systems, as well as office furniture and equipment design and functionality, and other general health and safety systems, including control of the facility. We are from time to time subject to inspections by the Danish Working Environment Authority for compliance with the Danish Working Environment Act.

Facilities

        Our corporate headquarters are located at Østergade 24A, 1, 1100 Copenhagen K, Denmark where we lease offices from Nordic Biotech Advisors ApS, an affiliate of certain of our principal shareholders, for administrative activities. In 2013, we paid DKK 465,564 (approximately $83,000) including VAT for such premises. For more, see "Related Party Transactions—Leased Premises."

        Forward Pharma GmbH, our wholly owned German subsidiary, has offices for administrative and operational activities in Leipzig, Germany. In 2013, we paid €20,087 (approximately $27,000) for such premises.

        Forward Pharma USA, LLC, our wholly owned U.S. subsidiary, is currently searching for premises in the United States, where we plan to open an office. Assuming we are able to find suitable premises for an office in the United States, where we plan to carry out certain administration functions, we believe our facilities will be suitable and adequate for our current needs.

Employees

        We have two employees based in our headquarters in Copenhagen, Denmark, we have five employees based in our office in Leipzig, Germany, and we have three employees based in the United States. All, but one employee, are employed on a full-time basis. None of our employees is represented by a labor union or covered under a collective bargaining agreement, and we have never experienced any work stoppages.

        All other operational tasks are outsourced to consultant experts, such as formulation and QA/GMP experts, or consulting service companies, such as regulatory, patent and legal experts. We engage approximately 20 experts as consultants.

        We are currently actively searching for additional internal experts in key areas such as MS clinical research, intellectual property management, regulatory compliance, and production/supply chain management.

        In the United States, our activities and personnel we intend to engage will primarily be focused on U.S. public company legal and accounting reporting and compliance, investor relations, and related administrative functions to support Forward Pharma A/S.

Insurance

        We maintain all insurance coverage required under applicable law, including in relation to its research, pre-clinical and clinical development. In the future, we may or will be required to obtain additional insurance to cover potential product liability and other risks, which are inherent in the manufacturing, marketing and the commercialization and use of drugs.

114


Table of Contents

        We believe that we currently maintain appropriate insurance coverage, and that our current insurance coverage is in line with insurance coverage for comparable companies.

Legal Proceedings

        We may, from time to time, become involved in legal proceedings in the ordinary course of business. We have not been a party to or paid any fees or damages in connection with any litigation, including any of our patent opposition actions pending before the EPO), that has had a material adverse effect on our business or financial position. Opposition proceedings against two of our European patents are currently pending and we are involved in an opposition proceeding in Europe against a Biogen patent. In addition, we are expecting an interference action involving one of our U.S. patents and one of Biogen's patents to soon commence in the U.S. As a result of these activities, there can be no assurance that these patent proceedings might not evolve into more significant or costly matters, including related litigation, which proceedings or litigation could have a material adverse effect on our financial position. See "Risk Factors—Risks related to intellectual property—Biogen may initiate legal proceedings alleging that we are infringing its intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business."

115


Table of Contents


MANAGEMENT

Executive Officers and Directors

        The following table sets forth information regarding our executive officers and board of directors as of the date of this Prospectus:

Name
  Age  
Position
Florian Schönharting     45   Chairman

Peder Møller Andersen

 

 

62

 

Chief Executive Officer and Chief Operating Officer

Joel Sendek

 

 

47

 

Chief Financial Officer

Thomas Carbone

 

 

57

 

Vice President, Finance and Controller

J. Kevin Buchi

 

 

59

 

Director

Torsten Goesch

 

 

54

 

Director

Jan G. J. van de Winkel

 

 

53

 

Director

Florian Schönharting, Chairman

        Mr. Schönharting is currently the chairman of our board of directors and has served on the board since the incorporation of the Company in July 2005. Mr. Schönharting is the co-founder of Forward Pharma. He has also founded or co-founded several other biopharmaceutical companies, including Genmab A/S, Veloxis A/S (f/k/a Life Cycle Pharma A/S) and Zealand Pharma A/S. Mr. Schönharting has a total over 22 years investment executive experience in public and private equity funds involved in the biopharmaceutical industry. He actively managed BI Healthcare SICAV and BI Bioteknologi SICAV for eight years. Mr. Schönharting currently manages the following funds: NB Public Equity K/S, Nordic Biotech K/S, NBOF, NBFPI and NBFPII. Mr. Schönharting has an M.Sc (Econ) from Copenhagen Business School.

Peder Møller Andersen, Chief Executive Officer and Chief Operating Officer

        Dr. Andersen previously served as our acting Chief Executive Officer and has served as our Chief Operating Officer since May 2012, and was made our permanent Chief Executive Officer on August 4, 2014. He has been in charge of the clinical development program for FP187 at Forward Pharma since 2008 and also holds the position of Managing Director of Forward Pharma GmbH, Leipzig. Dr. Andersen has more than 25 years of experience in the pharmaceutical industry. He has also worked for CROs and small biopharmaceutical companies as an external consultant. Dr. Andersen also has several years of business development experience, generic and proprietary, in Europe with PLIVA, Croatia and AWD, Germany. He has also founded a successful Nordic-based pharmaceutical company. Dr. Andersen has degree from Copenhagen Medical School and trained in surgery, anesthesiology and internal medicine for 6 years.

Joel Sendek, Chief Financial Officer

        Mr. Sendek has served as our Chief Financial Officer since August 2014. He also holds the position of Chief Financial Officer of Forward Pharma USA, LLC. Mr. Sendek has more than 20 years experience with the life sciences sector. Prior to joining us, Mr. Sendek was a Managing Director, Healthcare Equity Research, at Stifel Financial Corp., and prior to that he held Managing Director roles at each of Lazard and Lazard Capital Markets. He also served as an Analyst at both Gerard Clauer Mattison and, prior to that, Goldman, Sachs & Co.

116


Table of Contents

Thomas Carbone, Vice President, Finance and Controller

        Mr. Carbone has served as the Vice President, Finance and Controller of Forward Pharma USA, LLC since August 2014. Prior to joining us, he spent over 30 years providing auditing and accounting services to a diversified client base of public and private companies including many in the biotechnology and pharmaceutical industries. Mr. Carbone has extensive experience with the reporting requirements for publicly listed companies and the complex rules and regulations that public companies must comply with. He has been involved in numerous public offerings of debt and equity securities including many initial public offerings. His most recent role was Partner at a nationally recognized public accounting firm.

J. Kevin Buchi, Director

        Mr. Buchi has served on our board of directors since December 2012. Mr. Buchi has served as President, Chief Executive Officer and a director of Tetralogic since August 2013. Prior to joining Tetralogic, Mr. Buchi was Corporate Vice President, Global Branded Products at Teva Pharmaceutical Industries, or Teva, from October 2011 to May 2012 and Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through October 2011 prior to Teva's acquisition of Cephalon in October 2011. Mr. Buchi joined Cephalon in 1991 and also held the positions of Chief Financial Officer from 1996 through December 2009 and Chief Operating Officer from January 2010 through December 2010. Mr. Buchi also currently serves on the board of directors of Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) (2013 to present), Benitec Biopharma Ltd. (ASX: BLT) (2013 to present), EPIRUS Biopharmaceuticals, Inc. (2013 to present), and Stemline Therapeutics, Inc. (NASDAQ: STML) (2012 to present). Previously, Mr. Buchi served on the board of directors of Celator Pharmaceuticals, Inc. (2006 to 2010), Encysive Pharmaceuticals, Inc. (2004 to 2008), Lorus Therapeutics, Inc. (Canada) (2003 to 2009) and Mesoblast Limited (Australia) (ASX: MSB) (2010 to 2012). Mr. Buchi graduated from Cornell University with a B.A. in chemistry in 1976 and received a Masters of Management from the J.L. Kellogg Graduate School of Management at Northwestern University in 1980.

Torsten Goesch, Director

        Dr. Goesch has served on our board of directors since June 2006. He has also been the director of Rosetta Capital, a secondary life sciences investor since 2002. In this function, Dr. Goesch was responsible for the management of several Rosetta capital investments and served as a member of the board of directors of many biopharmaceutical companies, including Enobia Ltd and Cytochroma Ltd. Dr. Goesch is also the founder and former Managing Director of TRG Invest, a Munich-based consulting business providing companies in the life science sector. Additionally, Dr. Goesch served as the General Manager for the German Speaking Countries at Biogen from 1997 to 1999, and before that was the Commercial Head of Merck KGaA's worldwide generics drug business, Merck Generics. He practiced as a physician of internal medicine at the University Hospital Hamburg-Eppendorf from 1988 to 1990, focusing on nephrology, immunology and oncology. Dr. Goesch has a Master of Management from Northwestern University's J.L. Kellogg Graduate School of Management, as well as an M.D. and Ph.D. from Heinrich Heine University Dusseldorf.

Jan G. J. van de Winkel, Director

        Dr. Jan G. J. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of Genmab until his appointment as its President and Chief Executive Officer in 2010. Dr. van de Winkel has over 20 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to co-founding Genmab. He is the author of over 300 scientific publications and has been responsible for over 40 patents and pending patent applications. Dr. van de Winkel holds a professorship in

117


Table of Contents

Immunology at Utrecht University. He is chairman of the board of directors of Regenesance and member of the board of directors of ISA Pharmaceuticals and Celdara Medical, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund. Dr. van de Winkel holds M.S. and Ph.D. degrees from the University of Nijmegen.

Composition and Practices of the Board of Directors

        The board of directors has the overall responsibility for our corporate management. The board of directors determines our policies regarding business strategy, organization, accounting and finance, and the board of directors appoints and supervises our executive officers. The majority of the members of the board of directors must be directors who are not executive officers, and no executive officer may be chairman or vice-chairman of the board of directors. The chairman is elected among and by the directors.

        According to the Articles of Association that became effective immediately prior to this offering, the board of directors must consist of not less than three and not more than six members. All members of the board of directors are elected by our shareholders at the general meeting for one year terms. The board of directors plans to meet at least four times each year, and meetings can be called when deemed necessary by any of our directors or members of our executive officers or by our auditor.

        Under the shareholders' agreement that certain of our shareholders entered into prior to this offering, the shareholders party to such agreement have agreed that NBFPI will have the right to nominate four directors, Nordic Biotech K/S and NBOF will jointly have the right to nominate one director, and NBFPII shall have the right to nominate one director to the board.

        The Danish Companies Act requires granting employees in Danish companies a right of representation on the board of directors in companies with at least 35 employees. This requirement does not currently apply to us as we only have seven employees.

        The board of directors conducts its business in accordance with the Danish Companies Act and its own rules of procedure. The rules of procedure set out, among other things, that the board of directors shall establish our strategy, policies and activities to achieve its objective in accordance with the Articles of Association. It also establishes the responsibilities of the board of directors, e.g., that the board of directors shall ensure that our bookkeeping, accounting, asset management, information technology systems, budgeting and internal controls are properly organized. The rules of procedure also provide guidelines for the division of responsibilities between the board of directors, the executive officers and the audit committee. The rules of procedure may be amended by a simple majority vote of the board.

        A majority of the directors, including our Chairman, must be present to constitute a quorum. Unless otherwise set forth in our Articles of Association, decisions of the board of directors are decided by a simple majority of votes cast. In the event of a tie vote of the members of the board of directors, the chairman shall have a casting vote.

Management

        Our executive officers are responsible for our day-to-day business and operations. Dr. Peder Møller Andersen is our Chief Executive Officer and Chief Operating Officer. Joel Sendek is our Chief Financial Officer.

Board Committees

Audit Committee

        We have an audit committee, which was established on August 8, 2014, under our board of directors consisting solely of Messr. J. Kevin Buchi. Since there are no specific requirements under

118


Table of Contents

Danish law on the composition of our audit committee, we do not comply with Rule 4350(d) of the NASDAQ Marketplace Rules that requires the audit committees of U.S. companies have a minimum of three independent directors. Messr. J. Kevin Buchi, however, satisfies the director and audit committee "independence" requirements of each of the NASDAQ Marketplace Rules and Section 10A(m)(3)(B)(i) of the Exchange Act.

        The principal duties and responsibilities of our audit committee will be:

    making recommendations on the appointment and retention of our independent registered public accounting firm which will audit our consolidated financial statements, overseeing the independent registered accounting firm's work and advising on the determination of the independent registered accounting firm's compensation;

    reviewing in advance all audit services and non-audit services to be provided to us by our independent registered accounting firm;

    recommending procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls, auditing or compliance matters, as well as for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters;

    reviewing and discussing with management and our independent registered accounting firm the results of the annual audit;

    conferring with management and our independent registered accounting firm about the scope, adequacy and effectiveness of our internal accounting controls, the objectivity of our financial reporting and our accounting policies and practices;

    overseeing regulatory compliance and related matters; and

    reviewing related party transaction matters.

        We do not have a compensation committee or a nominations committee, nor is independent director involvement required in the selection of director nominees or in the determination of executive compensation. Our home country practice differs from Rule 5605 of the NASDAQ Marketplace Rules regarding independent directors' involvement in these areas, because there are no specific requirements under applicable Danish law on the establishment of compensation committees or nominations committees, and neither are there any requirements under applicable Danish law on independent directors' involvement in the selection of director nominees nor in the determination of executive compensation.

Scientific Advisors

        We have engaged a number of scientific advisors, and we regularly seek advice and input from these experienced scientific leaders on matters related to our research and development programs. Our scientific advisors are experts across a range of key disciplines relevant to our programs and science. We intend to continue to leverage the broad expertise of our advisors by seeking their counsel on important topics relating to our DMF drug discovery and development programs. Two of our scientific advisors, Messrs. Reich and Mrowietz described below, own warrants to subscribe for some of our Class A shares.

119


Table of Contents

        All of our scientific advisors are employed by or have consulting arrangements with other entities and devote only a small portion of their time to us. Our current advisors are:

 
 
Name
 
Title
MS
advisors
  Fred Lublin, MD   Professor of Neurology and the Director of the Corinne
Goldsmith Dickinson Center for MS
Mount Sinai Medical Center
New York, New York
    Giancarlo Comi, MD   Director of the Post-Degree School in Neurophysiopathology
University Vita-Salute San Raffaele
Milan, Italy
    Jerry Wolinsky, MD   Interim Chair, Department of Neurology and Director,
MS Research Group
University of Texas Medical School
Houston, Texas
    Per Soelberg Sørensen, MD   Professor of Neurology and Director of the Danish Multiple
Sclerosis Center, Rigshospitalet
University of Copenhagen and Copenhagen University Hospital
Copenhagen, Denmark

Psoriasis
advisors

 

Kristian Reich, MD

 

Professor of Dermatology, Göttingen University
Partner, Dermatologikum Hamburg
Hamburg, Germany
    Ulrich Mrowietz, MD   Head and Founder of the Psoriasis-Center Kiel
University Medical Center Schleswig-Holstein, Campus Kiel
Kiel, Germany

Code of Business Conduct

        In connection with this offering, we are adopting a written code of business conduct, or code of conduct, which outlines the principles of legal and ethical business conduct under which we do business. The code of conduct applies to all of our board members and employees. The full text of the code of conduct will be made available on our website at www.forward-pharma.com. This website address is included in this Prospectus as an inactive textual reference only. The information and other content appearing on our website are not part of this Prospectus. Any amendments or waivers from the provisions of the code of conduct will be made only after approval by our audit committee and will be disclosed on our website promptly following the date of such amendment or waiver.

Exemptions from Certain Corporate Governance Requirements of NASDAQ

    As a foreign private issuer, we are not required to have an audit committee comprised of at least three members. Our audit committee is comprised of one member.

    As a foreign private issuer, we are not required to have a board the majority of which is comprised of independent directors.

    As a foreign private issuer, we are not required to adopt a formal written charter or board resolution addressing the process for the nomination of directors. We do not have a nominations committee, nor have we adopted a board resolution addressing the nominations process.

    As a foreign private issuer, we are not required to hold regularly scheduled board meetings at which only independent directors are present.

    As a foreign private issuer, no quorum requirement will apply to our meetings of shareholders.

120


Table of Contents

    As a foreign private issuer, we are not required to obtain shareholder approval for material revisions to our share-based incentive plans.

    As a foreign private issuer, we are not required to solicit proxies or provide proxy statements to NASDAQ pursuant to NASDAQ corporate governance rules or Danish law. Consistent with Danish law and as provided in our Articles of Association, we will notify our shareholders of meetings with at least two weeks' but not more than four weeks' notice. This notification will contain, among other things, information regarding business to be transacted at the meeting. In addition, our bylaws provide that shareholders must give us not less than six weeks' advance notice to properly introduce any business at an annual meeting of shareholders.

        Other than as noted above, we are in compliance with other NASDAQ corporate governance standards applicable to U.S. domestic issuers.

Compensation of Executive Officers and Board

        For the year ended December 31, 2013, the aggregate compensation paid to our executive officers and members of our board of directors (including bonuses) was $325,000. For the year ended December 31, 2013, we also granted warrants to our executive officers offering the ability to subscribe for in the aggregate 18,719 Class A shares of nominal DKK 1.00 at an exercise price of DKK 150 per share. The total amount set aside or accrued by us to provide pension, retirement or similar benefits for our executive officers and members of our board of directors for the year ended December 31, 2013 was $0.

        As of December 31, 2013, Dr. Andersen, our Chief Executive Officer and Chief Operating Officer, had warrants to subscribe for 18,719 Class A shares of nominal DKK 1.00 at an exercise price of DKK 150 per share pursuant to a grant made on October 1, 2013; such warrants have vested on September 30, 2014 and the Company is extending the original expiration date from November 1, 2014 to May 1, 2015. Dr. Andersen also has 5,000 warrants to subscribe for Class A shares of nominal DKK 1.00 at an exercise price of DKK 100 per share pursuant to a grant made on January 1, 2010. Such warrants are fully vested.

        Dr. Jan G. J. van de Winkel, a member of our board of directors, was granted warrants to subscribe for 5,000 Class A shares in connection with his retention as director. See "—2014 Omnibus Equity Incentive Compensation Plan—Awards Granted under the 2014 Omnibus Equity Incentive Compensation Plan".

        Our Chief Financial Officer, Joel Sendek, was granted a deferred share award in connection with his employment and upon consummation of the offering received a non-qualified stock option to subscribe for such number of ordinary shares as are equal to 21,284 Class A shares. See "—2014 Omnibus Equity Incentive Compensation Plan—Awards Granted under the 2014 Omnibus Equity Incentive Compensation Plan".

        Our Vice President, Finance and Controller, Thomas Carbone, in connection with his employment and upon consummation of the offering, received a non-qualified stock option to subscribe for such number of ordinary shares as are equal to 4,500 Class A shares. See "—2014 Omnibus Equity Incentive Compensation Plan—Awards Granted under the 2014 Omnibus Equity Incentive Compensation Plan".

        None of our directors are employees of Forward Pharma A/S or its wholly owned subsidiaries, Forward Pharma GmbH and Forward Pharma USA, LLC, and accordingly, we do not have any written agreements with them providing for benefits upon termination.

121


Table of Contents

Service and Employment Agreements

        We have entered into a written service agreement with our Chief Executive Officer and Chief Operating Officer, Peder Møller Andersen. Upon the consummation of this offering, we intend to enter into an amended and restated service agreement with Dr. Andersen which will contain provisions standard for a company in our industry regarding non-competition, confidentiality of information and assignment of inventions.

        We entered into a written employment agreement with our Chief Financial Officer, Joel Sendek, who commenced working for us on August 5, 2014. Mr. Sendek's employment agreement contains, among other things, provisions regarding non-competition, confidentiality of information and assignment of inventions.

        Our Vice President, Finance and Controller, Thomas Carbone, commenced working for Forward Pharma USA, LLC on August 18, 2014. Mr. Carbone's employment agreement contains, among other things, provisions regarding base salary, bonus, stock options, and assignment of inventions.

2014 Omnibus Equity Incentive Compensation Plan

        We have granted share-based incentive compensation to employees, consultants and non-employee directors pursuant to our 2014 Omnibus Equity Incentive Compensation Plan as amended, or Share Plan. The Share Plan was approved by our board of directors and shareholders on July 24, 2014. The purpose of the Share Plan is to assist us in attracting motivating, and retaining our employees, consultants and non-employee directors by offering them a greater stake in our company's success and a closer identity with it, and to encourage ownership of our company's stock by such employees, consultants and non-employee directors.

        Share Reserve and Limitations.    The maximum number of ordinary shares available for awards pursuant to the Share Plan will be such number of ordinary shares which equals 10% of our Class A shares as of July 24, 2014, of which a maximum of 50% may be granted to an individual participant during a single year. The ordinary shares available for awards under the Share Plan may be new shares that are issued by the Company and/or existing shares, if any, acquired by the Company. Investors will experience dilution of their interests to the extent that new shares are issued under the Share Plan.

        Eligibility.    All of our employees, consultants and non-employee directors are eligible to receive awards under the Share Plan.

        Administration.    The Share Plan will be administered by our board of directors or a compensation committee appointed by our board of directors. The board of directors (or the committee, if applicable) will have the power to: (i) select the employees, consultants and non-employee directors who will receive awards pursuant to the Share Plan; (ii) determine the type or types of awards to be granted to each participant; (iii) determine the number of ordinary shares to which an award will relate, the terms and conditions of any award granted under the Share Plan (including, but not limited to, restrictions as to vesting, transferability or forfeiture, exercisability or settlement of an award and waivers or accelerations thereof, and waivers of or modifications to performance conditions relating to an award, based in each case on such considerations as the board of directors (or the committee, if applicable) shall determine) and all other matters to be determined in connection with an award; (iv) determine whether, to what extent, and under what circumstances an award may be canceled, forfeited, or surrendered; (v) determine whether, and to certify that, the performance goals to which the settlement of an award is subject are satisfied; (vi) correct any defect or supply any omission or reconcile any inconsistency in the Share Plan, and adopt, amend and rescind such rules and regulations as, in its opinion, may be advisable in the administration of the Share Plan; and (vii) construe and interpret the Share Plan and make all other determinations as it may deem necessary or advisable for the administration of the Share Plan. It may delegate some or all of its powers to any executive officer

122


Table of Contents

of our company or any other person, other than its authority to grant awards to certain specified executives.

        Types of Awards.    Awards that can be granted under the Share Plan include ordinary shares, deferred shares, restricted shares and options.

        Ordinary Shares.    For awards of ordinary shares, a participant receives or subscribes for a grant of ordinary shares that are not subject to any restrictions on transfer or other vesting conditions. Upon the grant date, the participant will have all of the customary rights of a shareholder with respect to such shares, including the right to vote such shares and to receive dividends with respect to such shares.

        Deferred Shares.    For awards of deferred shares, we agree to deliver, subject to certain conditions, a fixed number of our ordinary shares to the participant or allow the participant to subscribe for such fixed number of our ordinary shares at the end of a specified deferral period or periods. During such period or periods, the participant will have no rights as a shareholder with respect to any such shares. Except as provided in an award agreement, no dividends will be paid with respect to deferred shares during the applicable deferral period, and the participant will have no future right to any dividend paid during such period.

        Restricted Shares.    For awards of restricted shares, a participant receives or subscribes for a grant of shares of our ordinary shares that are subject to certain restrictions, including forfeiture of such shares upon the occurrence of certain events. During the restriction period, holders of restricted shares will have the right to vote such shares. During the restriction period, any dividends or distributions paid with respect to any restricted shares shall be subject to the same restrictions as apply to such restricted shares and shall be paid to the participant only if and when the applicable restriction period lapses.

        Share Options.    Share options granted under the Share Plan may be either incentive stock options or non-qualified options. The exercise price of an option (whether to subscribe for new shares or purchase existing shares held by the Company) shall be determined by the board of directors (or the committee, as applicable), but, except as provided in an award agreement, must be at least 100% of the fair market value of our company's ordinary shares on the date of the grant (110% in the case of an incentive stock option granted to a 10% shareholder).

        Effects of a Change in Control.    Upon the occurrence of a change in control of our company, the board of directors (or the committee, as applicable) may, in its discretion: (i) cancel any outstanding options in exchange for a cash payment of an amount (including zero) equal to the difference between the then fair market value of the option less the applicable option price; (ii) after having given the participant a chance to exercise any vested outstanding options, terminate any or all of the participant's unexercised options; (iii) cause the surviving corporation to assume all outstanding options or replace all outstanding options with economically comparable awards; or (iv) take such other action as the board of directors (or the committee, as applicable) shall determine appropriate; provided that such action shall substantially preserve the economic value of such options determined as of immediately prior to such change in control.

        Effects of Certain Corporate Transactions.    In the event of a recapitalization, forward or reverse stock split, reorganization, dissolution, division, merger, consolidation, spin-off, combination, share exchange, or other corporate transaction or event that affects our ordinary shares, the board of directors (or the committee, as applicable) shall adjust, recapitalize or modify (i) the number and kind of shares of ordinary shares, including any ADRs and ADSs in respect of any such shares, which may thereafter be issued in connection with awards, (ii) the number and kind of ordinary shares, including any ADRs and ADSs in respect of any such shares, issuable in respect of outstanding awards, (iii) the aggregate number and kind of ordinary shares, including any ADRs and ADSs in respect of any such shares, available under the Share Plan, and (iv) the exercise or grant price relating to any award.

123


Table of Contents

Notwithstanding the foregoing, no such adjustment shall take place merely as a result of the issuance of awards pursuant to the Share Plan in the normal course (even if, to the extent permitted by the Share Plan, such awards have an exercise price less than fair market value of the underlying shares, or other shares, including, without limitation, any ADRs and ADSs in respect of any such shares, on the grant date). In the event of a change in the Company's capital structure by reason of (i) a capital increase (including, without limitation, the issuance of additional ordinary shares or other shares of the Company, warrants to subscribe for shares of the Company, or awards under the Share Plan), (ii) a capital decrease (including, without limitation, any repurchase of shares of the Company or the cancellation or termination of warrants to subscribe for shares of the Company or the cancellation or termination of awards under the Share Plan), (iii) an issuance of bonus or compensatory shares of the Company, (iv) an issuance of convertible debt instruments of the Company, or (v) dividends, neither the purchase price or exercise price of awards under the Share Plan nor the number of shares which may be subscribed or purchased pursuant to the Awards under the Share Plan shall be adjusted unless otherwise specifically provided for in an Award Agreement, in all cases, even if the transaction giving rise to such change in the Company's capital structure shall take place at a price below the fair market value of the Company's shares at time of the transaction.

        Clawback.    Any award granted under the Share Plan, including an award of ordinary shares, will be subject to mandatory repayment by the participant to our company pursuant to the terms of any company "clawback" or recoupment policy that is directly applicable to the Share Plan and set forth in an award agreement or required by law to be applicable to the participant.

        Transfer Restrictions.    No award or other right or interest of a participant under the Share Plan shall be pledged, encumbered, or hypothecated to, or in favor of, or subject to any lien, obligation, or liability of such participant to, any party, other than the Company, or assigned or transferred by such participant otherwise than by will or the laws of descent and distribution, and such awards and rights shall be exercisable during the lifetime of the participant only by the participant or his or her guardian or legal representative. Notwithstanding the foregoing, the board of directors, in its discretion, may provide that awards or other rights or interests of a participant granted pursuant to the Share Plan be transferable, without consideration, to immediate family members, to trusts for the benefit of such immediate family members and to partnerships in which such family members are the only partners. In addition, a participant may, in the manner established by the board of directors, designate a beneficiary to exercise the rights of the participant, and to receive any distribution, with respect to any award upon the death of the participant.

Awards Granted under the 2014 Omnibus Equity Incentive Compensation Plan

Joel Sendek Deferred Share Award

        On August 12, 2014, Joel Sendek was granted a deferred share award with respect to 31,895 deferred Class A shares under the Share Plan, which was converted into a deferred share award allowing for the subscription of 56,861 ordinary shares immediately prior to the consummation of this offering, in connection with the Share Conversion, the Bonus Share Issuance and the Share Split. Subject to Mr. Sendek's continuing employment with the Company, 25% of the deferred shares shall vest and be issued to Mr. Sendek on the earlier to occur of (a) July 29, 2015 and (b) the first date following the consummation of this offering that the restrictions on the sale of securities lapse pursuant to an amended and restated lock-up agreement between Mr. Sendek, the Company and the underwriters (referred to as the Deferred Shares Initial Vesting Date) and 25% of the deferred shares shall vest and be issued to Mr. Sendek on each of July 29, 2016, 2017 and 2018. Subject to Mr. Sendek's continuing employment with the Company, 100% of the unvested deferred shares will vest and be issued to Mr. Sendek immediately prior to a change in control of the Company. Notwithstanding the foregoing, (i) if Mr. Sendek experiences an involuntary termination of employment after the consummation of this offering but prior to the Deferred Shares Initial Vesting Date, 25% of

124


Table of Contents

the deferred shares shall vest and be issued to Mr. Sendek on the Deferred Shares Initial Vesting Date and (ii) if Mr. Sendek experiences an involuntary termination of employment within six months prior to a change in control, 100% of the unvested deferred shares shall vest and be issued to Mr. Sendek immediately prior to the change in control. Pursuant to the terms of his employment agreement, Mr. Sendek will also be entitled to dividend equivalent payments on the deferred shares prior to vesting and issuance to Mr. Sendek with respect to aggregate distributions by the Company on Class A shares or ordinary shares, which dividend equivalent payments will be paid to Mr. Sendek on the earliest to occur of (i) July 29, 2018; (ii) the date of Mr. Sendek's termination of employment and (iii) the date of a change in control of the Company.

Joel Sendek Stock Option Award

        Upon the consummation of this offering, Mr. Sendek was granted a non-qualified stock option under the Share Plan to subscribe for such number of ordinary shares as are equal, pre the Share Conversion, Bonus Share Issuance and Share Split, to 21,284 Class A shares on an as-converted-to-ordinary-shares basis, at an exercise price per share equal to the initial public offering price (referred to in this paragraph as the Stock Option). Subject to Mr. Sendek's continuing employment with the Company, the Stock Option shall become exercisable with respect to 25% of the underlying ordinary shares on the earlier of (a) July 29, 2015 and (b) the first date following the consummation of this offering that the restrictions on the sale of ordinary shares lapse pursuant to the amended and restated lock-up agreement between Mr. Sendek, the Company and the underwriters (referred to as the Stock Option Initial Vesting Date) and with respect to an additional 25% of the underlying ordinary shares on each of July 29, 2016, 2017 and 2018. Subject to Mr. Sendek's continuing employment with the Company, the Stock Option shall become vested and exercisable with respect to 100% of the underlying ordinary shares immediately prior to a change in control of the Company. Notwithstanding the foregoing, (i) if Mr. Sendek experiences an involuntary termination of employment after the consummation of this offering but prior to the Stock Option Initial Vesting Date, then the Stock Option shall become exercisable upon Mr. Sendek's employment termination with respect to 25% of the underlying ordinary shares for a period of twelve (12) months thereafter and (ii) if Mr. Sendek experiences an involuntary termination of employment within six months prior to a change in control, the Stock Option shall become exercisable with respect to 100% of the underlying ordinary shares immediately prior to a change in control of the Company. Pursuant to the terms of his Employment Agreement, Mr. Sendek will also be entitled to dividend equivalent payments on the underlying shares prior to his exercising the Stock Option with respect to aggregate distributions by the Company on the ordinary shares in excess of $500,000,000, which dividend equivalent payments will be paid to Mr. Sendek on the earliest to occur of (i) July 29, 2018; (ii) the date of Mr. Sendek's termination of employment and (iii) the date of a change in control of the Company. The Stock Option will expire on the tenth anniversary of the stock option grant date.

Thomas Carbone Stock Option Award

        Upon the consummation of this offering, Thomas Carbone was granted a non-qualified stock option under the Share Plan to subscribe for such number of ordinary shares as are equal, pre the Share Conversion, Bonus Share Issuance and Share Split, to 4,500 Class A shares on an as-converted-to-ordinary-shares basis, at an exercise price per share equal to the initial public offering price (referred to in this paragraph as the Stock Option). Subject to Mr. Carbone's continuing employment with Forward Pharma USA, LLC, the Stock Option shall become exercisable with respect to 25% of the underlying ordinary shares on the earlier of (a) August 18, 2015 and (b) the first date following the consummation of this offering that the restrictions on the sale of ordinary shares lapse pursuant to the lock-up agreement between Mr. Carbone and the underwriters (referred to as the Stock Option Initial Vesting Date) and with respect to an additional 25% of the underlying ordinary shares on each of August 18, 2016, 2017 and 2018. Subject to Mr. Carbone's continuing employment,

125


Table of Contents

the Stock Option shall become vested and exercisable with respect to 100% of the underlying ordinary shares immediately prior to a change in control of the Company. The Stock Option will expire on the tenth anniversary of the stock option grant date.

Sharon Klahre Stock Option Award

        Upon the consummation of this offering, Sharon Klahre was granted a non-qualified stock option under the Share Plan to subscribe for such number of ordinary shares as are equal, pre the Share Conversion, Bonus Share Issuance and Share Split, to 600 Class A shares on an as-converted-to-ordinary-shares basis, at an exercise price per share equal to the initial public offering price (referred to in this paragraph as the Stock Option). Subject to Ms. Klahre's continuing employment with the Company, the Stock Option shall become exercisable with respect to 25% of the underlying ordinary shares on September 3, 2015 (referred to as the Stock Option Initial Vesting Date) and with respect to an additional 25% of the underlying ordinary shares on each of September 3, 2016, 2017 and 2018. Subject to Ms. Klahre's continuing employment with the Company, the Stock Option shall become vested and exercisable with respect to 100% of the underlying ordinary shares immediately prior to a change in control of the Company. The Stock Option will expire on the tenth anniversary of the stock option grant date.

Jan G. J. van de Winkel Grant of Warrants

        On August 13, 2014, upon his election as a director of the Company, Jan G. J. van de Winkel was granted warrants to subscribe for 5,000 Class A shares of nominal DKK 1 at an exercise price of DKK 1,158 per share. Subject to Dr. van de Winkel's continuing to serve as a director of the Company, the warrants shall become exercisable with respect to 1/48 of the shares by the end of each of the first 48 calendar months following their issuance date. The unvested portion of the warrants will be cancelled for no compensation upon termination of Dr. van de Winkel's service as a director of the Company for any reason, and the vested portion of the warrants shall remain exercisable to the extent provided in Section 9.6 of the Share Plan. Subject to Dr. van de Winkel's continuing to serve as a director of the Company, the warrants shall become vested and exercisable with respect to 100% of the underlying ordinary shares immediately prior to a change in control of the Company. The warrants will expire on the fifth anniversary of their issuance date.

Employee Warrants (issued prior to the adoption of the Share Plan)

        As of June 30, 2014, our former and existing key employees, board members and consultants hold an aggregate of 131,052 warrants issued prior to the adoption of the Share Plan to subscribe for new Class A shares (which were converted into warrants to subscribe for an aggregate of 229,383 ordinary shares, at a weighted average exercise price of approximately $15.10 per share, following the Share Conversion and the Bonus Share Issuance but not the Share Split) of nominal DKK 1.00 per share at specified exercise prices and a weighted average exercise price of DKK 156.4. The warrants are subject to a variety of terms and vesting schedules and many of them have vested and are exercisable. The consummation of this offering will constitute a change of control with respect to 17,500 warrants held by two of our consultants. Because the size of this offering equals or exceeds 10% of our share capital, their warrants will become exercisable upon consummation of this offering. Investors will experience dilution of their interests to the extent that shares are issued upon the exercise of the warrants. The Company has extended the original expiration date for the 18,719 warrants granted to Peder M. Andersen on October 1, 2013 from November 1, 2014 to May 1, 2015. The Company has also extended the original expiration date for the 9,360 warrants granted to J. Kevin Buchi on December 1, 2012 from December 31, 2014 until June 30, 2015.

126


Table of Contents

Investor Warrants

        As of the date of this Prospectus, all warrants held by investors have been exercised in accordance with the following:

    on March 17, 2014, NBOF cancelled its shareholder loan with a principal value of DKK 13.8 million ($2.5 million), which amount was used to offset the exercise price on an aggregate of 137,750 warrants to subscribe for Class A shares held by it at an exercise price of DKK 100 per share; and

    on March 17, 2014, NBOF subscribed for 260 Class A shares by way of exercise of 260 warrants, at a subscription price of DKK 100 per share.

Insurance and Indemnification

        In connection with this offering, we have entered into into indemnification agreements with our executive officers and members of our board of directors, undertaking to indemnify them, including with respect to liabilities resulting from this offering to the extent that these liabilities are not covered by insurance. In addition, we intend to enter into a new insurance policy which will insure our directors and executive officers for certain actions taken in their professional capacity and a separate insurance policy insuring our directors and officers against liabilities resulting from this offering, subject to specified exceptions.

        Insofar as indemnification of liabilities arising under the Securities Act may be permitted to directors or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

127


Table of Contents


PRINCIPAL SHAREHOLDERS

        The following table sets forth information relating to the ownership of our Class A shares and Class B shares prior to the Share Conversion, the Bridge Conversions, the Bonus Share Issuance, the Share Split and the Offering, by:

    each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding Class A shares or Class B shares;

    each of our directors and executive officers; and

    all of our directors and executive officers as a group.

        The number of Class A shares or Class B shares beneficially owned by each entity, person or director is determined in accordance with the rules of the SEC governing the beneficial ownership of securities, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which a person has sole or shared voting power or investment power as well as any shares that such person has the right to acquire within 60 days of the date of this Prospectus through the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person.

        The percentage of shares beneficially owned before the offering is computed on the basis of 1,736,540 of our Class A shares and 56,851 Class B shares outstanding as of June 30, 2014. The percentage of shares beneficially owned after the offering is based on the number of our ordinary shares to be outstanding after this offering, including the ordinary shares that we are selling in this offering, assumes no exercise of the underwriters' over-allotment option and is based on the initial public offering price of $21.00 per ADS. Shares that a person has the right to acquire within 60 days of the date of this Prospectus are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Unless otherwise indicated below, the

128


Table of Contents

address for each beneficial owner listed is c/o Forward Pharma A/S, Østergade 24A, 1, 1100 Copenhagen K, Denmark.

 
  Shares beneficially owned prior to the Share
Conversion, the Bridge Conversions, the Bonus Share
Issuance, the Share Split and the offering
  Shares
beneficially
owned after the
Share Conversion,
the Bridge
Conversions,
the Bonus Share
Issuance, the Share
Split and the
offering
 
 
  Class A   Class B   Percent of total
voting power
before the
offering(1)
   
   
 
 
  Ordinary
Shares
   
 
Name and address of beneficial owner
  Shares   %   Shares   %   %  

5% Shareholders

                                         

BML Healthcare I, L.P.(2)

    492,952     28.26       *     0.96     8,788,200     18.94  

Nordic Biotech K/S

    680,141     39.00       *     1.32     12,125,340     26.13  

Nordic Biotech Opportunity Fund K/S(3)

    563,447     32.31     10,136   17.83     18.32     10,588,940     22.82  

NB FP Investment K/S*

            46,715   82.17     79.39     2,507,360     5.40  

NB FP Investment II K/S(4)

                        602,260     1.30  

BVF Forward Pharma L.P.(5)

                        566,300     1.22  

Directors and Executive Officers(6)

                                         

Peder M. Andersen(7)

    23,719     *       *           422,850     +  

J. Kevin Buchi(8)

    9,360     *       *           166,860     +  

Torsten Goesch(2)

        *       *               +  

Florian Schönharting(9)

    1,243,588     71.29     56,851   100     99.03     25,823,950     55.65  

All directors and executive officers as a group (4 persons)(8)

    1,276,667     73.19     56,851   100     99.10     26,413,660     56.92  

*
Indicates beneficial ownership of less than 5% of the total outstanding Class A shares and Class B shares.

+
Indicates beneficial ownership of less than 1% of the total outstanding ordinary shares.

(1)
Each Class A share has one vote and each Class B share has 875 votes. Following the Share Conversion each ordinary share will have one vote.

(2)
Mr. Goesch has full investment and voting power over all of the shares held by BML Healthcare I, L.P. (an affiliate of BioScience Managers Limited), and so may be deemed to share beneficial ownership of the securities owned by the fund. The address for BML Healthcare I, L.P. is BML Healthcare I, L.P., c/o Corporation Service Company, 2711 Centerville Road, Suite 400, Wilmington, County of New Castle, Delaware, United States.

(3)
Under the terms of the Stock Lending Agreement, Nordic Biotech Opportunity Fund K/S has agreed to loan up to 10,500,000 ordinary shares (referred to as the Borrowed Shares) to the Company prior to and in connection with the consummation of the offering. The Company has agreed, concurrently with or immediately after the consummation of the offering, to cause the Borrowed Shares underlying the ADSs to be returned to Nordic Biotech Opportunity Fund K/S promptly upon the deposit by the underwriters of newly issued ordinary shares of equal number.

(4)
Consists of 33,782 ordinary shares issued upon conversion of the principal amount outstanding under the bridging financing, of €8.4 million principal amount plus accrued interest, for which we have drawn down the entire €8.4 million as of the date of this Prospectus, at the initial public offering price, less a discount of 15% prior to the Bonus Share Issuance and the Share Split.

129


Table of Contents

(5)
Consists of 31,764 ordinary shares issued upon conversion of the principal amount outstanding under the bridge financing, of $10.0 million principal amount plus accrued interest, for which we have drawn down the entire $10.0 million as of the date of this Prospectus, at the initial public offering price, less a discount of 15% prior to the Bonus Share Issuance and the Share Split. A number of entities affiliated with our bridge lender, BVF Forward Pharma L.P. (an affiliate of BVF Partners LP, which itself is affiliated with certain of our principal shareholders), have indicated an interest in purchasing up to an aggregate of $20.0 million of ADSs in this offering at the initial public offering price.

(6)
In connection with his engagement as our Chief Financial Officer on August 5, 2014, Joel Sendek has received an award of deferred Class A shares which are not exercisable within 60 days of the date of this Prospectus. Mr. Sendek also received an award of stock options upon consummation of this offering which will allow him to subscribe for ordinary shares. In connection with his engagement as Vice President, Finance and Controller of Forward Pharma USA, LLC on August 18, 2014, Thomas Carbone was granted upon consummation of this offering a stock option to subscribe for such number of ordinary shares as are equal to 4,500 Class A Shares which are not exercisable within 60 days of the date of this Prospectus. In connection with his retention as director, Jan G. J. van de Winkel has received an award of warrants to subscribe for 5,000 Class A Shares which are not exercisable within 60 days of the date of this Prospectus. For more information regarding Mr. Sendek's, Mr. Carbone's and Dr. van de Winkel's equity awards, see "Management—2014 Omnibus Equity Incentive Compensation Plan—Awards Granted under the 2014 Omnibus Equity Incentive Compensation Plan".

(7)
Consists of 23,719 Class A shares issuable upon exercise of warrants to subscribe for Class A shares.

(8)
Consists of 9,360 Class A shares issuable upon exercise of warrants to subscribe for Class A shares.

(9)
Through his ownership of Tech Growth Invest ApS, Mr. Schönharting controls (a) 45% of the ownership interests in Nordic Biotech General Partner ApS (which is the general partner of both Nordic Biotech K/S and Nordic Biotech Opportunity Fund K/S) and (b) a majority of the interests in NB FP Investment General Partner ApS (which is the general partner of NB FP Investment K/S and NB FP Investment II K/S) and therefore, Mr. Schönharting may be deemed to share beneficial ownership of the securities beneficially owned by Nordic Biotech K/S, Nordic Biotech Opportunity Fund K/S, NB FP Investment K/S and NB FP Investment II K/S. Mr. Schönharting disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Each of the funds referenced above shares, among other limited partner investors, the Danish government investment fund Vækstfonden.

130


Table of Contents


RELATED PARTY TRANSACTIONS

        The following is a description of our related party transactions we have entered into since January 1, 2010 with any of our members of our board of directors, executive officers and the holders of more than 5% of our Class A shares and Class B shares.

Framework Agreement

        Our principal shareholders, Nordic Biotech K/S, NBOF, BML Healthcare I, L.P. and NBFPI, as well as our EUR-denominated bridge loan lender, NBFPII, have entered into a Framework Agreement dated July 11, 2014. Our USD-denominated bridge loan lender, BVF Forward, entered into an adherence agreement pursuant to which it joined as party to the Framework Agreement on August 5, 2014. Morten Priskorn also entered into an adherence agreement pursuant to which it became party to the Framework Agreement on August 6, 2014. Pursuant to the Framework Agreement the following corporate actions occurred prior to the consummation of this offering:

    our board of directors and shareholders adopted our 2014 Omnibus Equity Incentive Compensation Plan, or the Share Plan, and our shareholders, at an extraordinary general meeting held on October 14, 2014, in order to ensure that there would be a sufficient amount of shares authorized under the Share Plan to account for the Bonus Share Issuance, authorized our board of directors to issue (i) up to 2,140,000 warrants, each to subscribe for one ordinary share, and (ii) 2,140,000 ordinary shares of DKK 0.10, to our employees, consultants and members of our board of directors and management;

    we held an extraordinary general meeting on October 14, 2014 pursuant to which our shareholders authorized our board of directors to issue new shares without preemptive rights for our existing shareholders. Such shares are to be issued in connection with the initial public offering and underlie the ADSs offered by this Prospectus;

    our board of directors approved the employment of a Chief Financial Officer and the negotiation of an employment agreement with the Chief Financial Officer and the issuance of warrants and granting of a right to deferred shares under the Share Plan to the Chief Financial Officer;

    our board of directors approved (i) the rules of procedure for the board, (ii) our internal rules on inside information, (iii) indemnification agreements with members of the board of directors and executive management, and (iv) our liability and director and officer insurance; and

    prior to our board of directors' approval of the offer price and the issuance of ADSs offered by this Prospectus, we held an extraordinary general meeting on October 14, 2014 pursuant to which we performed the following:

    (i)
    We issued additional Class A bonus shares to the holders of Class B shares. Since Class B shares had a distribution preference of at least DKK 4,419.48 per share, or at least 375.375% of the amount paid by the Class B shareholders upon the subscription of the Class B shares, we issued to the holders of Class B shares, in order to account for such distribution preference and in lieu of cash, an additional 114,309 Class A bonus shares based on the initial public offering price of $21.00 per ADS. As a result of this issuance of additional Class A bonus shares, the holders of Class B shares received a return of approximately $42.8 million in the aggregate, on their Class B shares, and the holders of Class A shares suffered dilution in an equivalent aggregate amount, prior to the consummation of this offering.

131


Table of Contents

    (ii)
    Following the issuance of additional Class A bonus shares to the holders of Class B shares described above, all of our outstanding Class A shares and Class B shares were converted into a single class of ordinary shares on a 1:1 basis.

    (iii)
    Our bridge loans (including all principal and accrued interest) obtained from NBFPII and BVF Forward, respectively, were converted into ordinary shares, at the initial public offering price less a discount of 15%, and the holders of the ordinary shares suffered dilution in an equivalent aggregate amount, prior to the consummation of this offering.

    (iv)
    In order to achieve a fixed number of issued and outstanding ordinary shares prior to the consummation of this offering, and due to the fact that the exact number of Class A bonus shares issued to the holders of Class B shares was variable based on the price per share in the offering, we issued in the aggregate 1,550,540 additional ordinary shares based on the initial public offering price of $21.00 per ADS, in the form of bonus shares to all existing shareholders on a pro rata basis.

    (v)
    We underwent a share split, pursuant to which existing shareholders received ten (10) shares in exchange for each share they owned to such extent that the undiluted share capital was set to equal 35,313,760 issued and outstanding ordinary shares immediately prior to the consummation of the offering.

    (vi)
    Our board of directors was authorized to (a) resolve to distribute extraordinary dividends, (b) have Forward Pharma A/S acquire its own shares, (c) issue new shares without preemptive rights for existing shareholders, and (d) adopt certain other amendments to our Articles of Association.

        We have decided to postpone the hiring of a new Chief Executive Officer at this time, and instead elevated our Chief Operating Officer Peder Møller Andersen to the position of Chief Executive Officer and Chief Operating Officer. In August 2014, we hired Joel Sendek to be our Chief Financial Officer.

Shareholders' Agreement

        On August 6, 2014, all of our existing shareholders entered into an amended and restated shareholders' agreement which will be terminated in connection with the consummation of this offering. The key terms of the shareholders' agreement are as follows:

    Appointment of Board.  Providing NBFPI, with the right to nominate three directors (including the chairman), NBOF, and Nordic Biotech K/S shall collectively have the right to nominate one director, and each of NBFPII and BML Healthcare I, L.P. shall have the right to nominate one director;

    Supermajority Voting.  Requiring approval of certain key decisions by approval of at least 85% of the outstanding share capital, including redemptions of shares;

    Veto rights of NBFPI.  Providing NBFPI with veto rights over certain key decisions including the annual business plan and budget, and certain significant transactions such as purchase or divestment of any asset of a value in excess of DKK 200,000; and

    Preemptive rights, drag- and tag-along rights.  Providing the shareholders with preemptive rights, and drag- and tag-along rights in certain situations.

Stock Lending Agreement

        To facilitate the orderly closing of this offering of ADSs, under the terms of a Stock Lending Agreement dated October 14, 2014, among NBOF, the underwriters and the Company, NBOF has agreed to loan to the Company 10,500,000 ordinary shares (referred to as the Borrowed Shares) in

132


Table of Contents

connection with the initial deposit of ordinary shares into the American Depositary Receipt Program immediately prior to and concurrent with the consummation of the offering.

        We have agreed to cause to be issued to the underwriters, and the underwriters have agreed to deposit into the American Depositary Receipt Program, 10,500,000 ordinary shares, concurrently with or immediately after the consummation of the offering. Following receipt from the underwriters of the newly issued ordinary shares equal to the number of the Borrowed Shares, the Depositary shall return the Borrowed Shares underlying the ADSs to NBOF.

        We have agreed to indemnify and hold harmless each of the underwriters and NBOF for any damages in connection with the Stock Lending Agreement and the transactions contemplated thereunder.

Investment Agreement

        We and each of our shareholders as of the date hereof are parties to an Investment Agreement dated January 19, 2013, pursuant to which NBFP agreed to subscribe for 46,715 Class B shares of nominal DKK 1.00, at our request, at a subscription price of DKK 1,177.35 per share.

        NBFPI subscribed for an aggregate of 46,715 Class B shares of nominal DKK 1.00 pursuant to the investment agreement, which consequently has no further force or effect.

New Shareholders' Agreement

        In connection with the consummation of this offering, Nordic Biotech K/S, NBOF, NBFPI and NBFPII currently holding an aggregate of 1,243,588 of our Class A shares and 56,851 of our Class B shares, representing 71.3% of the Class A shares and all of the Class B shares outstanding as of June 30, 2014, will enter into a shareholders' agreement.

        The key terms of the new shareholders' agreement are as follows:

    Appointment of the Board. Providing NBFPI with the right to nominate four directors (including the chairman), NBOF and Nordic Biotech K/S shall, collectively have the right to nominate one director, and NBFPII shall have the right to nominate one director;

    Veto rights of NBFPI. Prohibiting the other parties to the shareholders' agreement from voting in favor of certain key decisions without the approval of NBFPI;

    No dividends. Providing that dividends are not expected to be paid prior to an exit event as set forth in the shareholders' agreement;

    Drag-along rights. Providing NBFPI with drag-along and exit rights in certain situations; and

    Capital increases. NBFPI shall have the right to cause the other parties to approve an increase in share capital in certain situations.

Aditech Agreement

        In 2004, a private Swedish company called Aditech Pharma AB (collectively with its successor-in-interest, a Swiss company Aditech Pharma AG, or Aditech), controlled by Nordic Biotech General Partner ApS (an affiliate of one of our largest shareholders), began developing and filing patents for an innovative formulation and delivery system for DMF. In 2005 we entered into a patent license agreement with Aditech to license this patent family from Aditech, and in 2010 we acquired this patent family from Aditech pursuant to a patent transfer agreement. Under our agreements with Aditech, we obtained, among other things, Aditech's patents and associated know-how related to DMF formulations and delivery systems, subject to both diligence and minimum annual expenditure (€1.0 million per year) obligations on our part (with an option for Aditech to receive back, for no

133


Table of Contents

consideration, all of our DMF related assets should we fail to satisfy these obligations), as well as a payment by us to Aditech of up to 2% of net sales generated from our DMF products and processes. Further, our agreement with Aditech gives Aditech a 90-day right of first offer to acquire non-DMF related intellectual property assets we might choose to sell.

        As noted above, the agreement with Aditech is technically a patent transfer agreement, not a license agreement. This means that we have acquired exclusive and perpetual ownership to Aditech's patents and related rights. Aditech can terminate the agreement (in which event Aditech has an option to receive back, for no consideration, all of our DMF related assets) due to any of the following reasons:

    We seek a liquidation, dissolution or winding up of our business or assets, we become insolvent or we make any general assignment for the benefit of our creditors;

    A petition is filed by or against us, or any proceeding is initiated by or against us, or any proceeding is initiated against us as a debtor, under any bankruptcy or insolvency law, unless such petition or proceeding is held to be unfounded;

    A receiver, trustee or any similar officer is appointed to take possession, custody or control of all or any part of our assets or property;

    Upon the material breach by us of any material term or material condition of our agreement with Aditech, if such breach continues for 30 calendar days after the receipt of written notice thereof from Aditech; or

    If we do not meet applicable requirements in respect of the development and commercialization of the patent rights.

        While we have exclusive ownership of the patents, the duration of our obligation to make payments to Aditech lasts until (on a country by country basis) the latest to occur of the expiration of the registered patent rights or applicable data exclusivity.

Convertible Shareholder Loan

        We were the borrower under a convertible shareholder loan dated October 1, 2013 with NBOF as lender, in the principal amount of DKK 13.8 million ($2.5 million). The loan was cancelled, and in connection with such cancellation, the lender was issued 137,750 Class A shares, in March 2014. For more, see "Management—Investor Warrants."

        We were also the borrower under a convertible shareholder loan dated October 29, 2012 with NBOF as lender, in the principal amount of DKK 11.7 million ($2.1 million). The loan was converted per its terms, and in connection with such conversion, the lender was issued 10,136 Class B shares, in January 2013.

        For more, see "Management's Discussion and Analysis of Financial Condition and Results of Operations—Contractual obligations and commitments."

Leased Premises

        We sublease our headquarters in Copenhagen, Denmark from the management company of two of our principal shareholders, Nordic Biotech K/S and NBOF. In 2013, we paid DKK 465,564 (approximately $83,000) for such premises. We also sublease our offices in Leipzig, Germany. In 2013, we paid €20,087 (approximately $27,000) for such premises.

134


Table of Contents

Indemnification Agreements

        We have entered into indemnification agreements with members of our board of directors and our executive officers. See "Management—Insurance and Indemnification" for a description of these indemnification agreements.

NBFPII Bridge Financing

        On May 30, 2014, we entered into a bridge financing with NBFPII, an affiliate fund of our principal shareholders which is beneficially controlled by our Chairman, Mr. Schönharting, under which NBFPII made available to us a loan facility with an aggregate availability of up to €8.4 million during the period from the date of the agreement through December 31, 2018. In respect of this bridge financing with NBFPII, prior to the consummation of this offering, we have drawn down the entire amount available under the facility as of the date of this Prospectus and expect to use the net proceeds thereof in a manner consistent with our present plans and business condition. Pursuant to the bridge financing agreement, upon occurrence of this offering, all outstanding amounts drawn under the facility, together with accrued and unpaid interest, were converted into ordinary shares prior to completion of this offering at a rate equal to the price at which ordinary shares are sold to the public in this offering, less a discount of 15%. For more, see "Use of Proceeds". Drawing funds under the facility will result in an accrual of interest at a rate of 10% based on a 360 day year.

BVF Forward Bridge Financing

        On August 6, 2014, we entered into a bridge financing with BVF Forward (an affiliate of BVF Partners LP, which is itself affiliated with certain of our principal shareholders), under which BVF Forward made available to us a loan facility with an aggregate availability of up to $10.0 million during the period from the date of the agreement through December 31, 2018. In respect of this bridge financing, we have drawn down the entire amount available under the bridge financing and expect to use the net proceeds thereof in a manner consistent with our present plans and business condition. Pursuant to the bridge financing agreement, upon the occurrence of this offering, all outstanding amounts drawn under the facility, together with accrued and unpaid interest, were converted into ordinary shares at a rate equal to the price at which ordinary shares are sold to the public in this offering, less a discount of 15%. For more, see "Use of Proceeds". Drawing funds under the facility resulted in an accrual of interest at a rate of 10% based on a 360 day year.

        A number of entities affiliated with our bridge lender, BVF Forward Pharma L.P. (an affiliate of BVF Partners LP, which itself is affiliated with certain of our principal shareholders), have indicated an interest in purchasing up to an aggregate of $20.0 million of ADSs in this offering at the initial public offering price.

Registration Rights

        After this offering, certain holders of our ordinary shares, including those ordinary shares that were issued upon conversion of our Class A shares and Class B shares, will be entitled to certain rights with respect to registration of such shares under the Securities Act. These shares are referred to as Registrable Securities. The holders of these Registrable Securities possess the registration rights pursuant to the terms of a registration rights agreement dated as of September 11, 2014.

        The registration of ordinary shares pursuant to the exercise of registration rights would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. Unless our ordinary shares are listed on a national securities exchange or trading system and a market for our ordinary shares not held in the form of ADSs exists, any Registrable Securities sold pursuant to an exercise of the registration rights will be sold in the form of ADSs. Subject to any limitations under Danish law, we will pay the registration expenses, other than underwriting discounts, selling commissions and share transfer taxes, of the shares registered pursuant to the demand, piggyback and Form F-3 registrations provided for in the registration rights agreement.

135


Table of Contents


DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION

General

        Forward Pharma A/S was incorporated on July 1, 2005 as a limited liability company under Danish law. Upon consummation of this offering, our legal name will remain Forward Pharma A/S.

        We are registered with the Danish Business Authority under company registration number, or CVR, 28865880. Our corporate seat is in Copenhagen, Denmark, and our registered office is Østergade 24A, 1, 1100 Copenhagen K, Denmark.

        As of June 30, 2014, the issued and registered share capital of the Company is nominally DKK 1,793,391, divided into shares of DKK 1.00 each. As of June 30, 2014, our share capital was divided into two share classes, being nominally DKK 1,736,540 Class A shares and nominally DKK 56,851 Class B shares. The share capital is fully paid up.

        Based on the initial public offering price of $21.00 per ADS, prior to the consummation of this offering at an extraordinary general meeting of our shareholders held on October 14, 2014, all of our Class A and Class B shares were converted into an aggregate of 1,915,290 ordinary shares based on the amount of Class A shares and Class B shares outstanding as of June 30, 2014 as well as the issuance of 7,590 Class A shares to Morten Priskorn on July 3, 2014 (following which we currently have only one class of shares, ordinary shares), pursuant to the Share Conversion. Also, €8.4 million and $10.0 million we have drawn down under the bridge financings (representing the entire principal amounts available thereunder), along with accrued interest, were converted into 33,782 ordinary shares and 31,764 ordinary shares, respectively, at the initial public offering price, less a discount of 15%. Further, 1,550,540 ordinary shares were issued in the form of bonus shares to all existing shareholders and we underwent a Share Split to the effect that one share of DKK 1 was split into 10 shares of DKK 0.10 each. Following the Share Conversion, the Bridge Conversions, the Bonus Share Issuance, and the Share Split, as well as this offering, we will have 45,813,760 ordinary shares outstanding, each with a nominal value of DKK 0.10 per share (assuming no exercise of the underwriters' over-allotment option).

        Our ADSs have been approved for listing on the Nasdaq Global Select Market under the symbol "FWP."

        Initial settlement of the ADSs issued in this offering will take place on the consummation date of this offering through The Depository Trust Company, or DTC, in accordance with its customary settlement procedures for equity securities. Each person owning ADSs held through DTC must rely on the procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the ADSs.

Articles of Association

        Our current Articles of Association, or Current Articles, were last amended on September 30, 2014, in which amendment the exercise period of certain warrants was extended by up to seven months. In the amendment adopted on September 9, 2014, Computershare A/S was elected to act as registrar for our shareholders. Under our Current Articles, our corporate objective is to develop and market pharmaceuticals. We will, in connection with this offering, further amend our Current Articles in order to, among others, effectuate the Share Conversion pursuant to which all of our outstanding Class A shares and Class B shares will be converted into ordinary shares prior to consummation of this offering, to effectuate the conversion of €8.4 million and $10.0 million we have drawn down under the bridge financings entered into on May 30, 2014 and on August 6, 2014, respectively, into ordinary shares, and to authorize our board of directors to (a) resolve to distribute interim dividends, (b) have Forward Pharma A/S acquire its own shares and (c) issue new shares without preemptive rights for existing shareholders.

136


Table of Contents

        When we refer to our Articles of Association in the following, we refer to our Articles of Association as they will be in force after adoption of the contemplated amendments to our Current Articles prior to the completion of this offering.

Articles of Association and Danish law

        Below is a summary of relevant information concerning material provisions of our Articles of Association and applicable Danish law. This summary does not constitute legal advice regarding those matters and should not be regarded as such.

        See the section entitled "Comparison of Danish Corporate Law and Our Articles of Association and U.S. Corporate Law—Shareholder rights—Voting rights" for a description of the voting requirements for a resolution to amend the Articles of Association.

Company's shareholders' register

        Pursuant to our Current Articles, our shareholders' register is maintained by Computershare A/S who has been elected to act as our local share registrar.

Corporate objectives

        Our corporate objectives are, directly or indirectly through subsidiaries, to conduct business within development, manufacturing, distribution and sale of drugs and medicaments, as well as any other related activities at the discretion of the board of directors. Furthermore, we may, within our line of business, participate in partnerships or co-operate with other businesses, including by licensing out rights within our line of business.

Limitation on liability and indemnification matters

        Under Danish law, members of the board of directors and certain officers may be held liable for damages in the event of improper or negligent conduct in breach of their fiduciary duties. They may be held jointly and severally liable for losses incurred by the Company and third parties due to their improper or negligent conduct. In certain circumstances, they may also incur additional criminal liabilities. The members of our board of directors and certain officers are insured under an insurance policy protecting them against liability resulting from the conduct of our directors and such certain officers when acting in their capacities as such. Each year at the annual general meeting of shareholders, the discharge of the board of directors and the executive officers of certain responsibilities is an item on the agenda. We have entered into indemnification agreements with members of our board of directors and our executive officers. See "Management—Insurance and Indemnification" for a description of these indemnification agreements.

Authorizations to Increase Share Capital

        Prior to our board of directors' approval of the offer price and the issuance of ADSs offered by this Prospectus, it is expected that our board of directors will be authorized, among other things, to resolve to increase our share capital by cash contributions, contributions in kind or conversion of debt issuances by issuance of shares of no more than nominal DKK 3,500,000. Such authorization by our board of directors will be in force for up to five years. The increase may be effected either gradually or at once. Such new shares shall carry the same rights as our ordinary shares following the Share Conversion.

137


Table of Contents

Shareholders' meetings

General meetings

        See below "Comparison of Danish Corporate Law and Our Articles of Association and U.S. Corporate Law—Shareholder rights—Shareholder proposals" for a description of the rules on time and venue of general meetings under Danish law. See below "Description of American Depositary Receipts—Voting rights" for a description of the rules and procedures for ADS holders in connection with general meetings.

        Under our Articles of Association, general meetings shall be convened by our board of directors with at least two weeks' and not more than four weeks' notice. Notice of general meetings must be published on our website and in form and substance in accordance with the requirements of any stock exchange on which our shares are listed. Further, written notice of the general meeting must be mailed to all of our shareholders who have requested such notice be sent. The notice shall specify the time and place of the general meeting and the agenda containing the business to be transacted at the general meeting. If a proposal to amend our Articles of Association is to be considered at the general meeting, a summary of such proposal must be set out in the notice. For certain material amendments, the specific wording must be set out in the notice. The right of a shareholder to attend a general meeting is determined by shares held by such shareholder at the record date, which is the day one week prior to the date of the general meeting.

Quorum and voting requirements

        Each ordinary share carries one vote at the general meeting of shareholders. Shareholders may vote by proxy. The voting rights of any shares we hold in treasury are suspended as long as they are so held. Shares held in treasury will not be taken into account for the purpose of determining the number of shareholders that vote and that are present or represented, or the number of shares that are represented at our general meetings.

        In accordance with Danish law and generally common business practices, the Articles of Association do not provide for a quorum generally applicable to general meetings of shareholders. See below "Comparison of Danish Corporate Law and Our Articles of Association and U.S. Corporate Law—Shareholder rights—Voting rights" for a description of the rules on voting requirements under Danish law.

Members of the Board of Directors and executive officers

        Under our Articles of Association, members of the board of directors are elected at the general meeting of shareholders. Candidates are usually nominated by our existing board of directors or shareholders, but any shareholders are entitled to nominate other candidates. The members of the board of directors are elected for one year terms. Directors are not subject to term limits. Only persons who are younger than 70 years at the time of election may be elected to the board of directors. The board of directors appoints our executive officers.

        See below "Comparison of Danish Corporate Law and Our Articles of Association and U.S. Corporate Law—Corporate governance—Duties of directors" for a description of the general rules on duties and liabilities of the members of the board of directors under Danish law.

Obligation to disclose significant shareholdings and transactions

        Pursuant to the DCA, shareholders must notify a Danish company once they hold in excess of 5% of the company's share capital or voting rights, and must also provide notice to the company upon exceeding or falling below 5%, 10%, 15%, 20%, 25%, 331/3%, 50%, 662/3%, 90% and 100% of the company's share capital or voting rights. Such information must be registered by the company and

138


Table of Contents

made available for inspection by public authorities, shareholders and board members. This obligation does not apply to ADS holders.

Comparison of Danish Corporate Law and Our Articles of Association and U.S. Corporate Law

        The following comparison between Danish corporation law and our Articles of Association, which applies to us, and Delaware corporation law, the law under which many publicly listed corporations in the United States are incorporated, discusses additional matters not otherwise described in this Prospectus. Although we believe this summary is materially accurate, the summary is subject to Danish law, including the Danish Companies Act and Delaware corporation law, including the Delaware General Corporation Law. This summary does not constitute legal advice regarding those matters and should not be regarded as such. Further, please note that as an ADS holder you will not be treated as one of our shareholders and will not have any shareholder rights.

Corporate governance

Duties of directors

        Denmark.    The board of directors is responsible for overall and strategic management. In addition to performing overall management duties and strategic management duties and ensuring proper organization of the company's business, the board must ensure that:

    1.
    the bookkeeping and financial reporting procedures are satisfactory, having regard to the circumstances of the limited liability company;

    2.
    adequate risk management and internal control procedures have been established;

    3.
    the board of directors receives ongoing information as necessary about the limited liability company's financial position;

    4.
    the executive board performs its duties properly and as directed by the board of directors; and that

    5.
    the financial resources of the limited liability company are adequate at all times, and that the company has sufficient liquidity to meet its current and future liabilities as they fall due. The limited liability company is therefore required to continuously assess its financial position and ensure that the existing capital resources are adequate.

        The board of directors must appoint an executive board to be responsible for the day-to-day management of the company. The executive board must either consist of one or more persons who are also members of the board of directors, or consist of persons who are not members of the board of directors. In both cases, persons in charge of day-to-day management will be designated as executive officers, and together they form the executive board of the limited liability company. The majority of the members of the board of directors of public limited companies must be non-executive directors. No executive officer in a public limited company may be chairman or vice-chairman of the board of directors of that company.

        Delaware.    The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its shareholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise informed business judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action in connection with a change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board

139


Table of Contents

of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders. There is no prohibition on executive officers of Delaware companies serving as chairman or vice-chairman of their board of directors.

Director terms

        Denmark.    Under Danish law, directors are elected by the general meeting for the terms set out in the company's articles of association, provided however that the term shall expire with the closing of an annual general meeting held no later than four years after their election. Directors are usually elected for one-year terms. There is no limit in the number of terms a director may serve.

        Delaware.    The Delaware General Corporation Law generally provides for a one-year term for directors, but permits directorships to be divided into up to three classes with up to three-year terms, with the years for each class expiring in different years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted by the shareholders. A director elected to serve a term on a "classified" board may not be removed by shareholders without cause. There is no limit in the number of terms a director may serve.

Director vacancies

        Denmark.    Under Danish law, if there is no alternate member to replace a resigning member, the other members of the board of directors must arrange for the election of a new member to replace the resigning member during the remainder of his term of office. However, if the election is to be held at the general meeting, it may be postponed until the next annual general meeting for the election of members of the board of directors, provided that the number of remaining members and alternate members of the board of directors corresponds to the interval set out in the articles of association and amounts to at least three members.

        Delaware.    The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) unless (i) otherwise provided in the certificate of incorporation or bylaws of the corporation or (ii) the certificate of incorporation directs that a particular class of shares is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.

Conflict-of-interest transactions

        Denmark.    Under the DCA, no member of management may participate in the transaction of business that involves any agreement between the limited liability company and that member, or legal proceedings against that member, or the transaction of business that involves any agreement between the limited liability company and a third-party, or legal proceedings against a third-party, if the member has a material interest in such business and that material interest could conflict with the interests of the limited liability company.

        Delaware.    The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested director of that corporation if:

    the material facts as to the director's relationship or interest are disclosed and a majority of disinterested directors consent;

    the material facts are disclosed as to the director's relationship or interest and a majority of shares entitled to vote thereon consent; or

    the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of the board of directors or the shareholders.

140


Table of Contents

Proxy voting by directors

        Denmark.    A director of a Danish corporation may issue only to another director a proxy representing the director's voting rights at board meetings as a director.

        Delaware.    A director of a Delaware corporation may not issue a proxy representing the director's voting rights as a director.

Shareholder rights

Voting rights

        Denmark.    Under Danish law each share is entitled to one vote unless otherwise provided for by the articles of association. Our Current Articles provide for one class of shares, ordinary shares, and each ordinary share shall be entitled to one vote.

        A nominee shareholder is entitled to receive dividends and to exercise all subscription and other financial rights attached to the shares held in its name. The administrative rights attached to the shares (e.g., voting rights), however, cannot be exercised by the nominee unless (i) the beneficial owner of the shares discloses its identity and is registered by name in our register of shareholders and/or (ii) the nominee can present a valid power of attorney relating to this effect originating from the beneficial owner of the shares.

        The relationship between the nominee shareholder and the beneficial owner is governed solely by an agreement between the parties, and the beneficial owner must disclose its identity, if any of the aforementioned administrative rights are to be exercised directly by the beneficial owner.

        The right to appoint a nominee does not eliminate a shareholder's obligation to notify us of a major shareholding.

        All business transacted by the general meeting shall be decided by a simple majority of votes, unless otherwise provided by the Danish Companies Act or by the Articles of Association.

        A resolution to amend the Articles of Association requires that the resolution be adopted by at least two-thirds of the votes cast as well as the share capital represented at the general meeting, unless the Danish Companies Act or the Articles of Association requires a larger majority.

        Delaware.    Under the Delaware General Corporation Law, each shareholder is entitled to one vote per share, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation, or at elections held under specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event will a quorum consist of less than one third of the shares entitled to vote at a meeting.

        Shareholders as of the record date for the meeting are entitled to vote at the meeting, and the board of directors may fix a record date that is no more than 60 nor less than 10 days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given, or if notice is waived then the record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the shareholders of record entitled to notice or to vote at a meeting of shareholders shall apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting.

141


Table of Contents

Shareholder proposals

        Denmark.    The shareholders' rights to pass resolutions are exercised at the general meetings of the limited liability company. All shareholders, irrespective of voting rights, are entitled to attend and speak at general meetings.

        General meetings must be held at the registered office of the limited liability company, unless the articles of association specify another place at which the meetings must or can be held. If special circumstances require it, a general meeting may, in isolated cases, be held elsewhere.

        The annual general meeting must be held in time for the annual report adopted by the board of directors and the general meeting to reach the Danish Business Authority within five months from the end of the financial year, the time limit specified in the Financial Statements Act. The annual report must be submitted to the general meeting.

        Extraordinary general meetings must be held upon request from the board of directors or the auditor elected by the general meeting. Shareholders that hold 5% of the share capital can request an extraordinary general meeting in writing. Extraordinary general meetings to consider specific issues must be convened within two weeks of receipt of a request to such effect.

        Delaware.    Delaware law does not specifically grant shareholders the right to bring business before an annual or special meeting. However, if a Delaware corporation is subject to the SEC's proxy rules, a shareholder who owns at least $2,000 in market value, or 1% of the corporation's securities entitled to vote, may include a shareholder proposal in the corporation's proxy materials relating to an annual or special meeting in accordance with those rules.

Action by written consent

        Denmark.    Under Danish law, shareholders can, subject to certain exemptions, pass resolutions at a general meeting without complying with the requirements as to form and notice in the DCA and the company's articles of association, provided that all shareholders agree to do so. Further, unless otherwise provided by the company's articles of association, the board of directors may determine that in addition to a right to physically attend general meetings, shareholders may be given the right to attend electronically, including using electronic voting that does not require physical attendance at the meeting, so that the general meeting will be partly electronic. Moreover, the general meeting may resolve to hold general meetings electronically without any opportunity for parties to physically attend, so that the meeting is held by electronic means alone. A resolution to that effect must be recorded in the company's articles of association.

        Delaware.    Although permitted by Delaware law, publicly listed companies do not typically permit shareholders of a corporation to take action by written consent.

Appraisal rights

        Denmark.    The Danish Companies Act provides for certain shareholder appraisal rights in connection with certain mergers and demergers, and in relation to cross-border mergers also the right to demand payment in cash of the judicially determined fair value of the shareholder's shares.

        Delaware.    The Delaware General Corporation Law provides for shareholder appraisal rights, or the right to demand payment in cash of the judicially determined fair value of the shareholder's shares, in connection with certain mergers and consolidations.

142


Table of Contents

Shareholder suits

        Denmark.    Under Danish law, any resolution that the company should take legal action against its promoters, members of management, valuation experts, auditors, scrutinizers, keepers of the register of shareholders or shareholders under must be passed by the general meeting. Proceedings may be commenced notwithstanding any previous resolutions passed at a general meeting granting exemption from liability or waiving the right to take legal action if the information concerning the resolution or the subject matter of the proceedings provided to the general meeting before the resolution was passed was not essentially correct or complete. If shareholders that represent no less than one-tenth of the share capital oppose any resolution to grant exemption from liability or waive the right to take legal action, any shareholder can commence legal proceedings to recover damages for the company from the person(s) liable for the loss suffered. Shareholders who commence such proceedings must pay the legal costs involved, but may have such costs reimbursed by the company to the extent that they do not exceed the amount recovered by the company as a result of the proceedings. If the company is declared bankrupt, and the date of presentation of the bankruptcy petition is no later than 24 months after the date on which the general meeting resolved to grant exemption from liability or waive the right to take legal action, the bankrupt estate may, however, bring an action for damages without regard to the resolution passed at the general meeting. If a shareholder has suffered a loss, which is not an indirect loss due to a loss suffered by the company, such shareholder can commence legal proceedings to recover such loss independently and regardless of the above.

        Delaware.    Under the Delaware General Corporation Law, a shareholder may bring a derivative action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated shareholders where the requirements for maintaining a class action under Delaware law have been met. A person may institute and maintain such a suit only if that person was a shareholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a shareholder at the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile.

Repurchase of shares

        Denmark.    Under Danish law, a limited liability companies may acquire their own shares if they are fully paid up. The shares may be acquired both in ownership and by way of security. If a limited liability company acquires its own shares for consideration, such consideration may only consist of the funds that may be distributed as ordinary dividends under the provisions of the Danish Companies Act and the company's holding of its own shares must be disregarded when assessing whether the company satisfies the mandatory minimum capital requirements. An acquisition of a company's own shares for consideration cannot take place without the board of directors' obtaining authority from the general meeting, and such authority may only be given for a specified time, which may not exceed five years. The authority must specify (i) the maximum permitted value of the company's own shares; and (ii) the minimum and maximum amount that may be paid by the company as consideration for the shares. Prior to our board of directors' approval of the offer price and the issuance of ADSs offered by this Prospectus, it is expected that our board of directors will be authorized to repurchase some of our shares. See "Dividend Policy—Legal and Regulatory Requirements".

        Delaware.    Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are outstanding, any of

143


Table of Contents

its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations.

Anti-takeover provisions

        Denmark.    Danish company law does not contain specific anti-takeover provisions for unlisted companies but a company's articles of association may include poison pills to this effect, e.g., share classes with higher voting rights than other share classes or provisions to the effect that the board of directors shall approve share transfers.

        Delaware.    In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation.

        Section 203 of the Delaware General Corporation Law prohibits "business combinations," including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested shareholder that beneficially owns 15% or more of a corporation's voting shares, within three years after the person becomes an interested shareholder, unless:

    the transaction that will cause the person to become an interested shareholder is approved by the board of directors of the target prior to the transactions;

    after the completion of the transaction in which the person becomes an interested shareholder, the interested shareholder holds at least 85% of the voting shares of the corporation not including shares owned by persons who are directors and officers of interested shareholders and shares owned by specified employee benefit plans; or

    after the person becomes an interested shareholder, the business combination is approved by the board of directors of the corporation and holders of at least 66.67% of the outstanding voting shares, excluding shares held by the interested shareholder.

        A Delaware corporation may elect not to be governed by Section 203 by a provision contained in the original certificate of incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the corporation. Such an amendment is not effective until twelve months following its adoption.

Inspection of books and records

        Denmark.    Under Danish law, the company's annual report is public and shareholders have no access to inspect the company's books and records. They are instead referred to exercise their right to ask questions to the board or management at a general meeting or to submit a proposal for scrutiny of the company's formation, of any specific matter relating to the administration of the company, or of certain financial statements. If such a proposal is adopted by a simple majority of votes, the general meeting must elect one or more scrutinizers. The scrutinizer may demand from the company's management any information deemed to be of importance to the assessment of the company and shall submit a written report to the general meeting.

        Delaware.    Under the Delaware General Corporation Law, any shareholder may inspect for any proper purpose certain of the corporation's books and records during the corporation's usual hours of business.

144


Table of Contents

Removal of directors

        Denmark.    Under Danish law, members of the board of directors may be removed at any time by the electing or appointing party. Consequently, directors elected at a general meeting may be removed at another general meeting by a simple majority of votes.

        Delaware.    Under the Delaware General Corporation Law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board is classified, shareholders may effect such removal only for cause, or (ii) in the case of a corporation having cumulative voting, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of t